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ABSTRACT
Rapid rotation of guanine base derivatives about Pt–N7 bonds results in fluxional
behavior of models of the key DNA intrastrand G–G cross-link leading to anticancer
activity of Pt(II) drugs (G = deoxyguanosine). This behavior impedes the characterization
of LPtG2 models (L = one bidentate or two cis-unidentate carrier ligands; G = guanine
derivative). The objective of this study is to understand the types of conformers formed
as L is systematically varied. This work, relevant to Pt(II) anticancer drugs, has evolved
from published studies with sp3 N-ligands (e.g., 2,2′-bipiperidine), to C2 symmetrical or
unsymmetrical sp2 N-ligands having pyridine and/or triazine rings.
NMR spectroscopy provided conclusive evidence that LPtG2 (L = 5,5′-dimethyl2,2′-bipyridine (5,5′′-Me2bipy), 3-(4′-methylpyridin-2′-yl)-5,6-dimethyl-1,2,4-triazine)
(MepyMe2t), and bis-3,3′-(5,6-dialkyl-1,2,4-triazine)

(R4dt)) complexes exist as

interconverting mixtures of head-to-tail (HT) and head-to-head (HH) conformers. The
triazine rings have a N plus lone pair in the same position as the C6H of pyridine rings,
and NMR spectral studies indicate that the LPtG2 adducts are more dynamic when L has
a triazine ring. For the first time, the two possible HH conformers (HHa and HHb) were
identified for (MepyMe2t)Pt(5′-GMP)2, an adduct having an unsymmetrical L. Although
O6–O6 clashes involving the two cis G bases favor the HT over the HH arrangement, the
HH conformer of (R4dt)Pt(5′-GMP)2 adducts has a high abundance (~50%), a finding
attributed to a reduction in O6–O6 steric clashes permitted by the overall low steric
effects of R4dt ligands.
The (R4dt)Pt(d(G*pG*)) adduct (G* = N7 platinated G residue linked with a
sugar-phosphodiester backbone), is the first adduct having a high abundance of a fourth

xix

form. The characteristics of this form suggest it is the elusive ΛHT conformer; in
addition, this adduct had the normally observed HH1, HH2 and ∆HT conformers. Studies
with the (R4dt)Pt(d(G*pG*)) adducts provided the first clear evidence that the sugarphosphodiester backbone between two adjacent G’s slows the rate of exchange between
the conformers. For (R4dt)Pt(d(G*pG*)), a 3′-flanking T has no significant influence on
the structure of the d(G*pG*) cross-link or the distribution of conformers, whereas the 5′T residue led to the exclusive presence of the HH1 conformer.
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CHAPTER 1. INTRODUCTION
Rosenberg’s serendipitous discovery of the anticancer activity of cisplatin, cisPt(NH3)2Cl21, has stimulated extensive interest in the interaction of platinum complexes with
nucleic acids. Despite the success of cisplatin in treating several forms of cancer, including
ovarian, testicular, cervical, head and neck, and non-small-cell lung cancer,2-5 the exact features
that render this simple molecule an effective anticancer agent are still controversial. Also, the
treatment is limited by side effects including nephrotoxicity, emetogenesis and neurotoxicity.6-8
Thousands of platinum analogues have been synthesized and screened for anticancer activity in
an attempt to overcome these limitations and to broaden the range of treatable tumors.2,9-14
1.1 Cisplatin
1.1.1 Cellular Pathway

Figure 1.1 Schematic representation of cellular uptake and activation of cisplatin (cisPt(NH3)2Cl2) prior to DNA binding.
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Cisplatin circulates in the bloodstream, primarily as the chloride form. Upon entering the
cell, where the chloride ion concentration is significantly lower (~4 mM) than in the blood
plasma (100 mM), the chloride ligands are displaced by water to form aqua and hydroxo species
(Figure 1.1).5,15-20 These hydrolyzed cisplatin complexes are thought to be the active form of the
drug.5,15,16 Within the cell, cisplatin can form covalent adducts with a number of macromolecules
including peptides, proteins, and nucleic acids.16,21 However, DNA is widely accepted as the
critical target responsible for the anticancer activity of cisplatin.2,5,15,16,21
1.1.2 DNA Binding
Platinum compounds can bind to DNA by either covalent or non-covalent interactions.
X-ray structures and NMR data have established that at biologically relevant pH values platinum
complexes bind almost exclusively at the N7 atom in purine bases, with a preference for guanine
over adenine (Figure 1.2).2,5,10,15,22-29 Several types of DNA adducts occur with platinum
compounds, including monofunctional, intrastrand cross-links, and interstrand cross-links
(Figure 1.3).30-32 Cisplatin forms predominantly 1,2-intrastrand d(G*pG*) and d(A*pG*) crosslinks (G* = N7-platinated G), and to a lesser extent, 1,3-intrastrand and interstrand cross-links.3336

Consequently, attention has focused on these adducts as the active lesions responsible for the

anticancer activity of cisplatin.2,4,29,37-39 Additional support for this conclusion arises from the
inability of the inactive trans isomer (transplatin) to form this 1,2-intrastrand adduct because of
geometrical constraints.40,41 These discoveries suggested that the cytotoxicity of cisplatin
originated from the 1,2-intrastrand cross-links, which the geometry of transplatin does not
allow.25 The extent of this cross-link formation is correlated with treatment outcomes.42,43 The
distortions induced in the DNA structure upon formation of the 1,2-intrastrand cisplatin-DNA
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lesion have been shown to inhibit the processes of replication and transcription, resulting in cell
death.41,44

Figure 1.2 Structure and numbering scheme for DNA nucleobases. Dashed lines represent basepair hydrogen bonds. Base and sugar are in the anti conformation. N- and S-pucker
conformations are given for sugar moieties.

Figure 1.3 Chart showing common Pt-DNA binding modes resulting in monofunctional adducts
(A), interstrand (B) and 1,2-intrastrand bifunctional cross-links (C).
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Alterations of the B-DNA structure caused by cisplatin binding have been detected by
several methods such as melting temperature and CD spectroscopy.45-50 There is a degree of
uncertainty in defining the structure of duplexes bearing Pt drug lesions, and controversy exists
as to the details of the structure.26,29 For this reason and because one might gain better insight
into the causes of the distortions and interactions in duplexes by examining small models, many
investigators have been drawn to the study of small non-duplex models by both crystallography
and spectroscopy. Three classes of models are often employed to study the structural
consequences of platinum binding and formation of the 1,2-d(G*pG*) intrastrand adduct in
DNA:

(i) DNA oligonucleotide duplexes with intrastrand and interstrand G-Pt-G cross-

links,29,37,40,51-58 (ii) adducts with single-stranded DNA have been studied as models of the
intrastrand cross-link,22,29,39,59-65 and (iii) complexes formed with unlinked guanine derivatives
(G) are the simplest models.29,66-68 These model types also allow the practical application of
NMR spectroscopy, an invaluable technique for structural characterization in the biologically
relevant solution state.29,47
1.2 Conformations of LPtG2 Adducts
Although the Pt-duplex DNA adducts are the most reliable model types, their size often
complicates analysis designed to uncover the specific conformational changes inducted by
cisplatin bonding. For the other two simpler model types, namely cis-Pt(NH3)2G2 and cisPt(NH3)2(d(G*pG*)), bases can adopt a head-to-head (HH) or head-to-tail (HT) conformation
(Figure 1.4). In the HH conformer, the H8 atoms of both G bases are on the same side of the
platinum coordination plane, whereas in the HT conformer, the two H8 atoms are on the opposite
sides of the platinum coordination plane. Two chiralities are possible for the HT form: ∆ or Λ.
These conformers can interconvert via rotation of the bases about the Pt–N7 bond (Figure
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1.4).29,66 The untethered G’s normally preferentially adopt an HT orientation,69,70 whereas the
bases in d(GpG) cross-links having a sugar phosphate backbone preferably adopt the HH
orientation, especially when there is a 5′ residue.39,59,61,63-65,69,71-73

Figure 1.4 Schematic representation of possible HH and HT conformers in (a) LPtG2 and (b)
LPt(d(G*pG*)) type model complexes. The large arrows represent the guanine base, with the
arrowhead representing the H8 (shown below the scheme), and the small arrows in (b) indicate
the direction of propagation of the phosphodiester backbone. The platinum carrier ligand is to the
rear; for LPtG2 adducts when L is unsymmetrical (N′ ≠ N), there are two HH conformers, but
when symmetrical (N′ = N), only one HH conformer is possible. Rotation of one base about the
Pt–N7 bond leads to another conformer, but in each case the base orientation changes from HT
to HH and vice-versa.
1.3 Dynamic Motion Problem
Both cis-Pt(NH3)2G2 and cis-Pt(NH3)2(d(G*pG*)) model adducts exhibit only one set of
1

H NMR resonances for each type of G or G* residue.61,63,66,68 However, two different

interpretations have been proposed for this same observation. Detection of one set of 1H NMR
signals for cis-Pt(NH3)2G2 complexes has been attributed to a dynamic interchange between
multiple conformers.66,68 However, in the absence of an X-ray structure, the observation of only
5

one set of 1H NMR signals for cis-Pt(NH3)2(d(G*pG*))61,63 has been interpreted to imply that the
presence of the phosphodiester backbone in this cross-link model favors only one conformer
(anti, anti HH1), which undergoes slow Pt–N7 bond rotation.41,59,61,63-65 Because of these
conflicting interpretations, the cis-Pt(NH3)2(d(G*pG*)) model of the cisplatin-DNA intrastrand
adduct is said to suffer from the "dynamic motion problem".69,74-77
1.4 Retro-modeling
To resolve the “dynamic motion problem”, the “retro modeling” approach has been
employed. In this approach analogues of cisplatin are synthesized with bulky ligands designed to
reduce dynamic motion by destabilizing the transition state for Pt–N7 rotation.29,69-71,74,78,79 These
carrier ligands are more complex than the freely rotating ammonia groups of the parent
compound, cisplatin. An important feature of the design is to minimize steric effects of the
ground state equilibrium species to allow conformers likely to be present in dynamic cisPt(NH3)2G2 adduct to exist in the new adducts also. The carrier-ligand bulk plays a role in
influencing both the biological activity and the properties of adducts.
NMR spectroscopy provides evidence of coexistence of multiple conformers for LPtG2
models (L = one bidentate or two cis-mondentate N-donor carrier ligands) suggesting slow
rotation about the Pt–N7 bond. The number of observable NMR signals for LPtG2 complexes is
determined by the local symmetry of the ligand and the asymmetry of the G ribose residue. For
the most simple case, in which the L is C2 symmetrical and G does not have a ribose group (e.g.,
9-ethylguanine), the two HT rotamers (∆ and Λ) are enantiomers and the two HH forms are
equivalent because they are related by C2 symmetry; each base arrangement (HH or HT) gives
rise to only one 1H NMR resonance for each proton type because the two G bases, in either the
HH or HT arrangement, are equivalent. When the G contains a sugar moiety, the chirality of the
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ribose group breaks the enantiomeric relationship of the two HT conformers, but the two HH
forms are still equivalent;

the two G bases are still related by C2 symmetry in the HT

conformers, but are no longer equivalent in the HH arrangement. Thus, for a LPtG2 complexes
with a C2-symmetrical L and a G containing a sugar moiety, observation of up to four 1H NMR
signals for each proton type is possible (one for each HT form (∆ and Λ) and two signals of equal
intensity for the HH form). When L is an unsymmetrical carrier ligand, the two HH (HHa and
HHb) and the HT (∆ and Λ) conformers are not equivalent and maximum of eight H8 signals are
possible.
1.4.1 sp3 N-donor Ligands
Unlike the cis-Pt(NH3)2G2 complexes, for which conformer distributions are not known,
observation of individual forms for retro-model complexes allows assessment of conformers.
The downfield G H8 signals, in a less crowded, more disperse region of the spectra, are
particularly useful for assessing the nature and distribution of conformer. Early retro-modeling
studies employing Pt complexes of N,N′-dimethyl-2,3-diaminobutane (Me2DAB)71,72,78 and 2,2′bipiperidine (Bip)69,70 carrier ligands produced some interesting results. The Pt coordinated
chelate ligands have two energetically favored C2-symmetrical geometries, with S, R, R, S or R,
S, S, R configurations at the asymmetric N, C, C, and N chelate ring atoms (Figure 1.5). These
retro models provided the opportunity to define the solution structure of conformers by NMR
methods, allowing the identification of the HH form of an LPtG2 adduct for the first time80 and
to define the absolute conformation in solution.38
In addition to the commonly found HH1 conformer, a novel HH form (HH2) was
discovered for (R, S, S, R)-BipPt(d(G*pG*)).74 This new form, comparable in stability to the
HH1 conformer, differs from HH1 with respect to the direction of propagation of the
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phosphodiester backbone. HH1 and an HT form (∆HT1) were observed for the (S, R, R, S)BipPt(d(G*pG*)) adduct.79 Secondly, the stereochemistry of these ligands was found to dictate
the favored HT chirality; subsequently, they were termed chirality-controlling chelate (CCC)
ligands.78 Thirdly, for all Me2DABPtG2 adducts, the favored HT form was always one having
the G O6 atoms and the cis Me2DAB NH groups on opposite sides of the platinum coordination
plane; such results suggested that carrier ligand NH-G O6 H-bonds are not a great stabilizing
force in such conformers.78 Fourthly, it was found that the G N1H is a key feature stabilizing the
favored HT conformer by participating in hydrogen bonding to the phosphate group of the cis G;
such interligand phosphate-cis G N1H interactions were called “second-sphere communication”
(SSC).26,76,81,82 The fifth and the final key point that emerged from these studies was the
establishment of a strong correlation between the observed CD signal and the dominant HT
rotamer (∆ or Λ).78

Figure 1.5 Ball-and-stick representation of PtG2 adducts of sp3 N-donor ligands (Me2DAB and
Bip). Balloon-type structures (middle) depict the ligand bulk relative to the Pt coordination
plane. Stereochemistry is indicated for the N, C, C, and N ring atoms of the Bip and Me2DAB
ligands.
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Figure 1.6 Schematic representation of canting orientations for the BipPt(d(G*pG*)) HH1, HH2
and ∆HT conformers. Shaded balloon-like shapes depict the bulk of the Bip ligand distributed
slightly above and/or below the Pt coordination plane. Each arrow represents the guanine base.
The phosphodiester backbone is omitted for clarity. Double-headed arrows show the possible
Bip NH–G*O6 hydrogen bonds.
Studies on cross-linked adducts employing the Bip carrier ligand proved to be very
revealing. As for the BipPtG2 systems, the chirality of the Bip ligand was found to play a role in
conformer distribution in cross-linked adducts. Carrier-ligand chirality also influenced structural
properties of observed conformers; namely, G* base canting orientations. Canting can be either
right (R)- or left (L)-handed (Figure 1.6). (S, R, R, S)-BipPt(d(G*pG*)) forms had L-canting,
whereas conformers of (R, S, S, R)-BipPt(d(G*pG*)) favored R-canting (Figure 1.6). For all
conformers, the favored canting orientation was consistent with the presence of at least one Bip
NH-G O6 H-bond. Consequently, carrier ligand-NH group-G O6 H-bonds were postulated to
influence conformer stabilities and base canting for the forms of BipPt(d(G*pG*)) adducts.74,75,79
9

This proposed role regarding carrier-ligand NH-G O6 H-bonds thus seems to contrast with
conclusions drawn from unlinked model (i.e., G2) studies.
Another sp3 N-donor carrier ligand studied earlier is N,N′- dimethylpiperazine (Me2ppz,
Figure 1.5). The ligand possess in-plane bulk to slow the dynamic motion, but lack the chirality
and NH groups typically designed into cisplatin derivatives.66,83-85 The reduced dynamic nature
of Me2ppzPtG2 complexes allowed assessment and potential identification of factors relevant to
the relative stabilities of different conformers.76,86 The absence of NH groups in the Me2ppz
ligand eliminates the possibility of any carrier ligand NH-G O6/phosphate group H-bond. The
three typical conformers (∆HT, ΛHT, and HH) were observed for Me2ppzPtG2 adducts.
Furthermore, in a rare example of cross-link models, three conformers (HH1, HH2, and ∆HT1)
were observed and characterized for Me2ppzPt(d(G*pG*)).87 This marked the first report of
three conformers in one Pt cross-link adduct. Comparison of the results for BipPt(d(G*pG*))
and Me2ppzPt(d(G*pG*)) adducts suggested that carrier ligand NH-G O6 H-bond has no
influence on base canting orientations and is not a significant stabilizing factor for conformers.87
1.4.2 sp2 N-donor Ligands
Retro models with sp3 N-donor ligands have been studied more often69,86,88,89 than those
with sp2 N-donor heterocyclic chelating ligands. Studies of (Me2phen)Pt(Guo)2 complex90
(Me2phen

=

2,9-dimethyl-1,10-phenanthroline;

Guo

=

guanosine)

and

(5,5′′-

Me2bipy)Pt(d(G*pG*)),77 (5,5′′-Me2bipy = 5,5′-dimethyl-2,2′-bipyridine) have demonstrated the
coexistence of different rotamers exchanging slowly relative to the NMR time scale. A Pt(II)
complex having aromatic ligands can not only bind to nucleobases but can also intercalate into
DNA.8,91-97 Aromatic ring stacking between nucleobases and the intercalating molecule is
considered to be one of the driving forces leading to binding; the extent of binding is expected to
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depend on the planarity of the complex.94,98 Because of the planar nature of bipyridine ligands,
intercalation of Pt bipyridine complexes has been a focus of considerable interest.92,94,99,100

Figure 1.7 Line drawing and numbering scheme for the sp2 N-donor ligands; Me2bipy =
dimethyl-2,2′-bipyridine, R1pyR2R3t = 3-(Pyridin-2′-yl)-5,6-disubstituted-1,2,4-triazine and
R4dt = bis-3,3′-(5,6-alkyl-1,2,4-triazine).
The studies presented here utilize sp2 N-donor heterocyclic aromatic bidentate ligands,
namely dimethyl-2,2′-bipyridine (Me2bipy), 3-(Pyridin-2′-yl)-5,6-disubstituted-1,2,4-triazine
(R1pyR2R3t) and bis-3,3′-(5,6-disubstituted-1,2,4-triazine (R4dt) ligands (Figure 1.7). These
ligands like Me2ppz lack the NH group and the ligand bulk lie in the Pt coordination plane.
Platinum complexes of these ligands were synthesized and crystallized. Structural analysis of
these complexes allowed evaluation of the effect of substituents and their positions on distortions
from planarity of these complexes. In LPtG2 adducts, the effect of the presence of H6/6′ protons
in Me2bipy that project toward the G bases compared to the equivalently placed lone pairs on the
N atoms in R4dt ligands on the conformer distribution and canting of the bases is analyzed. The
unsymmetrical R1pyR2R3t ligand forms a connecting link between the two symmetrical ligands
above, in having both the pyridyl and the triazine ring.
Studies involving the above sp2 N-donor ligands, using linked (d(GpG) and oligos) and
unlinked (guanosine, 5′- and 3′-GMP's) model types were undertaken in order to have a better
understanding of the factors that contribute to the conformer stability and their structural
properties. Specifically, the importance of electrostatic interaction between the carrier ligand and
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the bases will be addressed. In addition to the characteristic H8 and sugar proton shifts of the G
bases, the chemical shifts of the H6 or H6′ proton signals will also be used to explain the
structural features of the adducts. The concept that the ability of the carrier ligand to favor
specific conformers may be related to the activity (or inactivity) of cisplatin derivatives has been
discussed.75 The populations of conformers other than the HH1 conformer favored by the
cisplatin-DNA intrastrand cross-linked adduct may reduce anticancer activity because such
lesions may be better recognized and more easily corrected by DNA repair mechanisms. For
example, proteins bearing the HMG domain are assumed to play an essential role in cisplatin’s
anticancer activity;44,101,102 such proteins recognize the cisplatin-DNA lesion and are believed to
protect the site from repair mechanisms. This protein may not recognize other conformers. Thus,
identification of carrier-ligand features which favor the biologically relevant lesion may
ultimately prove beneficial in designing better and hence more active platinum anticancer drugs.
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CHAPTER 2. CHEMISTRY OF HIV-1 VIRUCIDAL Pt COMPLEXES HAVING
NEGLECTED BIDENTATE sp2 N-DONOR CARRIER LIGANDS WITH LINKED
TRIAZINE AND PYRIDINE RINGS: SYNTHESIS, NMR SPECTRAL FEATURES,
STRUCTURE, AND REACTION WITH GUANOSINE*
2.1 Introduction
In comparison to agents of purely organic molecules, considerably less effort has been
devoted to studying metal-containing drugs. Platinum complexes, which have been found to be
the most promising,1-7 have the advantages of inertness, low coordination number, and
preferential binding to the more limited soft centers in proteins and nucleic acids. The nonleaving carrier ligand on Pt can modify binding sites and thus activity. Cisplatin (cisPt(NH3)2Cl2) and its analogues, cis-PtA2X2 (A2 = two amines or a diamine), interact with DNA
by forming a 1,2-intrastrand N7−Pt−N7 crosslink between two adjacent guanines.8 Pt(II)
compounds also have an extensive history of exhibiting antiviral activity against numerous
viruses, including topical antiviral activity.9-15 In addition, we have clear evidence that the carrier
ligand influences the antiviral activity.13 Structural modifications of the carrier ligand in cisplatin
may broaden the range of antitumor and antiviral activity and may provide valuable insight into
the mechanism of action of the drug.3,16
Development of multi-purpose drugs with wider application is desirable. Numerous
platinum coordination compounds have been synthesized and shown to have both antiviral and
antitumor activities.14 Hybrid drugs of the type, cis-[Pt(NH3)2(B)Cl]+, containing a cisplatin-like
moiety and an antiviral guanosine-type ligand (B = acyclovir or penciclovir),14,15 are known.
______________________________________________________________________________
* Reproduced with permission from American Chemical Society: Maheshwari, V.;
Bhattacharyya, D.; Fronczek, F. R.; Marzilli, P. A.; Marzilli, L. G., "Chemistry of HIV-1
Virucidal Pt Complexes Having Neglected Bidentate sp2 N-donor Carrier Ligands with Linked
Triazine and Pyridine Rings. Synthesis, NMR Spectral Features, Structure, and Reaction with
Guanosine," Inorganic Chemistry, 2006, 45, 7182-7190. Copyright 2006 American Chemical
Society.
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Collaborative studies from this laboratory have shown that platinum compounds
containing one or two N-donor aromatic 3-(pyridin-2′-yl)-1,2,4-triazine ligands (ptt) possess
great potential as anti-HIV microbicides.13
The [(ferene)PtCl2]2- and [(ferene)2Pt]2- (ferene = 3-(pyridin-2′-yl)-5,6-bis(5-sulfo-2furyl)-1,2,4-triazine; in Figure 2.1, R2 = R3 = 5-sulfo-2-furyl) complexes are among the most
virucidal ptt compounds.13 However, these agents with sulfonated ring substituents were not
isolated as crystals, have very complicated 1H NMR spectra, and thus were not well defined
chemically. For example, the triazine ring binding mode (N2 or N4, Figure 2.1) or a mixture of
such binding modes, could not be resolved for the ferene agents.

Figure 2.1 Synthesis of 3-(Pyridin-2′-yl)-5,6-disubstituted-1,2,4-triazine (L)
In this study, we utilize six ligands, L, bearing a 3-(pyridin-2′-yl)-1,2,4-triazine moiety
(Figure 2.1). Three ligands contain the pyridin-2′-yl group: 3-(pyridin-2′-yl)-5,6-dimethyl-1,2,4triazine (pyMe2t), 3-(pyridin-2′-yl)-5-phenyl-1,2,4-triazine (pyPht), and 3-(pyridin-2′-yl)-5,6diphenyl-1,2,4-triazine (pyPh2t)), and the other three ligands contain the 4′-methylpyridin-2′-yl
group: 3-(4′-methylpyridin-2′-yl)-5,6-dimethyl-1,2,4-triazine (MepyMe2t), 3-(4′-methylpyridin2′-yl)-5-phenyl-1,2,4-triazine (MepyPht), and 3-(4′-methylpyridin-2′-yl)-5,6-diphenyl-1,2,4triazine (MepyPh2t)). We describe here the synthesis of LPtCl2 and [L2Pt]X2 complexes (Figure
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2.2), along with their characterization by 1H NMR spectroscopy and, for selected examples, by
single-crystal X-ray diffraction methods. The pyridyl triazines are relatively neglected ligands; no
crystal structures involving 3-(pyridin-2′-yl)-1,2,4-triazines with Pt have been reported. However,
crystal structures of pyPh2t complexes of Cu,17 Sn,18 and Ru19 have been reported. Also known
is a crystal structure of [Ce(Mebtp)3]3+ (Mebtp = 2,6-bis(5,6-dimethyl-1,2,4-triazin-3-yl)pyridine) complex with the Mebtp tridentate ligand containing the pyMe2t moiety.20

Figure 2.2 Synthesis of LPtCl2 and [L2Pt]2+ Complexes. Reagents and conditions: (i) A:B = 1:1,
CH3OH, 60 °C, 12 h; (ii) A:B = 1:2, CH3OH, 60 °C, 24 h.
Pt(II) compounds have high affinity for reacting with S-containing biomolecules such as
methionine and also with N7 of purine bases in nucleic acids, but the target for virucidal activity
is not known. Carrier-ligand bulk plays a role in influencing both biological activity and the
properties of adducts. Because platinum complexes of 3-(pyridin-2′-yl)-1,2,4-triazines may form
1,2-intrastrand GG crosslinks with RNA in HIV-1 and because the observation of rotamers
formed by restricted rotation about the N7 bonds in Pt(Guo)2 adducts provides information on
ligand steric bulk, we assessed whether rotamers can be detected for [(MepyMe2t)Pt(Guo)2]2+.
The carrier ligands in cisplatin and other Pt(II) anticancer drugs usually are not bulky enough to
impede rotation of N7-bound guanine about the Pt–N7 bond, but planar sp2 N-donor ligands such

21

as 5,5′-dimethyl-2,2′-bipyridine (5,5′′-Me2bipy)21 and 1,10-phenanthroline (phen)22 allow
detection of rotamers on the NMR time scale. The aromatic portion of the 3-(pyridin-2′-yl)-1,2,4triazine carrier ligands in ptt compounds can also possibly intercalate into nucleic acids.23 Thus,
all these reasons prompted us to conduct this study of the synthesis and characterization of ptt
compounds related to ptt compounds with ferene that are known to be HIV-1 virucidal.13
2.2 Experimental Section
2.2.1 Starting Materials
The starting material, pyridine-2-carboxamide hydrazone (2-pyridylamidrazone), was
synthesized by a known method24 (Figure 2.1) in yields above 90%. 4′-Methyl-substituted
pyridine-2-carboxamide

hydrazone

(4′-methyl-2-pyridylamidrazone)

was

synthesized

as

described by Case.25 Guanosine (Guo) (Sigma) and pyPh2t (Fluka) were obtained from
commercial sources. cis-Pt(Me2SO)2Cl2 was prepared as described in the literature.26 Elemental
analyses (C,H,N) were performed by Atlantic Microlabs, Atlanta, GA.
2.2.2 NMR Measurements
1

H NMR spectra were recorded on Bruker spectrometers operating at 400 or 500 MHz.

We used the values of 0.00 and 4.78 ppm to reference signals to TMS in DMSO-d6 solutions and
to the residual HOD signal in D2O/DMSO-d6 solutions, respectively. DNO3 and NaOD solutions
(0.1 M in D2O) were used to adjust the pH of D2O/DMSO-d6 solutions. 2D ROESY
experiments27 were performed at 25 °C by using a 500 ms mixing time (128 scans per t1
increment). NMR data were processed with XWINNMR or Mestre-C software.
2.2.3 Synthesis of L = 3-(Pyridin-2′-yl)-5,6-disubstituted-1,2,4-triazine and 3-(4′Methylpyridin-2′-yl)-5,6-disubstituted-1,2,4-triazine
The pyMe2t, pyPht, pyPh2t ligands and their 3-(4-methylpyridin-2′-yl) analogues,
MepyMe2t, MepyPht, and MepyPh2t, were prepared as described in the literature25,28,29 (Figure
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2.1), with minor modifications. An ethanol solution (30 mL) containing 2-pyridylamidrazone, or
its 4′-methyl analogue (2.5 mmol), and an α-diketone (2.5 mmol) was heated at reflux for 3 h.
The volume of the solution was reduced to one-fourth by rotary evaporation. Addition of an
excess of hexane afforded the desired pure crystalline 3-(pyridin-2′-yl)-1,2,4-triazine in 90%
yield.
2.2.4 Synthesis of LPtCl2 Complexes
Two methods, A and B, were employed to obtain LPtCl2 complexes (Figure 2.2). Method
A involved heating a methanol solution (30 mL) of cis-Pt(Me2SO)2Cl2 (0.101 g, 0.24 mmol) and
L (0.24 mmol) at 60 °C for 12 h. The yellow solid that precipitated was collected, washed with
diethyl ether followed by chloroform, and dried in vacuo. Method A resulted in high yields of
powdered LPtCl2 product that required no further purification. Method B, employed to obtain Xray quality crystals, involved mixing an acetonitrile solution of cis-Pt(Me2SO)2Cl2 (4.22 mg,10
mM in 1 mL) with L (10 mM in 1 mL) and allowing this mixture to stand at 23 °C. Thin needles
of LPtCl2, varying in color from greenish-yellow to orange, were obtained in ~15% yield after 24
hours.
2.2.4.1 (pyMe2t)PtCl2 (1). Method A gave a yellow precipitate; yield, 0.077 g (71%).
Method B afforded orange needle-shaped crystals. 1H NMR (ppm) in DMSO-d6 : 9.57 (d, H6′),
8.60 (d, H3′), 8.48 (t, H4′), 8.03 (t, H5′), 2.75 (s, CH3), 2.59 (s, CH3). Anal. Calcd for
C10H10Cl2N4Pt: C, 26.56; H, 2.23; N, 12.39. Found: C, 26.77; H, 2.29; N, 12.37.
2.2.4.2 (pyPht)PtCl2 (2). Method A gave a yellow powder; yield, 0.084g (75%). Method
B produced yellow-green needles. 1H NMR (ppm) in DMSO-d6: 10.18 (s, H6), 9.62 (d, H6′),
8.78 (d, H3′), 8.54 (t, H4′), 8.11 (t, H5′), 8.64 (d, o-PhH), 7.85 (t, p-PhH), 7.71 (t, m-PhH). Anal.
Calcd for C14H10Cl2N4Pt: C, 33.61; H, 2.01; N, 11.20. Found: C, 33.48; H, 1.95; N, 11.10.
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2.2.4.3 (pyPh2t)PtCl2 (3). Method A gave a yellow solid; yield, 0.099 g (83%). Orange
needles were obtained by method B. 1H NMR (ppm) in DMSO-d6: 9.63 (d, H6′), 8.62 (d, H3′),
8.53 (t, H4′), 8.09 (t, H5′), 7.38-7.51 (PhH). Anal. Calcd for C20H14Cl2N4Pt: C, 41.68; H, 2.45;
N, 9.72. Found: C, 41.45; H, 2.37; N, 9.80.
2.2.4.4 (MepyMe2t)PtCl2 (4). Method A resulted in a yellow powder; yield, 0.096 g
(77%). X-ray quality crystals in the form of yellow needles were obtained by method B. 1H NMR
(ppm) DMSO-d6: 9.35 (d, H6′), 8.26 (s, H3′), 7.85 (d, H5′), 2.74 (s, CH3), 2.57 (s, CH3), 2.53 (s,
CH3). Anal. Calcd for C11H12Cl2N4Pt: C, 28.34; H, 2.59; N, 12.02. Found: C, 28.32; H, 2.58; N,
11.82.
2.2.4.5 (MepyPht)PtCl2 (5). The complex was obtained as a yellow powder by method
A; yield, 0.095 g (68%). 1H NMR (ppm) in DMSO-d6: 10.15 (s, H6), 9.41 (d, H6′), 8.61 (s, H3′),
7.91 (d, H5′), 8.65 (d, o-PhH), 7.84 (t, p-PhH), 7.70 (t, m-PhH), 2.59 (s, CH3). Anal. Calcd for
C15H12Cl2N4Pt: C, 35.03; H, 2.35; N, 10.89. Found: C, 34.81; H, 2.31; N, 10.65.
2.2.4.6 (MepyPh2t)PtCl2 (6). Method A resulted in a reddish-yellow precipitate; yield,
0.112 g (79%). Method B produced yellow needles. 1H NMR (ppm) in DMSO-d6: 9.44 (d, H6′),
8.49 (s, H3′), 7.93 (d, H5′), 7.75 (d, o-PhH), 7.45-7.63 (m, p-PhH), 2.58 (s, CH3). Anal. Calcd for
C21H16Cl2N4Pt: C, 42.72; H, 2.73; N, 9.49. Found: C, 42.75, H, 2.58; N, 9.43.
2.2.5 Synthesis of [L2Pt]X2 Salts
cis-Pt(Me2SO)2Cl2 (0.042 g, 0.1 mmol) was added to a methanol solution of L (0.4
mmol, 10 mL) and the resulting suspension became a solution when stirred at 60 °C for 24 h
(Figure 2.2). The mixture was allowed to cool to room temperature. Any precipitate that formed
was removed by filtration, and the clear filtrate was treated with a methanol solution of an excess
of NaBF4 or NaPF6 to precipitate the [L2Pt]X2 salt. The solid was collected, washed twice with
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methanol followed by anhydrous diethyl ether and allowed to dry in air. Yields of the [L2Pt]X2
salts were 35-45%. The 1H NMR spectra and shifts for representative [L2Pt]X2 complexes appear
in Supporting Information.
2.2.5.1 [(pyPht)2Pt](PF6)2 (7). The method described above afforded a yellow solid upon
addition of an excess of NaPF6; yield, 0.30 g (36%). The 1H NMR spectra of the BF4 and PF6
salts were identical. Anal. Calcd for C28H20N8P2F12Pt: C, 35.27; H, 2.11; N, 11.75. Found: C,
35.54; H, 1.89; N, 11.85.
2.2.5.2 [(pyPh2t)2Pt](BF4)2 (8). Crystals were obtained by the general method described
above, but by very careful dropwise addition of a methanol solution of NaBF4 (5 mmol) to the
filtrate, until the solution first became cloudy. Thin, yellow, needle-shaped crystals were obtained
by allowing the solution to stand undisturbed for 2 days.
2.2.5.3 [(MepyPh2t)2Pt](PF6)2 (9). This product was obtained as a yellow solid in the
same way as for (7); yield, 0.041 g (40%). The 1H NMR spectra of the BF4 and PF6 salts were
identical. Anal. Calcd for C42H32N8P2F12Pt: C, 44.49; H, 2.84; N, 9.88. Found: C, 44.58; H,
2.68; N, 9.94.
2.2.6 Reaction of ptt’s with Guo
A 14 mM (1.63 mg) solution of (MepyMe2t)PtCl2 (4) in DMSO-d6 (250 µL) was treated
with a Guo solution (1.98 mg, 15.5 mM in 450 µL of D2O) to give a 1:2 ratio (5 mM: 10 mM) of
Pt:Guo, and the solution (pH ~4.6) was kept at 25 °C. The mixture of D2O and DMSO-d6
solutions was used to improve the solubility of 4. The pH of the solution decreased with time and
had to be adjusted to ∼4.6. The solution was monitored for six days until the 1H NMR signals of
free Guo disappeared. However, the reaction was repeated several times, and to decrease the
time for the reaction to reach completion, an excess of Guo was often employed. A DMSO-d6
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solution (250 µL) of [(MepyMe2t)2Pt](BF4)2 (2.69 mg, 14 mM) was treated with Guo (1.98 mg,
15.5 mM) solution in D2O (450 µL) to give a 1:2 ratio of Pt:Guo, and the solution maintained at
pH ~4.6 at 25 °C. The solution was monitored by 1H NMR spectroscopy, and no evidence of any
reaction was found even after 36 h.
2.2.7 X-ray Data Collection and Structure Determination
Single crystals were placed in a cooled nitrogen gas stream at ~100 K on a Nonius Kappa
CCD diffractometer fitted with an Oxford Cryostream cooler with graphite-monochromated Mo
Kα (0.71073 Å) radiation. Data reduction included absorption corrections by the multi-scan
method, with HKL SCALEPACK.30
All X-ray structures were determined by direct methods and difference Fourier techniques
and refined by full-matrix least squares, using SHELXL97.31 All non-hydrogen atoms were
refined anisotropically. All H atoms were visible in difference maps, but were placed in idealized
positions. A torsional parameter was refined for each methyl group. For all structures, maximum
residual densities were located near the Pt positions.
2.3 Results and Discussion
2.3.1 X-ray Crystallography
Structures of pseudo square-planar complexes reported here include LPtCl2 (L = pyMe2t,
pyPht, pyPh2t), and [(pyPh2t)2Pt](BF4)2 (Tables 2.1 and 2.2; Figures 2.3 and 2.4). The atom
numbering systems in these ORTEP figures are used to discuss the solid-state structures. A
superscript i denotes the atoms of the other ligand in [L2Pt]X2 salts. When referring to the X-ray
numbering system, the number will appear in parentheses, whereas for other purposes (e.g.,
NMR discussion) we shall use the general numbering system in Figure 2.1, and the number will
not be enclosed in parentheses. Likewise, in some cases we shall designate the Pt-bound N’s as

26

N(t) and N(py), in the triazine and pyridine rings, respectively. The numbering scheme for
bipyridines is given below in Figure 2.5.
Table 2.1 Crystal Data and Structure Refinement for LPtCl2 (L = pyMe2t (1), pyPht (2), pyPh2t
(3)) and [(pyPh2t)2Pt](BF4)2 (8)
(pyMe2t)PtCl2

(pyPht)PtCl2

(pyPh2t)PtCl2

[(pyPh2t)2Pt]
(BF4)2

Empirical formula

C10H10Cl2N4Pt

C14H10Cl2N4Pt

C20H14Cl2N4P
t•CH3CN

C40H28B2F8N8Pt
•0.59H2O

Fw

452.21

500.25

617.40

1000.00

space group

Pbca

P21/c

P21/c

C2/c

a (Å)

7.3055 (10)

9.236 (5)

10.202 (2)

35.253 (5)

b (Å)

17.923 (4)

7.496 (4)

7.4820 (10)

7.8417 (15)

c (Å)

17.977 (4)

19.789 (13)

27.278 (7)

13.811 (3)

β (°)

90

94.312 (18)

93.513 (7)

99.270 (7)

V (Å3)

2353.8 (8)

1366.2 (14)

2078.3 (7)

3768.1 (12)

T (K)

102

100

100

110

Z

8

4

4

4

ρcalc (mg/m3)

2.552

2.432

1.973

1.763

abs coeff (mm-1)

12.356

10.658

7.029

3.809

2θmax (°)

65.2

55.0

63.0

56.6

R indicesa

0.029

0.062

0.034

0.033

wR2 = [I> 2σ(I)]b

0.060

0.155

0.059

0.065

data/param

4267/157

3085/190

6483/272

4639/275

Unit cell dimensions

a

R = (∑||Fο| - |Fc||)/∑|Fο|; bwR2 = [∑[w(Fο2 - Fc2)2]/∑[w(Fο2)2]]1/2, in which

w = 1/[σ2(Fο2) + (0.0787P)2] and P = (Fο2 + 2Fc2)/3
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Table 2.2 Selected Bond Distances (Å) and Angles (deg) for LPtCl2 (L = pyMe2t (1), pyPht (2),
pyPh2t (3)) and [(pyPh2t)2Pt](BF4)2 (8)
(pyMe2t)PtCl2

(pyPht)PtCl2

(pyPh2t)PtCl2

[(pyPh2t)2Pt](BF4)2

bond distances
Pt–N(1)

2.001(3)

1.996(11)

1.996(3)

2.019(3)

Pt–N(4)

2.020(3)

2.011(11)

2.027(3)

2.050(3)

Pt–Cl(1)

2.2969(11)

2.304(4)

2.2920(10)

Pt–N(4)i 2.050(3)

Pt–Cl(2)

2.2899(10)

2.292(4)

2.2972(10)

Pt–N(1)i 2.019(3)

bond angles
N(4)–Pt–N(1)

80.33(12)

79.8(4)

80.38(11)

78.68(13)

N(1)–Pt–Cl(1)

174.83(9)

173.3(3)

174.90(8)

N(1)–Pt–N(1)i 180.0

N(1)–Pt–Cl(2)

96.05(9)

96.2(3)

95.86(8)

N(1)–Pt–N(4)i 101.32(13)

N(4)–Pt–Cl(1)

94.50(10)

93.8(3)

94.60(8)

N(4)–Pt–N(1)i 101.32(13)

N(4)–Pt–Cl(2)

176.30(9)

176.0(3)

176.24(8)

N(4)–Pt–N(4)i 180.0

Cl(2)–Pt–Cl(1)

89.13(3)

90.12(13)

89.16(3)

N(4)i–Pt–N(1)i 78.68(13)

C(5)–C(4)–C(3)

123.0(3)

124.7(13)

122.9(3)

123.1(4)

N(4)–C(4)–C(3)

114.1(3)

113.6(12)

114.5(3)

114.4(3)

N(3)–C(3)–C(4)

120.1(3)

119.4(12)

121.0(3)

120.6(3)

N(1)–C(3)–C(4)

114.8(3)

114.2(11)

115.0(3)

114.6(3)

In order to discuss structural features of the pyridyl triazine ligands, we shall use some of
the terminology employed for the common symmetrical sp2 N-donor L’s, e.g. 2,2′-bipyridine
(bipy) or phen ligands. The M−N distance for which there would be no in-plane distortion
(Figure 2.5) has been estimated to be 2.72 Å.32 Hazell concluded that the stress in coordinated
2,2′-bipyridines caused by the close proximity of the hydrogen atoms on the carbons ortho to the
bridging atoms is reduced by the twisting of the pyridine rings about the bond bridging the two
pyridine rings and by an in-plane bending (Figure 2.5).33 Likewise, in compounds such as
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[(bipy)2Pt]2+ the M−N distance for which there would be no distortion of the overall
coordination environment from planarity has been estimated to be 2.8 Å.34 Therefore, we begin
our discussion of the structures with bond lengths and angles involving Pt.

Figure 2.3 ORTEP plots of (a) (pyMe2t)PtCl2 (1) and (b) (pyPht)PtCl2 (2). Thermal ellipsoids
are drawn with 50% probability.

Figure 2.4 ORTEP plots of (a) (pyPh2t)PtCl2 (3) and (b) [(pyPh2t)2Pt](BF4)2 (8). Thermal
ellipsoids are drawn with 50% probability.
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Figure 2.5 Distortions in bipyridyl ligands: (a) in-plane, (b) twist, and (c) bowing.
2.3.1.1 Structures of LPtCl2
•

Coordination Parameters. The size of the group on the C(1) and C(2) positions

has little effect on the coordinated bond distances and angles (Table 2.2). The Pt−Cl or Pt−N(py)
bond distances found for 1, 2, and 3 are not significantly different from those in the structure of
(4,4′′-Me2bipy)PtCl2 (work in progress). All three LPtCl2 complexes and (4,4′′-Me2bipy)PtCl2
have comparable N–Pt–N bite angles. For 1 and 3, in which the Pt−N distances are more
precisely determined, the Pt−N(py) bond (Pt−N(4)) is slightly longer than the Pt−N(t) bond
(Pt−N(1)) (Table 2.2). We attribute this apparently slightly smaller Pt−N(t) bond to an attractive
interaction of the positive Pt center with the lone pair on N(2), the triazine N bound to N(1). In
contrast, the hydrogen on the C(8) atom of the pyridine ring (in the position corresponding to
N(2)) will have a repulsive interaction with the positive Pt center.
In 1, 2, and 3, the cis N(t)–Pt–Cl(2) angle is significantly larger than the cis N(py)–Pt–
Cl(1) angle. There is a slight attractive interaction between Cl’s cis to a pyridyl ring and the
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nearby pyridine ring H atom (labeled A, Figure 2.6). The repulsion (labeled R, Figure 2.6)
between the lone pair on N(2) and the cis Cl creates a larger than normal N–Pt–Cl angle. The
apparent net effects of the non-bonding interactions involving the lone pair are a shorter Pt–N(t)
bond and a wider cis N(t)–Pt–Cl angle.

Figure 2.6 Attractive and repulsive interactions in LPtCl2 and (bipy)PtCl2.
•

Bidentate Ligand Parameters. Distortions in the ligand (Figure 2.5) will occur if

the M−N distance is typical (~2.0 to 2.2 Å).33 Because the distances of the C3H and C3′H atoms
of bipyridines (Figure 2.5) to the C3′ and H3′ atoms and the C3 and H3 atoms on the other ring,
respectively, are less than the sum of the van der Waals radii,35 it has been suggested that the
resulting repulsive interactions (labeled R, Figure 2.6) cause distortions.32,33 The difference in
two exocyclic angles (C(5)–C(4)–C(3) and N(4)–C(4)–C(3), see Figure 2.4) of the pyridine ring
can be used as a simple means for estimating the in-plane bending (Figure 2.5).33 The differences
in these two angles for (4,4′′-Me2bipy)PtCl2 are comparable to the differences for LPtCl2
complexes (Table 2.2), although for LPtCl2 complexes the hydrogen on the pyridyl C ortho to the
bridging carbons and the lone-pair-bearing triazine N(3) (in 3, Figure 2.4, the H(5) to N(3)
distance = 2.630 Å, and the C(5) to N(3) distance = 2.900 Å) should create a slight favorable
attractive interaction (labeled A, Figure 2.6). Therefore, any stress due to H3-H3′ repulsion in
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(4,4′′-Me2bipy)PtCl2 does not lead to an apparent substantial effect on the in-plane bending.
However, this repulsion could account for the slight twisting or bowing in (4,4′′-Me2bipy)PtCl2
compared to the minimal distortions found for the three LPtCl2 complexes (Figure 2.7).

Figure 2.7 In-plane views of the two rings in bipyPtCl2 (left) and LPtCl2 (right).
2.3.1.2 Structure of [(pyPh2t)2Pt](BF4)2 (8)
•

Coordination Parameters. The ORTEP drawing for 8 appears in Figure 2.4. The Pt–

N(py) bond length (2.050(3) Å) in 8 is similar to the Pt–N(py) bond length (2.032(3) Å) in [(4,4′′Me2bipy)2Pt](BF4)2 (work in progress), but it is significantly longer than the Pt–N(t) bond
distance (2.019(3) Å) in 8 (Table 2.2). The reason for the shorter Pt–N(t) bond distance was
suggested above. The N–Pt–N bite angle in 8 is similar to that in [(4,4′′-Me2bipy)2Pt](BF4)2.
These N–Pt–N bite angles are slightly smaller than those for LPtCl2 (Table 2.2). The Pt–N bond
distances in 8 are larger than the corresponding bond distances in 3.
•

Relative Bidentate Ligand Relationships. The ligand distortion due to in-plane bending

for [(pyPh2t)2Pt](BF4)2 (8) was less than that for [(4,4′′-Me2bipy)2Pt](BF4)2 but comparable with
those of LPtCl2 (Table 2.2). For bipyridine complexes with ~2 Å M–N distances, the strain
induced by the close approach of the hydrogen atoms of opposing ligands can be reduced by two
different types of distortions. First, a tetrahedral deformation at the metal can occur, resulting in
the ligands being canted relative to each other (Figure 2.8). Second, the ligand rings can be
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bowed away from the ring directly across (Figure 2.8).32,33,36 The opposing ligands in [(4,4′′Me2bipy)2Pt](BF4)2 are bowlike distorted (Figure 2.9), while canting of the two ligands occurs in
[(2,2′′-bipy)2Pt](NO3)2.33 In contrast, for [(pyPh2t)2Pt](BF4)2 (8) the platinum lies on an
inversion center, and the coordination geometry is totally planar and symmetrical (Figure 2.9). In
[(4,4′′-Me2bipy)2Pt](BF4)2 the distances found between the H6 (H on the C ortho to the N, Figure
2.5) and the opposing C6 of the other ligand are 2.557 and 2.597 Å. For [(pyPh2t)2Pt](BF4)2 (8),
in contrast, the distance between the related pyridyl proton (H(8), Figure 2.4) and the opposing
triazine non-bonded N(2) of the other ligand is 2.160 Å. The unusually small distance suggests a
possibility of two weak favorable H⋅⋅⋅N interactions between the two opposing pyPh2t ligands of
8. Thus, the metal center exhibits no distortion.

Figure 2.8 Canting (a) and bowing (b) of the two bipyridyl ligands with respect to each other in
[(bipy)2Pt]X2.

Figure 2.9 Side view of [(bipy)2Pt]X2 (left) and [(pyt)2Pt]X2 (right).
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2.3.2 NMR Spectroscopy
As mentioned, both the reaction of ferene with cis-Pt(Me2SO)2Cl2 and the resulting
products are difficult to assess by 1H NMR spectroscopy because of many overlapping signals.
Also, simpler 3-(pyridin-2′-yl)-1,2,4-triazines (L) analogues which form LPtCl2 and [L2Pt]2+
complexes with less complicated spectra have not been studied. Hence, we have investigated by
1

H NMR spectroscopy the formation and properties, such as degree of solvolysis, of these

simpler ptt compounds. We use the standard numbering system for these L (Figure 2.1).
Reactions of L (20 mM) with cis-Pt(Me2SO)2Cl2 (5 mM) in DMSO-d6 were monitored
with time until no further changes were observed. The H6′ doublet was usually observed between
~9.3 to 9.6 ppm within ~1 h of mixing. After ~1 day, a weaker doublet appeared farther
downfield (~10.0 to 10.2 ppm). (These findings are consistent with the ferene results: H6′
doublet at ~9.6 ppm for [(ferene)PtCl2]2- and at ~10.7 ppm for [(ferene)2Pt]2-).13 Addition of
[NEt4]Cl caused an increase in the intensity of the doublet between 9.3 and 9.6 ppm, and the
disappearance of the more downfield doublet (~10 to 10.2 ppm), indicating that these are signals
of LPtCl2 and [L2Pt]2+, respectively.
For all L, [L2Pt]2+ did not form completely and was less abundant than LPtCl2 in DMSOd6, even with a threefold excess of L. In order to form bis product exclusively, D2O (10% by
volume) was added to a separate solution of L and cis-Pt(Me2SO)2Cl2 (in a 4:1 ratio). After ~1 h
the [L2Pt]2+ signals were the only bound L signals present. The greater solvation of the chloride
ions in D2O compared to that in DMSO-d6 facilitates the formation of bis complexes. The
reaction of pyMe2t with cis-Pt(Me2SO)2Cl2 described in the Supporting Information provides a
detailed set of results that are representative of studies with other L.
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2.3.2.1 [(MepyMe2t)Pt(Guo)2]2+ Characterization. Within 30 min of mixing
(MepyMe2t)PtCl2 and Guo in a 1:2 molar ratio in a D2O/DMSO-d6 solution at pH = 4.60 at 25
°C, the [(MepyMe2t)Pt(Guo)2]2+ adduct was formed. The adduct has H8 signals at ~8.7 to 8.9
ppm, downfield from the free Guo H8 signal at 8.11 ppm, indicating that Guo is bound to Pt via
N7. Two guanine base arrangements HH (Head-to-Head) and HT (Head-to-Tail) are possible for
[LPt(Guo)2]2+ type adducts. Three rotamers (HH, ∆HT, ΛHT) may be observed when L = a
symmetrical bidentate ligand, whereas four rotamers (HHa, HHb, ∆HT, ΛHT) are possible when
L = an unsymmetrical bidentate ligand (Figure 2.10).

Figure 2.10 Possible base orientations of two cis guanine bases coordinated to Pt. Each arrow
represents a guanine base (bottom). The platinum carrier ligand is to the rear; when it is
unsymmetrical (N1 ≠ N2), there are two HH conformers. Rotation of one base about the Pt–N7
bond leads to another conformer, but in each case the base orientation changes from HT to HH
and vice-versa. When the carrier ligand has unsymmetrical bulk, it is possible that on the NMR
time scale the base next to the bulky side of the carrier ligand does not rotate quickly, whereas
the other base rotates rapidly. For example, the ∆HT conformer would interchange rapidly with
the HHa conformer if the base next to N1 rotated slowly while the base next to N2 rotated
readily. In contrast, the ∆HT conformer would form the HHb conformer only slowly.
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The symmetry of the carrier ligand influences not only the number of conformers but also
the number of sets of Guo signals detectable for each [LPt(Guo)2]2+ rotamer. For a non-bulky L,
rotation about the Pt–N7 Guo bond is very fast on the NMR time scale; the rapid equilibration of
rotamers in this case leads to one set or two sets of Guo NMR signals for [LPt(Guo)2]2+ adducts
with symmetrical and unsymmetrical L, respectively. Bulky carrier ligands restrict the rotation of
Guo about the Pt–N7 bond sufficiently to allow detection of different rotamers by NMR
spectroscopy.21,37-43 Because the Guo H8 signals are downfield, they can be particularly
informative for assessing the nature and distribution of rotamers. For an [LPt(Guo)2]2+ adduct
with an unsymmetrical L, the four rotamers should give two and eight H8 signals for rapidly and
slowly exchanging conformers, respectively.
For [(MepyMe2t)Pt(Guo)2]2+, three bound Guo H8 signals were present (Figure 2.11):
two H8 signals of comparable intensity at 8.90 and 8.87 ppm (integrating to a total of one proton)
and another larger H8 signal upfield at 8.75 ppm (integrating to a single proton). The observation
of three H8 signals (not two for fast or eight for slow isomerization) suggests the occurrence of a
complicated equilibration process between rotamers and/or an intermediate exchange rate.
The most likely process accounting for the three signals is rapid rotation of a Guo in one
of the coordination positions and slow rotation of the other Guo. This situation would give two
pairs of HT and HH conformers that interchange within the pair but not between pairs. In this
case, the presence of three H8 signals with one large (the upfield H8) signal requires an overlap
of two of the four expected H8 signals. The upfield Guo H8 signal could not be resolved, even at
-4.0 °C. However, when the pH was raised to 7.75, four distinct H8 peaks of comparable
intensity were observed at 8.88, 8.86, 8.71 and 8.68 ppm (Figure 2.11). At this pH the N1H of
coordinated Guo is deprotonated, resulting in greater dispersion of H8 signals, but less dispersion
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for the H1' signals, which all overlap. However, at pH 4.60 there are two H1' signals. One H1'
signal (at 6.06 ppm, for one Guo) is one-third as large as the other, overlapped H1' signal (at 6.04
ppm, for three Guo). Thus, results for both H8 and H1' signals at both pH’s support the presence
of four different Guo’s in two sets of similarly abundant HT/HH pairs.

Figure 2.11 Aromatic and H1′ signals of the 1H NMR spectrum of the [(MepyMe2t)Pt(Guo)2]2+
adduct in D2O/DMSO-d6 solution at pH 4.60 (top) and pH 7.75 (bottom) at 25 °C. Numbers are
taken from the numbering system in Figure 2.1 for L and are shown in Figure 2.10 for Guo.
Extensive studies in which both the symmetrical carrier ligand and the guanine derivative
(G) were varied systematically indicate that, for a given adduct, the HT rotamers (in total) are
favored over the HH rotamer(s) (in total).44 Although the reasons for this observation are not
fully understood, the most compelling explanations are that base dipole-dipole alignment favors
the HT over the HH arrangement of guanines and that clashes between the exocyclic O6 on each
guanine in the HH arrangement disfavor the HH rotamer. When G is a GMP, additional
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complications arise, increasing the abundance of the HH form in some cases, but in general Guo
adducts have a particularly low amount of the HH rotamer.21,41,43 In a previous study of
[LPtG2]2+ adducts with an unsymmetrical L, 2-aminomethylpiperidine (pipen), four H8 signals
were observed for each adduct,45,46 as found here. The results were interpreted as indicating that
each pair of H8 signals arose from a rapidly interchanging pair of conformers, ∆HT/HHa and
ΛHT/HHb (Figure 2.10), with the HT form dominating. In the pipen case, the amino group
allows rapid rotation of the cis G, whereas the piperidine ring hinders rotation of the cis G.45,46
The properties of the [(MepyMe2t)Pt(Guo)2]2+ adduct at pH 7.75 were explored further
by using 2D NMR spectroscopy. An additional equivalent of Guo was added to ensure that all
the Pt compound was consumed prior to a ROESY experiment, which allows us to probe the
exchange processes and the through-space interactions between Guo and the MepyMe2t ligand.
Neither NOE nor EXSY cross-peaks were observed between the H8 signals. An HH conformer
would give an H8-H8 NOE cross-peak, and even for a rapid HT/HH equilibrium, a cross-peak
would be found if either HT/HH pair had a significant amount of the HH conformer. The four
[(MepyMe2t)Pt(Guo)2]2+ H8 signals thus reflect mainly the two HT conformers, ∆HT and ΛHT,
present in a nearly 1:1 ratio. The H8 NMR signals of the HH conformer were not detectable,
indicating a more rapid rate of rotation about the Pt–N7 bond for one Guo in
[(MepyMe2t)Pt(Guo)2]2+, a result more similar to that found for (pipen)PtG2 adducts45,46 than
for

(5,5′′-Me2bipy)PtG2

adducts21

and

(Me2ppz)PtG2

adducts41

(Me2ppz

=

N,N′-

dimethylpiperazine).
NOE cross-peaks in the [(MepyMe2t)Pt(Guo)2]2+ ROESY spectrum between the Guo H8
at 8.86 ppm and the pyridyl H6′ doublet at 7.96 ppm and between the Guo H8 singlet at 8.88
ppm and the pyridyl H6′ doublet at 7.94 ppm indicate that the two most downfield H8 signals
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belong to the Guo bound cis to the pyridyl ring. The more upfield H8 signals, at 8.71 and 8.68
ppm, belong to the Guo bound cis to the triazine ring.
Compared to the signals of [(MepyMe2t)Pt(Me2SO-d6)Cl]+ in D2O/DMSO-d6 at pH 4.60,
the H5′ (7.76 ppm) and H3′ (8.60 ppm) signals of the [(MepyMe2t)Pt(Guo)2]2+ adduct at pH
4.60 shifted only slightly upfield and downfield, respectively. In contrast, the H6′ doublets at
8.04 and at 8.00 ppm (integrating to a total of one proton) for this adduct were shifted upfield by
~1.26 ppm from the H6′ signal at 9.28 ppm of [(MepyMe2t)Pt(Me2SO-d6)Cl]+. The anisotropy
of the cis-coordinated guanine base is responsible for these large upfield shifts. These shifts and
the H8-H6′ NOE cross-peaks leave no doubt that the guanine in the adduct is positioned very
close to H6′. Two considerations [a) the pyridyl H6′ proton is known to hinder the rate of
rotation about the Pt–N7 Guo bond,21 and b) two upfield-shifted H6′ signals are resolved for the
[(MepyMe2t)Pt(Guo)2]2+ adduct] leave no doubt that the slowly rotating Guo is cis to the pyridyl
ring and that the Guo cis to the triazine ring is in fast rotation. Otherwise, the H6′ doublets would
probably be time averaged.
2.4 Conclusions
Regardless of the presence of various exocylic groups, 3-(2′-pyridyl)-1,2,4-triazine
ligands are excellent bidentate sp2 N-donors and form both LPtCl2 and [L2Pt]2+ complexes. The
juxtaposition of the pyridyl H6′ proton and the triazine lone pair of electrons in [L2Pt]X2 allows
formation of a planar structure. Also, this juxtaposition favors the trans arrangement of the
bidentate ligands in [L2Pt]X2. The ligands prefer to bind via only the N2 of the triazine ring. No
evidence was found for isomers having N4 coordinated to Pt. Very likely this result arises from
the effect of the group ortho to the bound N. For a given bidentate ligand, the interactions
between the juxtaposed groups on the two rings ortho to the bridging carbons and on the
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periphery of the bidentate ligand are favorable for 3-(2′-pyridyl)-1,2,4-triazine ligands but
unfavorable for 2,2′-bipyridines. This favorable factor would be present if the triazine ring binds
to metals via either N2 or N4. For N2 binding, the N1 lone pair is readily accommodated
sterically, but the substituent on C5 would create steric clashes if metal binding were to occur via
N4. Thus, the observation that only N2 binding was detected can be understood. When combined
with the X-ray structural results, the H6′ NMR spectral shifts of the complexes containing the
L’s examined here establish that the structures of virucidal ptt compounds containing ferene
proposed earlier were correct.13
The dynamic properties of the[(MepyMe2t)Pt(Guo)2]2+ adduct indicate that the lone pair
on the non-bonded nitrogen, N1, of the triazine ring is not sterically demanding. This lone pair
does not strongly impede the rotation of Guo about the Pt–N7 bond, whereas the equivalently
placed CH group of the pyridyl ring does impede rotation. This behavior and the structural data
all point to a lower overall steric effect of the N2-metal-bound triazine ring compared to the
metal-bound pyridine ring. Dynamic behavior similar to that of the [(MepyMe2t)Pt(Guo)2]2+
adduct has been well documented previously only in the case of pipen complexes.45,46
Our result that Guo did not add to [(MepyMe2t)2Pt]2+ suggests the possibility that the
virucidal activity of the LPtCl2 and the [L2Pt]2+ ptt agents arises, respectively, from covalent and
non-covalent (possibly intercalative nucleic acid interactions favored by [L2Pt]2+ planarity)
binding to biomolecular targets. These results suggest that the relatively neglected 3-(2′-pyridyl)1,2,4-triazine ligands should be examined more widely in coordination chemistry.
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CHAPTER 3. NEGLECTED BIDENTATE sp2 N-DONOR CARRIER LIGANDS WITH
TRIAZINE NITROGEN LONE PAIRS. PLATINUM COMPLEXES RETROMODELING
CISPLATIN GUANINE NUCLEOBASE-ADDUCTS*
3.1 Introduction
Cisplatin (cis-Pt(NH3)2Cl2) is one of the most widely used anticancer drugs.1,2 Cisplatin
and its analogues, LPtX2 models (L = one bidentate or two cis-unidentate N-donor carrier
ligands), interact with DNA by forming a 1,2-intrastrand N7–Pt–N7 crosslink between two
adjacent guanines of d(GpG) sequences in DNA.1-6 The cross-links formed by cisplatin (and its
analogues) have been investigated and identified from X-ray structures,1,3 NMR spectroscopy,1,3
and enzyme digestion studies.2,3,5
Within the cross-link adduct, hydrogen bonding between the NH3 ligands of the cisPt(NH3)2 moiety and residues in or near the cross-link has been an important component of
hypotheses concerning both the mode of stabilization of distorted DNA induced by drug
binding.7-12 However, examination of an X-ray structure of an HMG-bound 16-oligomer13 and an
X-ray/NMR-derived model of a duplex 9-oligomer,14 both of which contain an intrastrand
cisplatin lesion, suggests that hydrogen-bonding interactions involving the NH3 ligands are weak
or even nonexistent. If the NH3 ligands are replaced by L carrier ligands having sp3 N atoms
bearing two or more alkyl groups, modeling with the 9-mer structure suggests that clashes will
occur.14 These results on duplex models have led to the hypothesis that the small size of the NH
group, not its hydrogen-bonding ability, facilitates the anticancer activity of Pt compounds
bearing multiple NH groups.15
A degree of uncertainty exists in defining the structure of duplexes bearing Pt drug
lesions.15,16 Relatively few X-ray structures are available,13,15,17 and NMR characterization is
____________________________________________________________________________
* Contents of this chapter are under review by American Chemical Society.
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because the carrier ligands in cisplatin are not bulky enough to impede the rotation of N7-bound
guanine about the Pt–N7 bond.16,18 Thus, cisplatin adducts with nucleic acids and their
constituents exist as a fluxional mixture of conformers, making elucidation of the structures in
the solution state difficult; this complication is termed the dynamic motion problem.14,16,18,19

Figure 3.1. Line drawing and numbering scheme for 5,5′-dimethyl-2,2′-bipyridine (5,5′′Me2bipy) (top), 3-(4′-methylpyridin-2′-yl)-5,6-dimethyl-1,2,4-triazine) (MepyMe2t) (bottom
left), and bis-3,3′-(5,6-dialkyl-1,2,4-triazine) (R4dt) (bottom right) ligands.

Figure 3.2. Possible base orientations of two cis guanine bases coordinated to Pt. Each arrow
represents the base with the H8 atom at its head. In all cases, two HT conformers are possible.
Two HH conformers are possible when L (to the rear) is unsymmetrical (N′ ≠ N, e.g., as in
MepyMe2t, N′ = pyridyl N and N = triazine N, see below), but only one HH conformer is
possible when L is symmetrical (N′ = N). Each rotation of one base about the Pt–N7 bond leads
to changes in the relative base orientation from HT to HH, or vice-versa.
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To overcome the dynamic motion problem, a retro-modeling approach can be used by
introducing features in the carrier ligand to make the spectral properties more informative.14,19-22
Retro models are essentially analogues of cisplatin with carrier ligands designed to reduce the
dynamic motion by destabilizing the transition state for Pt–N7 rotation, but having bulk in or
near the coordination plane, thereby allowing the coexistence of multiple conformers. In this
study, we compare the LPt(GMP)2 adducts containing the L depicted in Figure 3.1. For an LPtG2
adduct (G = guanine derivative not linked by a phosphodiester group), the G bases can have
head-to-tail (HT) or head-to-head (HH) orientations (Figure 3.2). The untethered G’s normally
adopt preferentially an HT orientation,16,23 whereas the bases in d(GpG) cross-links having a
sugar phosphate backbone are found most often in the HH orientation, especially when a 5′
residue is present.6,19,24-31
In order to gain a better understanding of a number of fundamental factors influencing
properties of LPtG2 adducts, we must know the effect of the carrier-ligand interactions with the
nucleic acid constituents (bases, sugars, etc.). These interactions, present in very small adducts,
also occur in larger models, including duplexes. However, they can be more difficult to assess in
the larger adducts, particularly because larger adducts manifest additional interactions involving
both flanking residues in the cross-link strand and residues in the complementary strand. Retro
models with sp3 N-donor ligands have been investigated more often16,19-21,32 than those with sp2
N-donor heterocyclic chelating ligands.
Studies

of

LPt(Guo)2

complexes

(L

=

2,9-dimethyl-1,10-phenanthroline,33

MepyMe2t;34 Guo = guanosine) and (5,5′′-Me2bipy)Pt(d(GpG))22 have demonstrated the
coexistence of different rotamers exchanging slowly relative to the NMR time scale. In cisplatin
intrastrand cross-linked DNA adducts, the dominant conformer appears to have the guanines in a
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HH orientation.21 For most LPtG2 adducts, the HH conformers are minor conformers, when
compared to the HT conformers, and are favored more in the 5′-GMP adduct than in the
corresponding 3′-GMP adduct.19,20,30,31,35 When the L carrier ligand is unsymmetrical, two HH
conformers are possible (Figure 3.2). However, in all previous work, even with the 5′-GMP
adducts, it was not possible to assign the HHa and HHb conformers (Figure 3.2). The
(MepyMe2t)Pt(5′-GMP)2 adduct studied here allowed, for the first time, the determination of the
conformation of two such HH conformers.
3.2 Experimental Section
3.2.1 Starting Materials

Figure 3.3 Synthesis of bis-3,3′-(5,6-dialkyl-1,2,4-triazine) (R4dt) ligands.
5′-GMP, 3′-GMP (Sigma), and 5,5′′-Me2bipy (Aldrich) were used as received. cisPt(Me2SO)2Cl2 was prepared as described in the literature.36 The syntheses of (5,5′′Me2bipy)PtCl2 and (MepyMe2t)PtCl2 are described elsewhere.22,34,37 Bis-3,3′-(5,6-dialkyl-1,2,4triazine) (R4dt, R = Me or Et) ligands were prepared by a known method38 (Figure 3.3).
Elemental analyses (C,H,N) were performed by Atlantic Microlabs, Atlanta, GA.
3.2.2 NMR Measurements
1

H NMR spectra were recorded on a Bruker spectrometer operating at 400 MHz. We used

the values of 0.00, 4.78, and 4.98 ppm to reference signals to TMS in DMSO-d6 solutions at 25
°C and to the residual HOD signal at 25 °C and 5 °C in D2O/DMSO-d6 solutions, respectively. A
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presaturation pulse to suppress the water peak was used when necessary. 2D ROESY
experiments39 were performed at 5 °C by using a 500 ms mixing time (128 scans per t1
increment). ROESY and 1D NMR data, processed with XWINNMR or Mestre-C software, were
used to assign signals and (along with CD data) to assess the conformation of the adducts under
various pH conditions. DNO3 and NaOD solutions (0.1 M in D2O) were used to adjust the pH of
D2O/DMSO-d6 solutions, especially during the reactions in which the pH decreased with time.
3.2.3 Circular Dichroism (CD) Spectroscopy
All samples used for CD experiments were prepared from the respective NMR samples
by diluting to ~0.025 mM Pt with deionized water. Spectra were recorded from 400 to 200 nm at
a scan speed of 50 nm/min on a JASCO J-600 CD spectropolarimeter. Six scans were recorded
and averaged for each sample.
3.2.4 Synthesis of (R4dt)PtCl2 Complexes
The (R4dt)PtCl2 complexes were obtained as yellow precipitates upon heating a methanol
solution (10 mL) of cis-Pt(Me2SO)2Cl2 (42.2 mg, 0.1 mmol) and the desired R4dt ligand (0.1
mmol) at 60 °C for 6 h. The precipitates were collected, washed with diethyl ether, followed by
chloroform, and then dried in vacuo.
3.2.4.1 (Me4dt)PtCl2. The method described above afforded a yellow precipitate; yield,
26.5 mg (55%). 1H NMR (ppm) in DMSO-d6 : 2.62 (s, 5-CH3), 2.81 (s, 6-CH3). Anal. Calcd for
C10H12Cl2N6Pt·1/3(H2O): C, 24.58; H, 2.59; N, 17.21. Found: C, 24.66; H, 2.69; N, 16.91.
3.2.4.2 (Et4dt)PtCl2. The product was obtained as a yellow powder; yield, 36.1 mg
(67%). 1H NMR (ppm) in DMSO-d6: 3.20 (quartet, 6-CH2), 2.96 (quartet, 5-CH2), 1.30-1.41 (m,
5,6-CH3). X-ray quality crystals were obtained by mixing equal volumes of 10 mM solutions of
cis-Pt(Me2SO)2Cl2 (8.44 mg, 10 mM) and the Et4dt ligand (5.44 mg) in 2 mL of acetonitrile and
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allowing this solution to stand at 25 °C. Thin yellow needles of (Et4dt)PtCl2 were obtained in
~25% yield after 24 h. The structure was determined by X-ray diffraction.
3.2.5. Formation of LPt(GMP)2 (L = 5,5′′-Me2bipy, MepyMe2t, Me4dt, Et4dt and GMP = 5′′and 3′′-GMP)
A typical preparation of LPt(GMP)2 involved mixing a solution containing ~2 equiv of
GMP dissolved in 350 µL of D2O at pH ~4 and a solution containing 1 equiv (~5 mM) of LPtCl2
complex in 250 µL of DMSO-d6 to give a 1:2 ratio of Pt:GMP, and the mixture (pH ~4) was kept
at 25 °C. The mixture of D2O and DMSO-d6 solutions was employed to improve the solubility of
the LPtCl2 complex. The solution was monitored by 1H NMR spectroscopy until no change in
the bound vs. free H8 signal intensity was observed. The LPtCl2 complex in a D2O/DMSO-d6
mixture forms a solvated complex that always remained in small amounts, along with some free
GMP.
3.3 Results and Discussion
3.3.1 Conformational Assignments and Conformer Properties
The asymmetry of the G ribose residue and the local symmetry of the LPt moiety
influence the number of NMR signals that can be observed for each LPtG2 conformer. 1H NMR
spectra in the ribose region are very crowded and complex, especially for adducts with
unsymmetrical carrier ligands. The downfield G H8 signals, in a less crowded, more disperse
region of the spectra, are particularly useful for assessing the nature and distribution of
conformers (Figure 3.2). Because the G bears a chiral ribose moiety, LPtG2 adducts with C2symmetrical carrier ligands (e.g., Me4dt, Et4dt) have one HH and two HT (∆HT and ΛHT)
NMR-distinguishable conformers (maximum total of four H8 signals), and models with
unsymmetrical carrier ligands (e.g., MepyMe2t) have two HH (HHa and HHb) and two HT (∆HT
and ΛHT) conformers (maximum total of eight H8 signals). The conformation and signal
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assignments of the HH atropisomers are based on the presence of NOE cross-peaks between the
two H8 signals.
At pH 6-7 for LPt(GMP)2 adducts, the phosphate group is deprotonated and N1 is
protonated,40,41 creating the possibility of H-bonding between the phosphate group and the imino
hydrogen (N1H) of the cis GMP. This interligand interaction is called “second-to-second sphere
communication” (SSC) because the interacting groups are at the periphery of the cis
nucleotides.21,42,43 Such SSC interactions have been identified as important factors stabilizing the
ΛHT and ∆HT conformers of the Pt adducts of 5′-GMP and 3′-GMP, respectively.35 The CD
signal shape provides a definitive means for assigning the chirality of the major HT form of
LPtG2 complexes when that form clearly dominates. A CD signal shape having a positive feature
at ~290 nm and a negative feature at ~256 nm is characteristic of the ΛHT LPtG2
conformer,21,31,32,42,44 whereas a CD signal shape having a negative feature at ~290 nm and a
positive feature at ~256 nm is characteristic of the ∆HT conformer of LPtG2 adducts.31,32,42,45
The CD signal of HH conformers is generally weak, a feature attributable to the inherent
symmetry of the base chromophore, with the two bases having a pseudo mirror relationship in
HH conformers.
3.3.2 H8 Shifts and Base Canting
In addition to the HH or HT G base orientation, G base canting is another significant
structural parameter of LPtG2 conformers. A given base is generally not oriented with its plane
exactly perpendicular to the coordination plane, but is canted. The canting can be either lefthanded (L) or right-handed (R) (Figure 3.4). Useful indications for assessing the degree of G
base canting are provided by the G H8 signal shifts.14 The H8 shift is influenced by the
positioning of the H8 atom with respect to the shielding cone of the cis G base. In an HT
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arrangement, the canting may move the six-membered rings either closer to the midpoint
between the N7 atoms (‘6-in’ form) or farther from this midpoint (‘6-out’ form). The canting of
the bases in the direction (‘6-out’ form) that moves each H8 toward the cis G will lead to greater
H8 shielding and, hence, an upfield H8 signal relative to the average H8 signal. The minor HT
conformer typically is ‘6-out’. In contrast, the canting of the base that moves its H8 away from
the cis G will lead to less H8 shielding or perhaps deshielding in the HT form26 and thus a more
downfield H8 signal. The major HT conformer typically is ‘6-in’.

Figure 3.4 Shorthand representation for left-handed (L) (a, c) and right-handed (R) (b, d) canting
for LPtG2 adducts. In the ∆HT conformer shown (a, b), L and R canting have the six-membered
ring far from the C2 axis for L canting (‘6-out’) and close to the axis for R canting (‘6-in’). For
the ΛHT conformer (not shown), the arrows are all rotated by 180°. The HH conformer can be
left-handed (c), right-handed (d) or not canted (e).
For the HH orientation, one base is typically more canted, with its H8 toward the other cis
base, which is less canted.19,30,31 The H8 atom of the more canted G is closest to the shielding
region of the cis G and has a relatively upfield H8 signal (HHu). The H8 signal of the less canted
base is relatively downfield (HHd) because this H8 is farthest from the cis G base shielding
region and may be in the deshielding region of this base.31,43 Typically the HHu and HHd H8
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signals are separated by ~1 ppm and straddle the HT H8 signals. In less common cases, the HH
bases are not canted and the two signals are relatively downfield.
3.3.3. (5,5′′-Me2bipy)Pt(5′′-GMP)2

Figure 3.5 Aromatic region of 1H NMR spectra of (5,5′-Me2bipy)Pt(5′-GMP)2 (top) and (5,5′Me2bipy)Pt(3′-GMP)2 (bottom) at pH ~ 4.0 and 25 °C. The H8 signals for the conformers are
designated by the conformation. (Pyridyl H6′ signals attributed to the solvated Pt complex are
indicated by asterisks.)
Four new H8 signals of the (5,5′-Me2bipy)Pt(5′-GMP)2 adduct downfield from the free
5′-GMP H8 signal at 8.22 ppm were observed at 25 °C (Figure 3.5). When the pH was raised
from 4.0 to 7.5, the H8 signal at 8.81 ppm shifted slightly upfield by 0.02 ppm and became the
most dominant signal. The CD signal shape observed for this adduct at pH 7.5 is characteristic of
the ΛHT conformer (Figure 3.6). For the 5′-GMP adducts, the ΛHT conformer is more favored
by SSC upon phosphate deprotonation;16 therefore, the dominant H8 signal of the (5,5′Me2bipy)Pt(5′-GMP)2 adduct was assigned to the ΛHT conformer. The intensity of the H8
signals at 9.11 and 9.01 ppm (pH 4.0) remained comparable throughout the pH titration. These
H8 signals shifted downfield by ~0.11-0.14 ppm when the pH was increased to 7.5. The two H8
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signals were connected through an NOE cross-peak in a ROESY spectrum collected at 5 °C and
were thus assigned to the HH conformer. The signal at 8.77 ppm was assigned to the ∆HT
conformer, the only remaining possible conformer. The H8 chemical shifts at pH 4.0 and 7.5 are
listed in Table 3.1. From pH 4.0 to 7.5, the distribution of the ΛHT, ∆HT and HH conformers
changed from 42%, 29%, and 29% to 58%, 23%, and 18%, respectively.

Figure 3.6 CD spectra of (5,5′′-Me2bipy)Pt(5′-GMP)2 and (5,5′-Me2bipy)Pt(3′-GMP)2 at 25 °C.
The H8 signals of the HH conformer of the (5,5′-Me2bipy)Pt(5′-GMP)2 adduct have low
dispersion (0.10 ppm) and both are relatively downfield when compared to the HT H8 signals. A
similar unusual H8 shift pattern was reported for the HH conformer of the (Me2ppz)Pt(5′-GMP)2
adduct (Me2ppz = N,N′-dimethylpiperazine) and was attributed to a low degree of base canting.21
The H8 signals of the (5,5′-Me2bipy)Pt(5′-GMP)2 HH conformer have a downfield shift because
the two bases have relatively little canting, and as a result H8 experiences less shielding by the
cis G and possibly greater deshielding by the anisotropic Pt atom.35,46-48 For the (5,5′Me2bipy)Pt(5′-GMP)2 adduct, the H8 signal of the major ΛHT conformer is downfield to that of
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the minor ∆HT conformer. In typical cases for the HT conformers, the ‘6-in’ form is favored.20,49
The H8 signal of the ‘6-in’ form is downfield because the H8 atoms are positioned away from the
cis base, while the H8 signal of the ‘6-out’ form is upfield because the H8 signals of the two
bases are shielded by the cis base. For the (5,5′-Me2bipy)Pt(5′-GMP)2 adduct, the major ΛHT
conformer is the ‘6-in’ form, thus L canted, and the minor ∆HT conformer is the ‘6-out’ form
with L canting (Figure 3.4).
Table 3.1 Chemical Shifts of the H8 Signals of LPt(GMP)2 Adducts (L = 5,5′-Me2bipy, Et4dt,
Me4dt) at 5 °C a
complex

pH

∆HT

ΛHT

HHd

HHu

(5,5′-Me2bipy)Pt(5′-GMP)2b

4.0

8.77

8.81

9.11

9.01

7.5

8.72

8.79

9.25

9.12

4.0

8.88

8.76

c

c

7.5

8.87

8.75

c

c

4.0

9.06

8.96

9.18

8.83

7.5

9.04

8.99

9.37

8.96

4.0

9.01

8.87

c

c

7.5

9.01

8.88

c

c

4.0

9.08

8.96

9.10

8.66

7.0

9.06

8.95

9.27

8.74

4.0

8.85

8.83

c

c

7.0

8.89

8.92

c

c

(5,5′-Me2bipy)Pt(3′-GMP)2b

(Et4dt)Pt(5′-GMP)2

(Et4dt)Pt(3′-GMP)2

(Me4dt)Pt(5′-GMP)2

(Me4dt)Pt(3′-GMP)2

a

Subscripted letters d and u are used to distinguish the downfield and the upfield H8 signals,
respectively. Signal assignments are based on the 2D NMR and pH titration studies. b NMR
spectrum recorded at 25 °C. c Signal not detected.
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The absence of H8–H8 EXSY cross-peaks in the ROESY spectrum of (5,5′Me2bipy)Pt(5′-GMP)2 indicates that interconversion between the rotamers is slow. Rotation is
probably impeded by the steric effect of the pyridyl H6/H6′ atoms of 5,5′-Me2bipy, which are the
pyridyl ring atoms closest to the cis 5′-GMP’s, as evident from models and from the observation
of H8–H6/H6′ NOE cross-peaks. During rotation, the G O6 clashes with the pyridyl ring C6H. A
further indication of this proximity is the finding that the pyridyl H6/H6′ signals of the (5,5′Me2bipy)Pt(5′-GMP)2 adduct are shifted upfield by 1.0-1.4 ppm, when compared to the H6/H6′
signals (9.19 and 8.81 ppm) of the solvated Pt precursor. The anisotropy of the cis-coordinated G
base is responsible for these large upfield shifts. A similar upfield shift was observed for the
H6/H6′ signal of the [(MepyMe2t)Pt(Guo)2]2+ adduct34 and for the signals of the similarly
positioned phenanthroline (phen) protons in the [(phen)Pt(Guo)2]2+ adduct.33
3.3.4. (5,5′′-Me2bipy)Pt(3′′-GMP)2
Two H8 signals downfield to the free 3′-GMP H8 signal at 8.11 ppm were observed at 25
°C and were assigned to the HT conformers of the (5,5′′-Me2bipy)Pt(3′-GMP)2 adduct (Table 3.1
and Figure 3.5). From pH 4.0 to 7.5, the intensity of the H8 signal at 8.88 ppm increased, while
that for the H8 signal at 8.76 ppm decreased. The CD signal shape at pH 7.5 was characteristic of
the ∆HT conformer (Figure 3.6). For the 3′-GMP adducts, the ∆HT conformer is known to be
stabilized by SSC upon phosphate deprotonation (pH ~7.0).19,32,35,45 Therefore, this major H8
signal was assigned to the ∆HT conformer. The H8 signal at 8.76 ppm was assigned to the ΛHT
conformer. From pH 4.0 to 7.5, the conformation distribution of the ∆HT and ΛHT conformers
changed from 73% and 27% to 80% and 20%, respectively. The H8 signal of the major ∆HT
conformer is 0.17 ppm downfield from that of the minor ΛHT conformer. From this relationship,
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the ‘6-in’ major form is ∆HT R, and the ‘6-out’ minor form is ΛHT R (cf. Figure 3.4). Neither
NOE nor EXSY cross-peaks were observed between the H8 signals of the (5,5′′-Me2bipy)Pt(3′GMP)2 adduct. Strong H8–H6/H6′′ NOE cross-peaks at 8.06, 8.88 ppm for the ∆HT conformer
and at 7.79, 8.76 ppm were observed for the ΛHT conformer. Of particular note, the HH
conformer was not detected for this adduct, even at 5 °C, thus reinforcing the general finding that
the 5′-phosphate group stabilizes the HH conformer more than the 3′-phosphate group does.35,43
When conformer interchange is slow, the HH conformer is usually found for LPt(3′-GMP)2
adducts. For example, at pH 3.3 for the (Me2ppz)Pt(GMP)2 adducts, the amount of HH
conformer observed for the 3′-GMP adduct was small (~8%), in comparison to ~24% HH
conformer for the 5′-GMP adduct.21 The (5,5′′-Me2bipy)Pt(3′-GMP)2 adduct, in fact, presents the
first case in which no HH conformer is found for a 3′-GMP adduct with slowly interchanging
rotamers.
3.3.5. (MepyMe2t)Pt(5′′-GMP)2
Within two hours of mixing (MepyMe2t)PtCl2 with 5′-GMP in a 1:2 molar ratio at pH
∼4.0 at 25 °C, four pairs of new H8 signals downfield from the free 5′-GMP H8 signal were
present. As the pH was varied from 2.5 to 7.5, the H8 signals at 8.96 and 8.78 ppm became the
most dominant signals (Figure 3.7). A CD signal shape characteristic of the ΛHT conformer was
observed for (MepyMe2t)Pt(5′-GMP)2 at pH 7.5 and below (Figure 3.8). The CD signal intensity
was stronger at pH 7.5 than at pH 2.5, consistent with the higher stability of the ΛHT conformer
caused on phosphate deprotonation resulting from SSC.21,42,43 Thus, the larger H8 signals (at 8.96
and 8.78 ppm at pH 2.5) were assigned to the ΛHT conformer.
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Figure 3.7 Aromatic region of 1H NMR spectra of (MepyMe2t)Pt(5′-GMP)2 at pH 2.5 (bottom)
and pH 7.5 (top) at 25 °C. The H8 signals for the conformers are designated by the conformation.
(Pyridyl signals attributed to the solvated Pt complex are indicated by asterisks.)

Figure 3.8 CD spectra of (MepyMe2t)Pt(5′-GMP)2 at pH 2.5 and pH 7.5 at 25 °C.
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Figure 3.9 ROESY spectrum of the (MepyMe2t)Pt(5′-GMP)2 adduct in the aromatic region at
pH 2.5 and 25 °C. The cross-peak labeled as HHa is an NOE between the two H8 signals of the
HHa conformer. The other labeled cross-peaks are EXSY peaks between the H8 signals of two
different conformers.
Table 3.2 Chemical Shifts of the H8 Signals of (MepyMe2t)Pt(GMP)2 Adducts at 25 °C a
complex

pH ∆HT

ΛHT

∆HTd ∆HTu ΛHTd
(py)
(MepyMe2t)Pt(5′-GMP)2
(MepyMe2t)Pt(3′-GMP)2

HHa
ΛHT
u

HHb

HHad HHau HHbd

HHbu

(t)

(py)

(t)

(py)

(t)

(py)

2.5 8.96

8.83

8.96

8.78

9.08

8.71

8.94

8.88

7.5 8.962

8.814

8.958

8.807

9.31

8.91

9.23

9.10

4.5 8.95

8.84

8.89

8.74

b

b

7.5 8.89

8.81

8.89

8.74

b

b

(t)

a

The py and t notations designate G's cis to the pyridyl and triazine rings, respectively.
Subscripted letters d and u are used for downfield and upfield H8 signals, respectively. Third
decimal place subscripted numbers are used to distinguish signals with very similar chemical
shifts. Signal assignments are based on the 2D NMR and pH titration studies. b Signal not
detected.
In a ROESY spectrum of the (MepyMe2t)Pt(5′-GMP)2 adduct at pH 2.5 (where the H8
signals of this adduct were most widely dispersed), a weak NOE cross-peak present between the
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two comparably sized H8 signals at 9.08 and 8.71 ppm establishes the HH conformation (Figure
3.9 and Table 3.2). This HH conformer (assigned as HHa, see below) is the second most
abundant conformer of the (MepyMe2t)Pt(5′-GMP)2 adduct. These two HH H8 signals are well
dispersed and straddle the signals of the HT conformers, the usual H8 chemical shift
pattern.19,30,31 The remaining two pairs of H8 signals must belong to the ∆HT and HHb
conformers. However, because of the unusual properties of these conformers and the
unsymmetrical nature of the carrier ligand, we turned to a pH study to make the assignment of
conformation.
From pH 2.5 to pH 7.5 the H8 signals for the (MepyMe2t)Pt(5′-GMP)2 HHa rotamer
shifted significantly downfield by 0.23 and 0.20 ppm (Figure 3.7). Typically, a ca. 0.2 ppm
downfield shift was observed for HH rotamers20,21 upon phosphate deprotonation; this effect may
be explained by the “wrong-way shift” attributed to the higher deshielding effect of the
deprotonated phosphate group as it is positioned in the HH conformer.20,50 However, the H8
signals of the HT conformers do not shift significantly in the pH ~2-7 range.21,35,43 Consistent
with this pattern, the H8 signals of the (MepyMe2t)Pt(5′-GMP)2 ΛHT conformer shifted very
little (Table 3.2, Figure 3.7), whereas a ca. 0.2 ppm downfield shift occurred for the H8 signal of
the HH conformer of the (R4dt)Pt(5′-GMP)2 adducts discussed below.
One of the two pairs of H8 signals of the (MepyMe2t)Pt(5′-GMP)2 adduct (at 8.94 and
8.88 ppm) not assigned above shifted downfield by more than 0.2 ppm from pH 2.5 to 7.5 (Table
3.2, Figure 3.7); this pair is assigned to HHb. However, because of the low abundance of the
HHb conformer, no H8 to H8 NOE cross-peak was observed in the ROESY spectrum for the
(MepyMe2t)Pt(5′-GMP)2 adduct. The remaining pair of H8 signals shifted only slightly upfield
(Table 3.2, Figure 3.7), consistent with an assignment to the only other possible conformer, ∆HT.
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For the (MepyMe2t)Pt(5′-GMP)2 adduct, the H8 to pyridyl H6′ NOE cross-peaks can be
used to determine which H8 signal belongs to the 5′-GMP cis to the pyridyl ring and by default
which H8 signal belongs to the 5′-GMP cis to the triazine ring. Because the ∆HT and ΛHT
conformers are assigned, the orientation of the G bases relative to these ligand rings is
established for the HT conformers. The pyridyl H6′ signals of the (MepyMe2t)Pt(5′-GMP)2
adduct (overlapping at 8.0-8.1 ppm) have NOE cross-peaks to the downfield H8 signals of the
ΛHT and ∆HT conformers (overlapping at 8.96 ppm) and to the upfield H8 signals of the HHa
conformer (at 8.71 ppm) and the HHb conformer (at 8.88 ppm). These H8 signals are assigned to
the 5′-GMP cis to the pyridyl ring.
As can be seen from Figure 3.2, where N′ represents the pyridyl ring, the base next to this
ring has an orientation with respect to the coordination plane that is the same in the ΛHT and
HHa pair. Likewise, the orientation of this base is the same in the ∆HT and HHb pair. The
rotation of the 5′-GMP cis to the pyridyl ring is expected to be slow; thus, conformer interchange
involving such rotation will be too slow to generate detectable EXSY cross-peaks. (Slow
interconversion between rotamers is depicted by short arrows in this figure.) Each HT conformer
can exchange rapidly (depicted by long arrows) with only one HH conformer because only the
base cis to the triazine ring can rotate rapidly. For example, the H8 signal of the G in the ∆HT
rotamer cis to the triazine ring at 8.83 ppm has an EXSY cross-peak with the downfield H8
signal of the HHb rotamer at 8.94 ppm; this H8 signal of the HHb rotamer belongs to the 5′-GMP
cis to the triazine ring. Such EXSY cross-peaks between the H8 signals of the 5′-GMP cis to the
triazine ring of the HH and HT rotamers were used for the unambiguous assignment of the HH
conformers as HHa and HHb because the ∆HT and the ΛHT H8 signals of the 5′-GMP cis to the
pyridyl ring overlap at 8.96 ppm.
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We apply the foregoing reasoning to all four H8-H8 EXSY cross-peaks in the ROESY
spectrum of the (MepyMe2t)Pt(5′-GMP)2 adduct at 25 C (Figure 3.9). The EXSY cross-peaks
observed are between the H8 signals of the HHa and the ΛHT rotamers (9.08 and 8.78 ppm (cis
to the triazine ring) and 8.71 and 8.96 ppm (cis to the pyridyl ring)) and between the H8 signals
of the HHb and the ∆HT rotamers (8.94 and 8.83 ppm (cis to the triazine ring) and 8.88 and 8.96
ppm (cis to the pyridyl ring)).
For the (MepyMe2t)Pt(5′-GMP)2 adduct, as the pH was increased from 2.5 to 7.5, the
population of the ΛHT, HHa, ∆HT, and HHb conformers changed from 40%, 30%, 20%, and
10% to 65%, 10%, 20%, and 5%, respectively (Figure 3.7). For this adduct, the combined
abundance of the HT conformers is greater than the combined abundance of the HH conformers,
a typical situation.49 It is also typical for the percentage of the HH conformers to decrease with
increasing pH.20
At pH 7.5 and below, the HHa conformer of (MepyMe2t)Pt(5′-GMP)2 is more abundant
and has more H8 to H8 signal dispersion (0.37 ppm) than the HHb conformer (0.06 ppm). For
HHa, the 5′-GMP cis to the pyridyl ring has the upfield shift so the base is canted with its H8
atom projecting toward the shielding region of the 5′-GMP cis to the triazine ring. This 5′-GMP
is either not canted or only slightly canted. Canting in the HHa conformer (Figure 3.2, where N′
represents the pyridyl ring) is right-handed (R). However, the small H8 signal dispersion for the
HHb conformer of the (MepyMe2t)Pt(5′-GMP)2 adduct is associated with a low degree of
canting,21,22 similar to that observed for the (5,5′′-Me2bipy)Pt(5′-GMP)2 adduct. The orientation
of the two 5′-GMP bases in HHb may be nearly perpendicular to the Pt coordination plane or
may be slightly canted. Alternatively, the two bases may be “wagging”, rapidly changing the
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canting direction between the R- and L-canted orientations, leading to shift averaging and thereby
accounting for the small HH H8 signal dispersion.
3.3.6. (MepyMe2t)Pt(3′′-GMP)2
Qualitatively, for G derivatives the rate of rotation about the Pt–N7 bond increases in the
order, 5′-GMP < 3′-GMP < Guo < 9-EtG (9-EtG = 9-ethylguanine).19,31,32,46,51 Previously we
observed only four H8 signals for (MepyMe2t)Pt(Guo)2.34 We attributed this finding to fast
interchange within each of the pairs (ΛHT, HHa and ∆HT, HHb), a process involving G base
rotation for the Guo cis to the triazine ring (Figure 3.2). Also, rotation of the Guo cis to the
pyridyl group was postulated to be a slow process, as now confirmed for the (MepyMe2t)Pt(5′GMP)2 adduct, which exhibited no interchange (no EXSY peaks) between the two pairs.

Figure 3.10 Aromatic region of 1H NMR spectra of (MepyMe2t)Pt(3′-GMP)2 at pH 4.5 (bottom)
and pH 7.5 (top) at 25 °C. The H8 signals for the conformers are designated by the conformation.
Two pairs of H8 signals in a 2:1 ratio were observed for the (MepyMe2t)Pt(3′-GMP)2
adduct at pH 4.5 and 25 °C (Figure 3.10). Neither NOE nor EXSY cross-peaks were observed
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between these H8 signals; an NOE cross-peak is expected for an HH conformer. Therefore, even
for a rapid HT/HH equilibrium, an NOE cross-peak would be found if either HT/HH pair had a
significant amount of the HH conformer. The H8 NMR signals of the HH conformer were not
detectable even at low temperature (0 °C), a result similar to that found for the (pipen)Pt(3′GMP)245 (pipen = 2-aminomethylpiperidine) and [(MepyMe2t)Pt(Guo)2]2+ adducts. Thus, the H8
signals of the (MepyMe2t)Pt(3′-GMP)2 adduct arising from two sets of rapidly interchanging
pairs of conformers, ∆HT/HHa and ΛHT/HHb, reflect primarily a dominant HT conformer, as
discussed previously.34 The two pairs of HT and HH conformers interchange within the pair but
not between pairs. The four H8 signals for the (MepyMe2t)Pt(3′-GMP)2 adduct thus reflect
mainly the two HT conformers, ∆HT and ΛHT. From the order of rotation rates for the various G
derivatives it was uncertain what pattern of behavior to expect, but now it is clear that
(MepyMe2t)Pt(3′-GMP)2 has dynamic properties more similar to those of (MepyMe2t)Pt(Guo)2
than to those of (MepyMe2t)Pt(5′-GMP)2.

Figure 3.11 CD spectra of (MepyMe2t)Pt(3′-GMP)2 at pH 4.5 and 7.5 at 25 °C.
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From 4.5 to 7.5, the more downfield of the two H8 signals of the major HT rotamer of
(MepyMe2t)Pt(3′-GMP)2 (at 8.95 ppm) shifted slightly upfield, overlapping with the downfield
H8 signal of the minor HT rotamer at 8.89 ppm (Table 2). The other H8 signals showed no
significant shift until pH 7.5. As the pH was increased from 4.5 to 7.5, the major HT rotamer
became the almost exclusively observed atropisomer (Figure 3.10). The CD spectra collected at
pH 4.5 and 7.5 are characteristic of the ∆HT conformer (Figure 3.11). Therefore, at pH 4.5, the
H8 signals at 8.95 and 8.84 ppm belonging to the major HT conformer are assigned to the ∆HT
conformer stabilized by SSC, while the H8 signals at 8.89 and 8.74 ppm are assigned to the ΛHT
conformer (minor). This previously reported downfield relationship of the H8 signal of the major
HT conformer to the respective H8 signal of the minor HT conformer19,23,30,31,43 is consistent
with the major ∆HT conformer being ‘6-in’ (R canting) and the minor ΛHT conformer being ‘6out’ (L canting).
The properties of the (MepyMe2t)Pt(3′-GMP)2 adduct at pH 4.5 were explored further in
ROESY studies. From the NOE cross-peaks, the H8 signals belonging to the 3′-GMP cis to the
pyridyl ring of the HT conformers of the (MepyMe2t)Pt(5′-GMP)2 adduct were also downfield
compared to those of the 3′-GMP cis to the triazine ring. For the (MepyMe2t)Pt(3′-GMP)2
adduct, the H6′ doublets of the ∆HT and ΛHT conformers (Supporting Information) were shifted
upfield by 1.01 and 1.24 ppm from the H6′ signal of the solvated Pt complex at 9.26 ppm (Figure
3.10); similar behavior was observed for the H6′ signal of (5,5′-Me2bipy)Pt(3′-GMP)2 adduct.
These large H6′ upfield shifts can be attributed to the anisotropic effect of the cis coordinated
base but cannot easily be correlated with the degree of canting.
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3.3.7 (Et4dt)Pt(5′′-GMP)2

Figure 3.12 H8 region of the 1H NMR spectra of (Et4dt)Pt(5′-GMP)2 at 5 °C.
Four new H8 signals of comparable intensities were observed within 24 h of mixing 1
equiv of (Et4dt)PtCl2 with 2 equiv of 5′-GMP at 25 °C (Figure 3.12). Sharp 1H NMR signals
were observed at 25 °C for the (Et4dt)Pt(5′-GMP)2 adduct at pH ~4; however, in order to
compare the data with the (Me4dt)Pt(5′-GMP)2 adduct (Supporting Information), 1D 1H NMR
spectra and a ROESY spectrum were collected at 5 °C. At 25 °C, the full width at half
maximum (fwhm) of the H8 signals for (Et4dt)Pt(5′-GMP)2 was 6 Hz for all three rotamers, as
compared to the fwhm of the H8 signals of (Me4dt)Pt(5′-GMP)2 of 11 (∆HT), 10 (ΛHT), 12
(HHd) and 11 (HHu) Hz. These H8 signals of the (Et4dt)Pt(5′-GMP)2 adduct at 25 °C were even
sharper than those of the (Me4dt)Pt(5′-GMP)2 adduct at 5 °C, where all fwhm values were ~7
Hz. These comparisons clearly indicate that the rotation rate about the Pt–N7 bond is
considerably slower for (Et4dt)Pt(5′-GMP)2 than for (Me4dt)Pt(5′-GMP)2, probably because of
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steric clashes between the 5′-GMP O6 and the methyl group of the 6,6′ ethyl groups of the Et4dt
ligand in the (Et4dt)Pt(5′-GMP)2 adduct as the G base rotates (Figure 3.13).

Figure 3.13 Greater steric clashes between substitutents at the 6,6′ position of the R4dt carrier
ligand and the G O6 for the Et4dt adduct compared to the Me4dt adduct.

Figure 3.14 CD spectra of (Et4dt)Pt(5′-GMP)2 and (Et4dt)Pt(3′-GMP)2 at 25 °C.
When the pH of solutions containing (Et4dt)Pt(GMP)2 adducts was raised from ~4 to 7.5
(above pH 7.5 the adduct decomposed, as evidenced by an increase in the intensity of the free
GMP H8 signal), the H8 signal at 8.96 ppm shifted slightly downfield to 8.99 ppm and became
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the most dominant signal (Figure 3.12); this peak was assigned to the ΛHT conformer because
the CD signal shape observed for this solution is characteristic of the ΛHT conformation (Figure
3.14).31,32,35,44,45 SSC interactions stabilize the ΛHT conformer of LPt(5′-GMP)2 adducts at or
near neutral pH.35,42,43 At pH 4.0, an NOE cross-peak was observed between the two dispersed,
comparably sized H8 signals at 9.18 and 8.83 ppm (Figure 3.15). These characteristics allow
unambiguous assignment of these H8 signals to the HH rotamer. The H8 signals of the HH
rotamer for the (Et4dt)Pt(5′-GMP)2 adduct at both high and low pH values were ~0.08-0.22 ppm
more downfield than those for the (Me4dt)Pt(5′-GMP)2 adduct (Table 3.1). The remaining H8
signal of the (Et4dt)Pt(5′-GMP)2 adduct at 9.06 ppm (pH 4.0) was assigned to the ∆HT rotamer.
From pH 4.0-7.5, no significant shift was observed for the H8 signals of the HT rotamers;
however, the HHd and the HHu signals shifted downfield by 0.19 and 0.13 ppm, respectively.
In contrast to the typical H8 chemical shift pattern of the major and the minor HT
conformers,19,23,30,31,43 the H8 signal of the major HT conformer (ΛHT) of the (Et4dt)Pt(5′GMP)2 adduct (at pH 7.5) is upfield to that of the minor HT conformer (∆HT). Because the H8
signals of the HT conformers are relatively more downfield and the difference in the chemical
shifts is small (0.10 ppm), it is not clear if this unusual HT H8 signal shift pattern is because of a
relatively more upfield ΛHT H8 signal or a more downfield ∆HT H8 signal. The H8 signals of
the HT conformers of the (Et4dt)Pt(5′-GMP)2 adduct are positioned between the two H8 signals
of the HH conformer. Thus, the H8 shifts of the HT conformers are not particularly unusual.
Because of the symmetrical nature of the carrier ligand in (Et4dt)Pt(5′-GMP)2, the bases in HT
conformers may ‘wag’ between R and L canting, causing the H8 signals of the conformers to
have similar shifts. The H8 chemical shift pattern (separation of 0.35 ppm) for the HH conformer
of (Et4dt)Pt(5′-GMP)2 is similar to that of the HH conformer of (MepyMe2t)Pt(5′-GMP)2. The
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moderately large H8 signal dispersion (0.35 ppm) for the (Et4dt)Pt(5′-GMP)2 HH conformer is
attributable to different canting of the two bases.

Figure 3.15 H8 region of the ROESY spectrum of (Et4dt)Pt(5′-GMP)2 at pH 4.0 and 5 °C. The
cross-peak labeled as HH is an NOE between the H8 signals of an HH conformer. The other
labeled cross-peaks are EXSY peaks between the H8 signals of different rotamers.
Five EXSY cross-peaks were observed in a ROESY spectrum of (Et4dt)Pt(5′-GMP)2,
collected at 5 °C (Figure 3.15). The two H8 signals of the HH rotamer have cross-peaks with the
H8 signals of both the ΛHT and ∆HT rotamers. Also, a weak EXSY cross-peak was observed
between the H8 signals of the ΛHT and the ∆HT rotamers. Because both 5′-GMP’s are cis to the
sterically less impeding triazine rings, Pt–N7 rotation is fast enough for the H8 signals of the
rotamers to have EXSY cross-peaks. In contrast, interchange between rotamers is slower in
ligands containing a pyridyl moiety, as evidenced by the absence of any H8-H8 EXSY crosspeaks for (5,5′′-Me2bipy)Pt(5′-GMP)2. In addition H8-H8 cross-peaks between the ΛHT and the
∆HT conformers were absent for the (MepyMe2t)Pt(5′-GMP)2 adduct. The broad NMR signals
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observed at 25 °C for the (Me4dt)Pt(5′-GMP)2 adduct can be attributed to exchange between
conformers and provide further evidence for facile interchange between rotamers in the
(R4dt)Pt(5′-GMP)2 adducts.
For the (Et4dt)Pt(5′-GMP)2 adduct, increasing the pH from 4.0 to 7.5 changed the
distribution of the HH, ΛHT and ∆HT rotamers from 50%, 25% and 25% to 40%, 37% and 23%,
respectively (Figure 3.12). For both (Et4dt)Pt(5′-GMP)2 (Figure 3.12) and (Me4dt)Pt(5′-GMP)2
(Supporting Information) at pH 4.0, the two HT conformers are almost equally abundant, and the
HH conformer has a relatively high abundance; these features are unusual when compared to the
other LPt(5′-GMP)2 adducts, including the (5,5′′-Me2bipy)Pt(5′-GMP)2 and (MepyMe2t)Pt(5′GMP)2 adducts studied here. This larger abundance of the HH conformer of the (R4dt)Pt(5′GMP)2 adducts is attributable to the overall low steric effects of the R4dt (R = Me and Et)
ligand.
The chemical shift of the H8 signals and the HH rotamer abundance in (Et4dt)Pt(5′GMP)2, when compared to values for (Me4dt)Pt(5′-GMP)2 (Supporting Information), suggest
some interaction between the ethyl groups of Et4dt and the bound 5′-GMP’s. As mentioned
above, the 6,6′ ethyl groups impede G base rotation. However, at pH 4 the 50% abundance of the
HH rotamer for the (Et4dt)Pt(5′-GMP)2 adduct was slightly higher than the 40% abundance
observed for the (Me4dt)Pt(5′-GMP)2 HH rotamer. Thus, the greater bulk of Et vs. Me is
reflected primarily in the G base rotation rate.
3.3.8 (Et4dt)Pt(3′′-GMP)2
The two H8 signals observed in a 2:1 ratio for the (Et4dt)Pt(3′-GMP)2 adduct (Figure
3.16) did not shift when the pH was raised from 4.0 to 7.5. However, the signal at 9.01 ppm
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became the dominant H8 signal. The CD signal shape at pH 7.5 (Figure 3.14) is characteristic of
the ∆HT conformation.31,32,42,45 Thus, the 9.01 ppm signal was assigned to the ∆HT conformer,
the conformer stabilized by SSC on phosphate deprotonation for 3′-GMP adducts.35,42,43 The
other H8 signal (at 8.87 ppm) is assigned to the ΛHT conformer. The conformer distributions
(respective amounts of ∆HT and ΛHT = 67% and 33% at pH 4.0 and 75% and 25% at pH 7) are
comparable with those for (Me4dt)Pt(3′-GMP)2 (Supporting Information).

Figure 3.16. H8 region of the 1H NMR spectra of (Et4dt)Pt(3′-GMP)2 at 5 °C.
The HH conformer was not detected for either (R4dt)Pt(3′-GMP)2 adduct. The dispersion
of the two H8 signals of the (Et4dt)Pt(3′-GMP)2 adduct (Table 3.1) was sufficient for us to
resolve an EXSY cross-peak between these H8 signals. The cross-peak confirms that the two
observable HT signals are mainly from rapidly interchanging ∆HT and ΛHT conformers;
interchange undoubtedly proceeds via the HH conformer (Figure 3.2). The same exchange
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process obviously occurs for the (Me4dt)Pt(3′-GMP)2 adduct, but the H8 signals are not
separated well enough for us to detect the EXSY cross-peak (Supporting Information).
3.4 Conclusions
The bulk of the bidentate sp2 N-donor ligands is sufficient to impede the rotation of the
GMP’s about the Pt–N7 bonds of the LPt(GMP)2 adducts; thus, H8 signals for conformers could
be resolved and assigned. From NMR data (including EXSY results), the qualitative rates of
conformer interconversion follow the order, Me4dt > Et4dt > MepyMe2t > 5,5′′-Me2bipy. Thus,
we conclude that the pyridyl H6′ atom strongly impedes the rotation of the cis G base about the
Pt–N7 bond by clashing with G O6, whereas the equivalently placed lone pair of the relevant
non-bonded N of the triazine does not so strongly impede G rotation. Thus, the triazine ring has a
lower overall steric effect than the pyridyl ring. The intermediate properties of MepyMe2t, with
one triazine and one pyridyl ring led to EXSY data for the (MepyMe2t)Pt(5′-GMP)2 adduct that
allowed us to unambiguously determine and assign the conformation of the two HH conformers,
HHa and HHb.
The nature of both the GMP and the carrier ligand in LPtG2 adducts influences the
distribution of conformers and their characteristics. The LPtG2 adducts studied here have a
higher abundance of the HH conformer when G = 5′-GMP’s than when G = 3′-GMP’s,
supporting the general finding that the 5′-phosphate group stabilizes the HH conformer.35,43
Typically, one HT conformer dominates over the other HT and the HH conformer at low pH
(~4), especially at neutral pH. We have discovered that carrier ligands of the type, R4dt, lead to
the HH having almost comparable abundance to the total of the two HT conformers for the
(R4dt)Pt(5′-GMP)2 adduct at equilibrium at pH 4. We conclude that the sterically less demanding
nature of the R4dt ligand allows ample space for the HH conformer to exist with less significant
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clashes between the O6 atoms of the 5′-GMP’s. Normally, second-sphere communication raises
the abundance of one HT conformer as the pH is raised to near neutrality. This trend was found
for the (R4dt)Pt(5′-GMP)2 adducts. However, the abundance of the HH isomer remains high.
Given the finding that carrier ligands favoring the HH conformer in the cross-link are associated
with anticancer activity,16 Pt complexes of R4dt ligand should be tested for activity.
In previous studies of LPt(5′-GMP)2 complexes, the CD and NMR spectroscopic data
indicate that the ΛHT atropisomer predominates in solution at neutral pH.19,21,35,42,44,45 The
distribution of conformers for the (5,5′′-Me2bipy)Pt(5′-GMP)2 and (MepyMe2t)Pt(5′-GMP)2
adducts agrees with the results for other LPt(5′-GMP)2 adducts. However, the two HT
conformers of the (R4dt)Pt(5′-GMP)2 (R = Me or Et) adducts are unusual in having an
approximately equal abundance at low pH and in having an H8 signal for the minor HT form
(∆HT) downfield to that of the major HT form (ΛHT) near physiological pH. At this time the
reason for these differences is not apparent, and additional studies are in progress in order to
understand the unique features of (R4dt)PtG2 complexes. However, because R4dt ligands are
sterically less demanding when compared to other sp2 N-donor ligands, it is possible that steric
factors may limit the abundance of the minor HT conformer for LPt(GMP)2 adducts for other L.
Nevertheless, we have made the surprising observation that placing greater bulk at the 6,6′
positions by changing R in R4dt from Me to Et has a clear effect on the G base rotation rate
about Pt–N7 bond. We attribute this effect to clashes between the G O6 and the methyl group of
the 6,6′ ethyl groups (Figure 3.13).
Finally, our results indicate that adduct formation between LPtCl2 (L = 5,5′-Me2bipy and
MepyMe2t) and 5′- and 3′-GMP does not go to completion, and residual solvated Pt complexes
exist at equilibrium. Because the solutions contain DMSO, this solvent both complicates the
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identification of the solvato species and probably is responsible for incomplete adduct formation.
However, this situation presents a rare opportunity to compare the relative binding affinity of 3′GMP vs. 5′-GMP toward Pt(II) in cis bis adducts. The ratio of LPt(3′-GMP)2 : solvated Pt
complex was 46:1 for L = 5,5′-Me2bipy and 38:1 for L = MepyMe2t, but the ratio of LPt(5′GMP)2 : solvated Pt complex was only 5:1 for L = 5,5′-Me2bipy and only 4:1 for L =
MepyMe2t. This greater stability of LPt(3′-GMP)2 compared to LPt(5′-GMP)2 parallels the
results observed for the fac-[Re(CO)3(H2O)(3′-GMP)2]- and fac-[Re(CO)3(H2O)(5′-GMP)2]adducts.52 This difference in the binding propensity of 3′-GMP vs. 5′-GMP is very unlikely to be
due to electronic effects because N7 should have very similar donor ability for both 3′-GMP and
5′-GMP. Rather, the difference more likely arises from SSC effects involving the positioning of
the phosphate groups. Perhaps the 3′-phosphate group is better positioned to form stabilizing Hbonds with N1H of the cis 3′-GMP than is the 5′-phosphate group. Such stabilization of an HT
conformer could also explain the generally observed low abundance of the HH conformer of
LPt(3′-GMP)2 adducts. The (5,5′′-Me2bipy)Pt(3′-GMP)2 adduct studied presents an unusual
case, in which no HH conformer was detected by using high-field NMR spectroscopy for a 3′GMP adduct that has rotamers interchanging relatively slowly on the NMR time scale.
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CHAPTER 4. USE OF NEGLECTED BIS(TRIAZINE)-TYPE LIGANDS TO ASSESS
COMPARATIVE CARRIER-LIGAND EFFECTS RELATIVE TO THE LIGANDS IN
CLINICALLY USED Pt ANTICANCER DRUGS: d(GpG) AND OLIGONUCLEOTIDES
CONTAINING THE N7–Pt–N7 CROSS-LINK
4.1 Introduction
Cisplatin (cis-Pt(NH3)2Cl2) and related analogues continue to enjoy expanding clinical
use in the fight against cancer, even though the original discovery was made many years ago.1-8
Although analogues of the type LPtX2 (L = one bidentate or two cis-unidentate N-donor ligands,
X2 = anionic leaving ligands) are generally less active,2,5,9-12 there is evidence that the carrier
ligand can modulate the anticancer and mutagenic properties. Oxaliplatin [(1R,2Rdiaminocyclohexane)oxalatoplatinum(II)] is a third generation Pt based anticancer agent that
forms the same kind of intra- and interstrand DNA cross-links as cisplatin13-16 and has activity
against some cisplatin-resistant tumor cells.13,17 An intrastrand DNA cross-link with Pt linking
N7’s of adjacent guanines of DNA, Pt(d(G*pG*))

(G* = N7-platinated G linked by a

phosphodiester backbone), is thought to be the critical lesion accounting for activity.5,15,18-23 The
guanine base G* residues in such cross-links are generally accepted to have a head-to-head (HH)
orientation, with the two G* residues maintaining the anti conformation characteristic of BDNA;24-32 this HH conformation is designated as HH1 (Figure 4.1). Virtually all reports on both
single-stranded and duplex adducts indicate that the HH1 conformer predominates.27,30,33-35
An implicit assumption in drug design is that the HH conformers are relevant to
activity.36 It is hypothesized that the cisplatin anticancer activity involves specific recognition of
kinked DNA adducts by proteins with an HMG domain.12,37-42 Tight binding to the HMGcontaining protein may be required for such recognition, which by inhibiting repair, leads to cell
death. The most favorable protein-DNA contacts may require this HH1 conformation, and,
indeed, even variations in the flanking sequence influence protein binding.41 However, carrier
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ligands that favor a non-HH1 conformation for the cross-link could form DNA adducts with this
different conformation (Figure 4.1). Such cross-link adducts might bind the HMG proteins less
strongly, and thus may be readily repaired (repair diminishes activity).36,43 On the basis of this
HMG protection mechanism, we hypothesize that understanding those factors that favor HH1
over other conformers is important for designing new anticancer drugs. In turn, if we can force
unusual conformations onto the cross-link, such conformers may be useful 'tools' for probing the
mechanism of action, which has still not been fully elucidated.

Figure 4.1. The possible base orientations (head-to-head, HH and head-to-tail, HT) of two G*
bases coordinated to cis positions on Pt. The large arrows represent the G* base, with the
arrowhead denoting the G* H8 (shown below the scheme). The small curved arrows connecting
the G* base arrows indicate the direction of propagation of the sugar-phosphodiester backbone.
G* coordination sites are forward, and the carrier ligand (not shown except for N-donor atoms) is
to the rear. The four recognized conformers are shown. Interconversion between these
conformers requires base rotation about the Pt–N7(G*) bond. Slow isomerization from the two
HH conformers to the ΛHT conformer is depicted by short counter-parallel arrows.
In simple LPtG2 adducts (boldface G indicates a guanine derivative not linked to another
nucleoside by a phosphodiester group), the bases favor the head-to-tail (HT) arrangement,44,45
whereas the adducts with single-stranded d(G*pG*) cross-links are thought to favor the HH1
78

conformation.32,33,46-48 In the absence of an X-ray structure, the observation of only one set of 1H
NMR signals33,46 for the simplest cross-link adduct, cis-Pt(NH3)2(d(G*pG*)) has been taken to
imply that the presence of the backbone favors the HH base arrangement over the otherwise
favored HT arrangement.33,43,46,47,49-52 We believe that the observation of only one set of 1H
NMR signals for the cis-Pt(NH3)2(d(G*pG*)) adduct is best attributed to dynamic interchange
between multiple conformers. Because of these conflicting interpretations, the cisPt(NH3)2(d(G*pG*)) model of the cisplatin-DNA intrastrand adduct is said to suffer from the
‘dynamic motion problem'.23,43,44,50,53,54
To overcome this dynamic motion problem, a retro-modeling approach has been
employed. In this approach, the carrier ligands are designed to reduce the dynamic motion by a
billion-fold compared to cis-Pt(NH3)2 adducts, thereby permitting the coexistence of multiple
conformers and leading to more informative spectral properties.23,36,55-57 The study of the reaction
of chiral enantiomers of [BipPt(H2O)2]2+ (Bip = 2,2′-bipiperidine) with d(GpG) provided the first
definitive evidence for the existence of LPt(d(G*pG*)) non-HH1 conformers.43,50 For (S,R,R,S)BipPt(d(G*pG*)), conformers of comparable stability, HH1 and HH2, were found (the 2
indicates that the direction of propagation of the sugar-phosphodiester backbone is opposite to
that in B-DNA, Figure 4.1);50 these conformers are designated as HH1 R and HH2 R to indicate
that the canting is right-handed for both HH conformers. For (R,S,S,R)-BipPt(d(G*pG*)), the
HH1 L conformer and the ∆HT conformer (with an anti-5′-G* and a syn-3′-G*, Figure 4.1) were
abundant.43 After the initial discovery of these conformers, retro-models with the N,N′dimethylpiperazine (Me2ppz)58 and 5,5′-dimethyl bipyridine (5,5′′-Me2bipy)23 ligands allowed
the simultaneous detection of both the HH2 and the ∆HT conformers, in addition to the wellknown HH1 conformer.
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The antiparallel alignment of the base dipole and the minimal O6 clash of the two G
bases favor the HT over the HH arrangement. To observe the conformers in solution, the carrier
ligand must be made bulky. In early work, no HH conformer was found when the carrier ligand
had two sp3 N's and no NH groups.59,60 Later, less bulky ligands of the type used in the
retromodeling approach, but with one hydrogen on each of the two sp3 N's, revealed that the HH
form could be observed.45,55,56,61-63 With such models, it was found that the nature of the G
derivative influenced the distribution. The percentage of HH conformer generally increases along
the series, Guo < 3'-GMP < 5'-GMP. The reason for this order is not totally clear, but it was
found that the phosphate groups of one G interacted with the base of the other G in the cis
position. This interaction favors a particular HT chirality and may be stronger in 3'-GMP than in
5'-GMP. If such is the case, the higher abundance of the HH conformer in 5'-GMP adducts is
explained.58,62,64

Figure 4.2. Numbering scheme for 5,5′-dimethyl bipyridine (5,5′′-Me2bipy) and bis-3,3′-(5,6disubstituted-1,2,4-triazine) (R4dt) ligands.
The abundance for the HT conformers was similar for some LPtG2 adducts having inplane ligand bulk (L = 5,5′′-Me2bipy and 3-(4′-methylpyridin-2′-yl)-5,6-dimethyl-1,2,4triazine)).65 However, we have discovered that carrier ligands of the type, bis-3,3′-(5,6-dialkyl1,2,4-triazine) (R4dt, Figure 4.2), led to almost comparable abundance of HH and HT
conformers for the (R4dt)Pt(5′-GMP)2 adduct.65 The overall low steric effects of the R4dt ligand,
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with two N + N lone pair groupings, allow enough space for the HH conformer to exist without
significant clashes between the O6 atoms of the 5′-GMP’s.65 The R4dt ligand is unique in that it
has the in-plane bulk needed to reduce the Pt–N7(G) rotation, but at the same time it is sterically
less demanding, enough to allow a high abundance of the HH conformer. Given the finding that
carrier ligands favoring the HH conformer in the cross-link are associated with anticancer
activity,44 we evaluate here the (R4dt)Pt(d(G*pG*)) adduct for the distribution and the
characteristics of its conformers.
Earlier studies with the LPt(d(G*pG*)) adduct having L = the sp2 N-donor 5,5′′-Me2bipy
achiral carrier ligand was particularly informative. The 5,5′′-Me2bipy H6/H6′ protons (Figure
4.2), which project toward the cis G*, were used as probes to elucidate conformer structures.23
We have now investigated (R4dt)Pt(d(G*pG*)) (R4dt = Me4dt, Et4dt) (Figure 4.2) adducts
containing another sp2 N-donor achiral carrier ligand. This ligand has in-plane bulk that is
expected to destabilize the transition state for rotation about both Pt–N7(G*) bonds and thus
eliminate the dynamic motion problem. Nevertheless, the presence of the sterically less
demanding lone pairs on the N1/N1′ atoms in R4dt (positioned in the same location as the
H6/H6′ protons of 5,5′′-Me2bipy, Figure 4.2) pointing toward the 5′-G* and the 3′-G* alters the
steric properties.
We begin with our results on (R4dt)Pt(d(G*pG*)) adducts, followed by the
(R4dt)Pt(oligo) adducts (oligo = GGT, TGG, TGGT), in which 5′- and 3′-flanking residues are
introduced. The flanking residues can be viewed as substituents on the Pt(d(G*pG*)) chelate
ring. The oligos examined have T residues because GGT and TGG are a part of the repetitive
sequence found in telomeres, a potential cisplatin single-strand (ss) DNA target,66,67 and also
because T residues were used in the (Me2ppz)Pt(oligo) studies.68 Comparison of results obtained
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for (R4dt)Pt(oligo) with (Me2ppz)Pt(oligo)68 will allow us to understand the effect of carrier
ligands on conformer distribution and their characteristics. A comparative study for
LPt(d(G*pG*)) and LPt(oligo) is presented here for the first time for L = sp2 N-donor carrier
ligand to assess the effect of a flanking residue on the conformer distribution in DNA cross-link
adducts.
4.2 Experimental Section
4.2.1 Starting Materials
2′-Deoxyguanyl(3′→5′)-2′-deoxyguanosine (d(GpG)) from Sigma was used as received.
Bis-3,3′-(5,6-dialkyl-1,2,4-triazine) (R4dt) ligands (Figure 4.2) were synthesized by a known
method.69 (Me4dt)PtCl2 (Me4dt = bis-3,3′-(5,6-dimethyl-1,2,4-triazine)) and (Et4dt)PtCl2 (Et4dt
= bis-3,3′-(5,6-diethyl-1,2,4-triazine)) were prepared as described elsewhere.65 d(TGG), d(GGT),
and d(TGGT) oligonucleotides, obtained from the Microchemical Facility at Emory University,
were purified by ÄKTA FPLC (Amersham Biosciences). Failure sequences were removed by
using ion exchange chromatography on an Amersham Biosciences Mono Q HR 10/10 anion
exchange FPLC column (A = 2 M NaCl, B = H2O, 0-50% A over ~50 min). Collected fractions
were desalted on an Amersham Biosciences HiTrap desalting FPLC column (A = H2O, 3.5
mL/min for 20 min), taken to dryness by rotary evaporation, and then dissolved in ~0.5-1.0 mL
of D2O.
4.2.2 Reaction of (R4dt)PtCl2 with d(GpG)
A 5 mM and a 7 mM solution containing an equimolar ratio of Pt:d(GpG) were prepared
by mixing a DMSO-d6 solution of (Me4dt)PtCl2 (1.32 mg, 200 µL) and (Et4dt)PtCl2 (2.07 mg,
400 µL), respectively, with a D2O solution of d(GpG) (1.70 mg, 350 µL and 2.38 mg, 150 µL,
respectively). Because of low solubility of (R4dt)PtCl2 in D2O, the reaction was carried out in a
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mixture of D2O and DMSO-d6 (64:36 by volume when R = Me and 27:73 by volume when R =
Et). The solutions were maintained at pH 4.0 and 5° C and carefully monitored for two days by
1

H NMR spectroscopy until no free d(GpG) signals were observed. For comparison, 275 µL of

the (Et4dt)Pt(d(G*pG*)) solution was diluted with 275 µL of D2O, to obtain a 64:36 ratio of D2O
and DMSO-d6, the same ratio as that used for (Me4dt)Pt(d(GpG)). The final concentration of Pt
in the (Et4dt)Pt(d(GpG)) solution was 3.5 mM. The (R4dt)Pt(d(GpG)) solutions were monitored
by 1H NMR spectroscopy every 24 h for the initial 6 days and then weekly up to 4 months until
no change in the H8 signal intensity was observed.
4.2.3 Reaction of (R4dt)PtCl2 (R4dt = Me4dt, Et4dt) with Oligonucleotides
The concentration of the FPLC purified oligos (dissolved in 500 µL of D2O) was
determined by using UV spectroscopy. (Oligo ε260 values were calculated70 to be 30.0, 29.1 and
37.6 cm-1mM-1 for d(GGT), d(TGG) and d(TGGT), respectively.) A 1:1 molar Pt:oligo solution
was prepared (~1.5 mM) in 550 µL of a 64:36 mixture of D2O:DMSO-d6. A solution of the
desired (R4dt)PtCl2 complex was dissolved in 200 µL of DMSO-d6 and mixed with the
appropriate volume of the oligo in D2O. The volume of the solution was brought to 550 µL by
adding the required amount of D2O. The pH of the solution was maintained at 4.0 and the
solution was kept at 5 °C. The solution was carefully monitored by 1H NMR spectroscopy until
no free oligo signals were observed and then weekly up to 2 months to monitor any change in the
H8 signal intensity.
4.2.4 NMR Measurements
1

H NMR spectra were recorded on a Bruker spectrometer operating at 400 MHz or a

Varian spectrometer at 700 MHz. We used a value of 4.78 ppm to reference signals to the
residual HOD signal in D2O/DMSO-d6 solutions. A presaturation pulse to suppress the water
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peak was used when necessary. 31P NMR spectra were referenced to external trimethyl phosphate
(0 ppm) in a 64:36 mixture of D2O:DMSO-d6. DNO3 and NaOD solutions (0.1 M in D2O) were
used to adjust the pH of D2O/DMSO-d6 solutions. NMR data were processed with XWINNMR
or Mestre-C software.
1

H-1H COSY and ROESY spectra were recorded in order to assign the signals of the

products. Matrixes (512 x 2048) were collected for COSY and (500 ms delay) ROESY
experiments, both conducted at 25 °C with a spectral window of ~6000 Hz, and a presaturation
pulse of ~1 s to reduce the HOD signal. Typically, 32 scans were collected per block. An
exponential apodization function with a line broadening of 0.2 Hz and a phase-shifted 90° sine
bell function were used to process the ROESY t2 and t1 data, respectively.
4.2.5 Circular Dichroism (CD) Spectroscopy
All samples used for CD experiments were prepared from the respective NMR samples
by diluting to ~0.025 mM Pt with deionized water. The concentration of the CD samples was
determined by measuring the absorption at 260 nm on a UV-vis spectrometer (d(GpG) ε260 = 21.6
cm-1mM-1). Spectra were recorded from 400 to 200 nm at a scan speed of 50 nm/min on a
JASCO J-600 CD spectropolarimeter. Six scans were recorded and averaged for each sample.
4.2.6 High Performance Liquid Chromatography (HPLC)
Chromatograms were obtained on a Varian ProStar HPLC instrument with a PDA
detector operating at 254 nm. Separations employed a Microsorb 100-5 C8 150 x 4.6 mm
reverse-phase column. Eluants A and B both contained 0.02 M ammonium acetate buffer, pH
5.5. Solvent A was water and solvent B was a 2:1 methanol:water mixture. A flow rate of 0.70
mL/min was maintained over the course of a 40 min linear gradient (0 min = 95% A and 5% B,
40 min = 48% A and 52% B) for the (R4dt)Pt(d(G*pG*)) adducts. The NMR sample was diluted
to obtain a 1.7 mM solution. Each eluted fraction was collected, concentrated to a small volume
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(200 µL), and stored at 25 °C to see if equilibration occurred. An aliquot of each fraction was reinjected after 2 h and then after intervals of 24 h for 7 days, and finally at weekly intervals for
two months. The percentage of each product separated by HPLC was measured by integration of
the corresponding peak area.
4.3 Results
4.3.1 Conformer Assignment and Conformational Features
For the (R4dt)Pt(d(G*pG*)) adducts 1H-1H ROESY and COSY data were used to assign
H8 and sugar proton signals. Structural features were assessed by standard methods. The S- and
N-sugar pucker conformations were identified from the characteristic H1′ coupling patterns and
the existence of H8-H3′ NOE cross-peaks for N-sugars.71,72 For all conformers of LPtd(G*pG*)
adducts, the sugar residue of the 5′-G* typically adopts an N-pucker conformation, while the 3′G* sugar has the S-pucker.43,44,50,54 The anti or syn G* nucleotide conformations can be assessed
by strong intraresidue H8-H2′/H2′′ NOE cross-peaks and weak (or unobservable) H8-H1′ crosspeaks for the anti conformation and stronger H8-H1′ NOE cross-peaks for the syn conformation
.72-74 Because the G* H8 atoms are closer to each other in the HH conformers than in the HT
conformers, the observation of an H8-H8 cross-peak is characteristic of an HH conformer,
whereas the absence of such a cross-peak is indicative of an HT conformer.43,75 HH and ∆HT
conformers of LPt(d(G*pG*)) complexes often give rise to characteristic NMR shift changes
compared

to

free

d(GpG);

more

downfield

H8

conformers,27,29,33,46,48,76 whereas more upfield H8 and
conformer.43,53

Such

observations

are

used

(R4dt)Pt(d(G*pG*)) and (R4dt)Pt(oligo) adducts.
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4.3.2 (Me4dt)Pt(d(G*pG*))

Figure 4.3. 1H NMR spectra (400 MHz) in the H8 region for (Me4dt)Pt(d(G*pG*)) collected at
room temperature after 1 week (bottom) and after 8 weeks (top) (pH 4.0, in D2O/DMSO-d6). The
H8 signals for the various conformers are labeled.
Within ~30 min of mixing (Me4dt)PtCl2 and d(GpG) in a 1:1 molar ratio in 64:36
D2O:DMSO-d6 solution at pH ∼4.0 at 5 °C, the (Me4dt)Pt(d(G*pG*)) adduct was fully formed.
This reaction was repeated several times with similar results; however, small variations in
conditions, such as the ratio of D2O:DMSO-d6 in the reaction solvent mixture due to adventitious
water and the temperature in the various NMR probes used, eight H8 signals for the
(Me4dt)Pt(d(G*pG*)) adduct were resolved in some cases (Supporting Information, Figure C2)
while some H8 signals overlapped in other cases (Figure 4.3). In the spectrum in Figure 4.3, six
new peaks downfield from the free d(GpG) H8 signals at 8.06 and 7.83 ppm, indicating that the
adduct consisted of several species with both bases of d(GpG) bound to Pt via N7. The intensity
of these peaks and the spectrum in Supporting Information (Figure C2) indicate that some peaks
contain overlapping signals. Indeed the G* H8 peak at 9.03 ppm in 1H 400 MHz NMR spectra
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can clearly be interpreted as three overlapped signals (Figure 4.3). However, for the same sample
at 700 MHz this peak was slightly better resolved to give two distinct G* H8 peaks at 9.03 and
9.02 ppm, with ROESY and COSY data indicating that two G* H8 signals still overlapped to
give the peak at 9.03 ppm.

Figure 4.4. 1H-1H ROESY spectrum (700 MHz, 600 ms mixing time) of a 1-week-old
(Me4dt)Pt(d(G*pG*)) sample at pH 4.0 and 25 °C, showing G* H8 to sugar NOE cross-peaks.
The NOE cross-peaks (not shown) in the ROESY spectrum between H8 signals at 9.02
and 8.98 ppm and at 9.23 and 9.03 ppm (most abundant and next most abundant conformers,
respectively) indicate that both are HH conformers (Table 4.1 and 4.2). For the more abundant
HH conformer, the G* H8-H2′/H2′′ cross-peaks were stronger than the H8-H1′ cross-peaks
(Figure 4.4), indicating a predominantly anti conformation for both the 5′-G* and 3′-G* residues.
Because the 5′-G* and 3′-G* H1′ resonances overlap, the coupling patterns could not be
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determined. However, the presence of an NOE cross-peak between the H8 signal at 8.98 ppm and
that of H3′ confirms the N-sugar pucker (Figure 4.4). This signal is therefore assigned to the 5′G* residue, which typically has an N-pucker in such cross-links.21,27,43,50,54,76 The H8 signal at
9.02 ppm, which must be the 3′-G* H8 signal, has no H8-H3′ cross-peak, thus indicating an Ssugar pucker. Therefore, the dominant (Me4dt)Pt(d(G*pG*)) conformer is one of the anti,antiHH conformers (either HH1 or HH2).
Table 4.1. 1H and
pH ~4 and 25 °C a

31

P NMR Signal Assignments (ppm) for the (R4dt)Pt(d(G*pG*)) Adducts at

adduct

conformer

G*/T

H8

H1′

H2′

H2′′

H3′

H4′

base

31

P

sugara
(Me4dt)Pt(d(G*pG*))

(Et4dt)Pt(d(G*pG*))

(Me4dt)Pt(d(G*pG*))

(Et4dt)Pt(d(G*pG*))

(Me4dt)Pt(d(G*pG*))

(Et4dt)Pt(d(G*pG*))

(Me4dt)Pt(d(G*pG*))

(Et4dt)Pt(d(G*pG*))

(Me4dt)Pt(d(TG*G*T))

HH1

HH1

HH2

HH2

∆HT

∆HT

ΛHT

ΛHT

HH1

5′

8.98

6.44

2.60

2.89

5.00

4.16

anti

3′

9.02

6.46

2.69

2.60

4.70

4.25

anti

5′

9.04

6.39

2.55

2.80

4.92

4.08

anti

3′

8.97

6.43

2.61

2.53

4.64

4.22

anti

5′

9.03

6.42

3.19

2.91

4.96

4.14

anti

3′

9.23

6.40

2.51

2.82

4.74

4.50

anti

5′

9.10

6.37

3.15

2.88

5.01

4.08

anti

3′

9.23

6.32

2.32

2.72

4.65

4.41

anti

5′

8.24

6.40

3.22

2.49

4.74

4.19

anti

3′

8.31

6.24

3.48

2.66

4.81

4.12

syn

5′

8.32

6.35

3.52

2.65

4.76

4.02

anti

3′

8.29

6.19

3.35

2.61

4.88

4.10

syn

5′

9.03

6.57

3.04

2.90

4.13

4.99

anti

3′

8.65

5.84

2.40

2.84

4.83

4.69

anti

5′

8.99

6.50

2.82

2.78

4.59

b

anti

3′

8.66

5.98

2.39

2.72

b

b

anti

5′

8.98

6.49

2.84

2.66

4.87

4.32

anti

88

-3.43

-3.41

-2.76

-2.51

-5.01

-4.72

-4.09

-4.01

(table 4.1 continued)

(Me4dt)Pt(d(TG*G*))

(Me4dt)Pt(d(G*G*T))

HH1

HH1

HH2

∆HT

ΛHT

3′

9.40

6.42

2.77

2.91

4.06

4.45

5′-T

7.52

6.09

2.15

2.51

3.67

4.08

3′-T

7.84

6.40

2.42

2.35

4.64

4.19

5′

8.97

6.51

2.50

2.78

4.72

4.28

anti

3′

9.41

6.44

2.98

2.58

4.60

4.25

anti

5′-T

7.48

6.05

2.15

2.55

4.75

3.50

5′

8.98

6.45

2.57

2.89

anti

3′

9.03

6.41

2.73

2.62

anti

5′

9.02

6.39

3.18

2.93

3′

9.25

6.41

2.41

2.96

anti

5′

8.21

6.41

3.12

2.44

anti

3′

8.31

6.24

3.47

2.83

syn

5′

8.86

6.60

3.12

2.86

anti

3′

8.59

6.10

2.44

2.81

anti

4.96

anti

anti

-3.49

-2.64

a

Conformational assignment (anti/syn) based on the relative strength of NOE cross-peaks
between H8 resonances and H1′ or H2′/H2′′ signals in the ROESY spectrum. b Signals not
detected.
For the other HH conformer of the (Me4dt)Pt(d(G*pG*)) adduct, the G* H8 signal at
9.03 ppm has a strong H8-H3′ cross-peak, indicating a 5′-G* N-sugar pucker, and the H8 signal
at 9.23 ppm has no H8-H3′ NOE cross-peak, indicating a 3′-G* S-sugar pucker (Figure 4.4). The
observation of stronger 5′-G* H8-H2′/H2′′ cross-peaks than the H8-H1′ cross-peak is consistent
with an anti conformation.19,23,43,49,54 For the 3′-G*, weak H8-H2′ and H8-H1′ NOE cross-peaks
were observed (Figure 4.4). Thus, the minor HH conformer adopts an anti,anti conformation. The
distances between the H8 atom and sugar protons determined by molecular mechanics/dynamics
computations on the HH conformers of (Me2ppz)Pt(d(G*pG*)) indicated that observable H8-
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sugar NOEs are unlikely for the 3′-G* residue of the HH2 conformer.54 The observation of weak
3′-G* H8-to-sugar cross-peaks for the minor HH conformer and strong 3′-G* H8-to-sugar crosspeaks for the major HH conformer led us to assign the minor and the major HH conformers to
the HH2 and HH1 conformers, respectively. Our results for the minor and the major HH
conformers are consistent with the HH2 and HH1 conformers of (R,S,S,R)-BipPt(d(G*pG*))50
and (Me2ppz)Pt(d(G*pG*)).54
Table 4.2. H8 Chemical Shifts of the (R4dt)Pt(d(G*pG*)) and (R4dt)Pt(oligo) Adducts at pH ~4
at 25 °C
H8 shifts (ppm)
adduct

G*
HH1

HH2

∆HT

ΛHT

5′

8.98

9.03

8.24

9.03

3′

9.02

9.23

8.31

8.65

5′

8.98

9.02

8.21

8.86

3′

9.03

9.25

8.31

8.59

5′

8.97

3′

9.41

5′

8.98

3′

9.40

5′

9.04

9.10

8.32

8.99

3′

8.97

9.23

8.29

8.66

5′

9.07

9.17

8.36

3′

9.11

9.33

8.35

5′

9.04

3′

9.59

(Me4dt)Pt(d(G*pG*))

(Me4dt)Pt(d(G*G*T))

(Me4dt)Pt(d(TG*G*))

(Me4dt)Pt(d(TG*G*T))
(Et4dt)Pt(d(G*pG*))

(Et4dt)Pt(d(G*G*T))

(Et4dt)Pt(d(TG*G*))

For the (Me4dt)Pt(d(G*pG*)) adduct, there are two other pairs of H8 signals at 8.31 and
8.24 ppm and at 8.65 ppm and within the 9.03 ppm peak; except for the overlapped signal, these
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signals are upfield to the G* H8 signals of the HH1 and HH2 conformers. These two pairs of
signals, which indicate the presence of two conformers, showed no H8-H8 NOE cross-peaks, in
the ROESY spectra collected for the 1-week-old as well as for the 3-months-old
(Me4dt)Pt(d(G*pG*)) sample indicating that the bases of these conformers adopt the HT
arrangement.23,43,50,53
On the basis of the relative intensity of the H8 signals and the 31P NMR signals, the H8
signals at 8.31 and 8.24 ppm and the
conformer. Such an upfield

31

31

P NMR signal at -5.01 ppm were assigned to one HT

P NMR shift is characteristic of the ∆HT conformer and is

consistent with the shift values of the ∆HT conformer of both (5,5′′-Me2bipy)Pt(d(G*pG*)) (4.74 ppm) and (Me2ppz)Pt(d(G*pG*)) (-5.12 ppm). For the (Me4dt)Pt(d(G*pG*)) ∆HT
conformer, the G* H8 signal at 8.24 ppm exhibits an intraresidue H8-H3′ NOE cross-peak
(Figure 4.4) consistent with a 5′-G* N-sugar pucker. A strong 5′-G* H8-H2′′ cross-peak and a
weak H8-H1′ cross-peak indicate an anti 5′-G* conformation (Figure 4.4). For the H8 signal at
8.31 ppm, the absence of an H8-H3′ NOE and the observation of a doublet of doublets coupling
pattern for the H1′ signal (6.24 ppm) are indicative of a 3′-G* S-sugar pucker. Strong 3′-G* H8H1′ NOE and weak H8-H2′′ cross-peaks indicate a syn 3′-G* conformation. Thus, the ∆HT
conformer adopts an anti,syn conformation, as has been found previously.23,43,53,54
The intensity of the H8 signals for the other HT conformer (a fourth conformer at 8.65
and 9.03 ppm remained relatively unchanged for ∼3 weeks after initiation of the reaction.
However, these signals increased slowly over a period of ~3 months, finally becoming the most
dominant. Thus, this HT conformer, which is thermodynamically favorable, could possibly be the
elusive ΛHT conformer. The distribution of the HH1, HH2, ∆HT, and the putative ΛHT
conformers changed from 42%, 37%, 11% and 10% (after 1 week) to 36%, 18%, 6% and 40%
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(after ~3 months), respectively (Supporting Information Figure C2). The CD signal shape
provides a definitive means for assigning the chirality of the major HT conformer when that
conformer clearly dominates.54 For the (Me4dt)Pt(d(G*pG*)) sample, 8 weeks after initiation of
the reaction, the distribution of the HH1, HH2, ∆HT, and the putative ΛHT conformers was 40%,
25%, 10% and 25%. A positive feature at ~290 nm (Figure 4.5) in the CD spectrum for this
sample is characteristic of the ΛHT conformer of LPtG2 adducts.36,53,57,58,61,77 This feature is
consistent with the suggestion that the slowly forming HT conformer is the elusive ΛHT
conformer.

Figure 4.5. CD spectra of an (Me4dt)Pt(d(G*pG*)) sample recorded in water at pH ~ 4 and 25
°C. The positive feature at ~290 nm is indicative of a ΛHT conformation.
For the putative ΛHT conformer of the (Me4dt)Pt(d(G*pG*)) adduct, the G* H8 signals
at 8.65 and 9.03 ppm have H8-H2′/H2′′ cross-peaks stronger than the H8-H1′ cross-peak (Figure
4.4), indicating an anti conformation for both G* resdiues. The H8-H3′ NOE cross-peak (9.034.13 ppm) and an H1′ doublet for this residue are consistent with a 5′-G* N-sugar pucker. The
absence of an observable H8-H3′ cross-peak (8.65-4.83 ppm) and the doublet of doublets
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coupling pattern for the H1′ signal indicate a 3′-G* S-sugar pucker for the putative ΛHT
conformer.
EXSY cross-peaks were absent in the ROESY spectrum of the (Me4dt)Pt(d(G*pG*))
adduct, indicating that interconversion between the rotamers is very slow. These slowly
interconverting rotamers were separated and analyzed by HPLC (see below).

Figure 4.6. 31P NMR spectrum (400 MHz) of (Me4dt)Pt(d(G*pG*)) after 6 days (bottom) and
after 8 weeks (top) in D2O/DMSO-d6 at pH 4.0 and 25 °C.
4.3.2.1

31

P NMR Spectroscopy. Compared to the -4.2 ppm value of the unstrained

d(GpG) phosphodiester group, the

31

P NMR signal of HH conformers is downfield and that for

the ∆HT conformer is upfield. From their relative intensities, 31P NMR signals at -2.76, -3.43 and
-5.01 ppm for the (Me4dt)Pt(d(G*pG*)) adduct were assigned to the HH2, HH1, and the ∆HT
conformers, respectively (Figure 4.6). In addition, a fourth peak at -4.09 ppm slowly increased
with time, indicating that this signal belongs to the putative ΛHT conformer of the
(Me4dt)Pt(d(G*pG*)) adduct (Figure 4.6). The

31

P NMR chemical shifts for the ∆HT and the

two HH conformers are more upfield than those reported for (5,5′′-Me2bipy)Pt(d(G*pG*))23 (-
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2.23 (HH2), -2.64 (HH1) and -4.74 (∆HT) ppm) and more comparable to those of
(Me2ppz)Pt(d(G*pG*)).54
4.3.2.2 HPLC Analysis. The rate of interconversion between the (R4dt)Pt(d(G*pG*))
rotamers is considerably slower than that for the adducts lacking the sugar-phosphodiester
backbone (e.g., (R4dt)Pt(GMP)265), thus permitting the separation of the (R4dt)Pt(d(G*pG*))
conformers by HPLC.

Figure 4.7. HPLC chromatograms of a week-old (Me4dt)Pt(d(G*pG*)) sample (bottom), an 8week-old (Me4dt)Pt(d(G*pG*)) sample (middle), and a week-old (Et4dt)Pt(d(G*pG*)) sample
(top).
For the (Me4dt)Pt(d(G*pG*)) adduct at 25 °C, three fractions were collected with
retention times (RT) of 10.8, 15.7 and 20.3 min and present in 28%, 52% and 20% abundance,
respectively (Figure 4.7). The percent population of each product was determined by calculating
the area under each peak. An aliquot of each fraction when re-injected gave a chromatogram with
four peaks (RT = 11.3, 12.2, 16.0 and 20.9 min). The small difference in the retention times of
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the products at equilibrium and those found upon re-injecting the fractions can be attributed to
the presence of ammonium acetate in the fractions after initial collection. Because of very similar
retention times, the two products eluting at 11.3 min and 12.2 min came together at 10.8 min
when the (Me4dt)Pt(d(G*pG*)) adduct was first injected into the column. Because the product in
each fraction equilibrated with time to give all four product peaks, each peak must belong to one
of the four (Me4dt)Pt(d(G*pG*)) conformers. The intensity of the peak at RT = 20.3 min
increased with time, suggesting that this fraction contains the ΛHT conformer (Figure 4.7).
For the (Me4dt)Pt(d(G*pG*)) adduct, the fraction eluted at 15.7 min, after 1 day, gave a
chromatogram with peaks at 11.3 (16%), 12.2 (12%), and 16.0 (72%) min. After four days, upon
re-injecting an aliquot of the same fraction, the conformers redistributed [11.3 min (14%), 12.2
min (32%), and 16.0 min (51%)]. Also, a small peak (~3%, RT = 20.9 min) was detected. The
fraction that eluted at 10.8 min after one day gave a chromatogram with three peaks at 11.3, 12.2
and 16.0 min. After four days the distribution of these products changed from 42%, 40% and
18% to 21%, 30% and 48%. A very small peak at RT = 20.9 min (1%) was also observed after
four days. The fraction collected at 20.3 min redistributed very slowly into the other conformers.
The peaks at smaller retention times were not detected when this fraction was injected even after
2 days. Re-injection of this fraction after four days revealed four product peaks at 11.3 min (5%),
12.2 min (27%), 16.0 min (9%) and 20.9 min (59%). Clearly, the conformers eluting at 11.3, 12.2
and 16.0 min interconvert more rapidly than the one eluting at 20.9 min. A correlation of the
intensities of the H8 signals in the NMR spectrum with the product peaks in the HPLC
chromatograms suggests that the fraction eluting at 16.0 min contains the most abundant HH1
conformer, and the fraction at 20.9 min contains the fourth form of the (Me4dt)Pt(d(G*pG*))
adduct. The HPLC data suggest that the fourth form seen by 1H NMR spectroscopy could be the
elusive ΛHT conformer. The rotation of one base about the Pt–N7 bond leads to changes in the
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relative base orientation from HH to HT, or vice-versa. The HH1 conformer with RT = 16.0 min
converts to the ∆HT conformer (RT = 11.3 min), which rapidly interconverts to the HH2
conformer (RT = 12.2 min). The postulated ΛHT conformer eluting at 20.9 min converts first to
the HH2 conformer, which then equilibrates to give the ∆HT and HH1 conformers. The rate of
interconversion for the HH1, HH2 and ∆HT conformers is faster than that of the ΛHT conformer.
4.3.3 (Et4dt)Pt(d(G*pG*))
Four new pairs of G* H8 signals, downfield of the H8 signals of free d(GpG), were
observed within minutes after mixing (Et4dt)PtCl2 and d(GpG) solutions. After 1 day no free
d(GpG) signals were observed, indicating complete reaction. A 275-µL aliquot of this solution
was diluted with D2O to obtain a ratio of 64:36 for D2O:DMSO-d6 (as used for the
(Me4dt)Pt(d(G*pG*)) reaction). Signal assignments and conformational features were
determined by established methods using ROESY and COSY data.23,43 The H8 peaks at 9.23 and
9.10 ppm and 8.97 and 9.04 ppm were connected by H8-H8 NOE cross-peaks, indicating two
HH conformers. The 2D NMR data indicate that the two HH conformers have an anti,anti HH
conformation, with a 3′-G* S-sugar and a 5′-G* N-sugar (Table 4.1 and Supporting Information).
NOE cross-peaks between the H8 signals at 8.66 and 8.99 ppm and at 8.29 and 8.32 ppm were
absent, indicating HT conformers (Tables 4.1 and 4.2). The

31

P NMR signals for the

(Et4dt)Pt(d(G*pG*)) adduct were observed at -3.41, -2.51, -4.72 and -4.01 ppm. On the basis of
the characteristic shifts of the

31

P NMR signals and the relative intensities of the

(Et4dt)Pt(d(G*pG*)) H8 signals and their similarity to the shifts of the (Me4dt)Pt(d(G*pG*)) H8
signals, the more downfield H8 signals belonging to the minor HH conformer were assigned to
the HH2 conformer and those at 8.97 and 9.04 ppm were assigned to the major HH1 conformer
(Table 4.1). For HT conformers, the most upfield H8 signals were assigned to the ∆HT
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conformer, and the H8 signals at 8.66 and 8.99 ppm were assigned to the ΛHT conformer (Table
4.1). The ∆HT conformer has an anti,syn HT conformation and the ΛHT conformer has an
anti,anti HT conformation with a 3′-G* S-sugar and a 5′-G* N-sugar (Supporting Information).

Figure 4.8. H8 region of the 1H NMR spectrum (400 MHz) of (Et4dt)Pt(d(G*pG*)) after 1 week
(bottom) and after 8 weeks (top) in D2O/DMSO-d6 at pH 4.0 and 25 °C.
For (Et4dt)Pt(d(G*pG*)), the distribution of the HH1, HH2, ∆HT and ΛHT conformers
changed from 42%, 37%, 11%, and 10%, respectively, at one week after initiation of the reaction
to 41%, 33%, 9% and 17%, respectively, after another seven weeks (Figure 4.8). The abundance
of the ΛHT conformer increased slowly with time, as found for the (Me4dt)Pt(d(G*pG*)) adduct.
However, at equilibrium the 17% relative abundance of the ΛHT conformer of the
(Et4dt)Pt(d(G*pG*)) adduct was considerably less than the 40% observed for the
(Me4dt)Pt(d(G*pG*)) adduct. Evidently, the ΛHT conformer for (Et4dt)Pt(d(G*pG*)) adduct is
less favored than for (Me4dt)Pt(d(G*pG*)) adduct because of the bulk of the Et group, a result
suggesting that in-plane bulk does not disfavor the ΛHT conformer.
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In a ROESY spectrum of (Et4dt)Pt(d(G*pG*)), NOE cross-peaks were observed between
the G* H8 signals and the Et4dt methyl signals, which overlap in the 0.90 to 1.10 ppm region.
NOE cross-peaks were observed between these methyl signals and the H8 signals of the 3′-G* of
the HH2 conformer, the 3′- and the 5′-G* of the HH1 conformer and the 3′-G* of the ΛHT
conformer. Also, NOE cross-peaks between the methyl signals and the H1′ sugar signals were
observed. No such NOE cross-peaks were observed in the ROESY spectrum of the
(Me4dt)Pt(d(G*pG*)) adduct. The NOE cross-peaks between the G* residue and the carrier
ligand clearly indicate that the substituents at the 6/6′ position in a bis-3,3′-(1,2,4-triazine) can
interact with the Pt-bound guanine derivatives, and thus affect the rate of rotation of G* bases
about the Pt–N7 bond.
4.3.3.1 HPLC Analysis. For the (Et4dt)Pt(d(G*pG*)) adduct, the three fractions
collected, with retention times of 27.2 (42%), 29.5 (44%), and 31.9 (14%) min (Figure 4.7),
followed a pattern similar to that for (Me4dt)Pt(d(G*pG*)). The HH1 conformer eluted at 29.5
min, the HH2 and ∆HT conformers eluted together at 27.2 min, and the ΛHT conformer eluted at
31.9 min. Because of the more hydrophobic ethyl group, the retention times for the
(Et4dt)Pt(d(G*pG*)) peaks were longer than those for (Me4dt)Pt(d(G*pG*)) peaks.
Each

product

upon

re-injecting

into

the

HPLC

column

as

observed

for

(Me4dt)Pt(d(G*pG*)), redistributed to give four product peaks (RT = 27.7, 28.4, 30.0 and 32.5
min). Because of very similar retention times, the two products eluting at 27.7 min and 28.4 min
came together at 27.2 min when the (Et4dt)Pt(d(G*pG*)) adduct at equilibrium was first injected
into the column. Again, as we found for the R = Me analogue, the results indicate that each peak
belongs to one of the four (Et4dt)Pt(d(G*pG*)) conformers. For reasons given above, these
HPLC observations provide compelling evidence that the four forms detected by NMR spectra

98

must be conformers that re-equilibrate. However, each fraction, upon re-injecting, redistributed
significantly only after two days, indicating that the rate of interconversion between the
conformers was slower than that observed for the (Me4dt)Pt(d(G*pG*)) conformers, which
interconvert after ~1 day.
For (Et4dt)Pt(d(G*pG*)), each isolated fraction when injected after 1 day, gave a
chromatogram with ~99% of the peak of the fraction injected, the peaks for other conformers
were observed only after two days indicating slow redistribution in comparison to
(Me4dt)Pt(d(G*pG*)). After four days, substantial conformer redistribution was observed for
each isolated fraction. The fraction that eluted at 27.2 min redistributed to give four peaks [27.7
min (18 %), 28.4 (50%), 30.0 (21%) and 32.5 (11%)]. Likewise, four conformer peaks were
observed for the fractions for the HH1 conformer eluting at 29.5 min (27.7 min (10 %), 28.4
(19%), 30.0 (63%), and 32.5 (8%) and for the ΛHT conformer eluting at 31.9 min (27.7 min
(7%), 28.4 (38%), 30.0 (26%), and 32.5 (29%)). In contrast to the slowly redistributing ΛHT
conformer of (Me4dt)Pt(d(G*pG*)), the ΛHT conformer of (Et4dt)Pt(d(G*pG*)) redistributed
somewhat faster than the other conformers. This provides further support to the NMR finding
that the ΛHT conformer is less favored for the more bulky Et4dt ligand than for the Me4dt ligand
in the (R4dt)Pt(d(G*pG*)) adducts.
The sequence of conformer interconversion for (Et4dt)Pt(d(G*pG*)) was similar to that
observed for (Me4dt)Pt(d(G*pG*)). The HH1 conformer with RT = 30.0 min converts to the
∆HT conformer (RT = 27.7 min), which rapidly interconverts to the HH2 conformer (RT = 28.4
min). The postulated ΛHT (RT = 32.5 min) converts first to the HH2 conformer, which then
equilibrates to give the ∆HT and HH1 conformers.
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4.3.4 (Me4dt)Pt(d(TG*G*T))
Within 1 h after mixing a 2.2 mM solution of d(TGGT) in D2O (350 µL) with a 3.9 mM
solution of (Me4dt)PtCl2 in DMSO-d6 (200 µL) solution, four new pairs of G* H8 signals were
observed downfield to the H8 signals of the free d(TGGT). The reaction was complete after ~1
day, as indicated by the disappearance of the free d(TGGT) signals. After 1 day only one pair of
G* H8 signals remained, and thus the short-lived H8 signals were from intermediates or unstable
conformers.

Figure 4.9. H8 region of the 1H NMR spectra (400 MHz) of (a) (Me4dt)Pt(d(G*G*T)), (b)
(Me4dt)Pt(d(G*pG*)), (c) (Me4dt)Pt(d(TG*G*)), and (d) (Me4dt)Pt(d(TG*G*T)) after 7 days in
D2O/DMSO-d6 at pH ~4 and 25 °C.
For the (Me4dt)Pt(d(TG*G*T)) adduct, the two G* H8 signals at 9.40 and 8.98 ppm
(Figure 4.9) were connected by an NOE cross-peak, which is consistent with an HH arrangement.
A weak H8-H1′ and a strong H8-H2′/H2′′ NOE cross-peak indicated that both G* residues of the
HH conformer are anti. The 3′- and 5′-T H6 signals were observed at 7.52 and 7.84 ppm,
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respectively. NOE data were used to assign the sugar signals for the G* and T residues (Table
4.1). The H1′ coupling patterns indicated an S- and N-sugar for the 3′- and 5′-G* residues,
respectively, and an S-sugar for both the 3′- and 5′-T residues. The (Me4dt)Pt(d(TG*G*T))
adduct at equilibrium existed as ~100% HH1 conformer. The

31

P NMR signals for the HH1

conformer of the (Me4dt)Pt(d(TG*G*T)) adduct were observed at -4.24, -4.30 and -4.52 ppm.
The signal for the phosphate group between the adjacent G* residues is ~1 ppm upfield to that of
the HH1 conformer of the (Me4dt)Pt(d(G*pG*)) adduct.
4.3.5. (Me4dt)Pt(d(TG*G*))
Within two hours after mixing a 1.9 mM solution of d(TGG) in D2O (350 µL) with a 3.3
mM solution of (Me4dt)PtCl2 in DMSO-d6 (200 µL), a new set of signals was observed (Figure
4.9) in addition to those of free d(TGG) signals (8.09 (3′-G H8), 7.92 (5′-G H8) and 7.41 (5′TH6) ppm). These free d(TGG) signals disappeared after a day, indicating that the reaction was
complete. The two G* H8 signals (at 9.41 and 8.97 ppm) of the adduct were connected by an
NOE cross-peak, indicating an HH conformation. The ROESY data indicate that this dominant
conformer has a normal anti,anti-HH conformation. The 5′-G* has an H8-H3′ NOE (a finding
typical for an N-sugar), while the absence of an H8-H3′ NOE indicated an S-sugar for the 3′-G*.
The H1′ coupling pattern of the signals at 6.44 and 6.51 ppm for the 3′-G* and the 5′-G*,
respectively, was also consistent with this sugar pucker assignment. The H6 signal of the 5′-T
was observed at 7.48 ppm. The doublet of doublets coupling pattern of the 5′T H1′ signal (6.05
ppm) indicated an S-sugar. The (Me4dt)Pt(d(TG*G*)) adduct at equilibrium existed as ~100%
HH1 conformer. The

31

ppm upfield from the

P NMR signals for the HH1 conformer at -4.51 and -4.66 ppm are ~1
31

P NMR signal (at -3.43 ppm) for the HH1 (Me4dt)Pt(d(G*pG*))

conformer.
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4.3.6 (Et4dt)Pt(d(TG*G*))
For (Et4dt)Pt(d(TG*G*)), one new set of signals downfield to the free d(TGG) signals
was observed when a 1.4 mM solution of d(TGG) in D2O (350 µL) was treated with a 2.5 mM
solution of (Et4dt)PtCl2 in DMSO-d6 (200 µL). The three singlets at 9.59, 9.04 and 7.41 ppm
belonged to the 3′-G* and 5′-G* H8 signals and the 5′-T H6 signal, respectively. The H1′ signals
at 6.51, 6.53, and 5.98 ppm belonged to 3′-G*, 5′-G* and 5′-T, respectively. From the H1′
coupling pattern, the 5′-G* has an N-sugar, and the 3′-G* and the 5′-T have an S-sugar. The
presence of exclusively one conformer for the (Et4dt)Pt(d(TG*G*)) adduct (Figure 4.10), as
found for the (Me4dt)Pt(d(TG*G*)) adduct, led us to assign these signals to the HH1 conformer.
The 31P NMR signals for the HH1 conformer of the (Et4dt)Pt(d(TG*G*)) adduct were observed
at -4.58 and -4.86 ppm.

Figure 4.10. H8 region of 1H NMR spectra (400 MHz) of (a) (Et4dt)Pt(d(G*G*T)), (b)
(Et4dt)Pt(d(G*pG*)), and (c) (Et4dt)Pt(d(TG*G*)) after 7 days in D2O/DMSO-d6 at pH ~4 and
25 °C.
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4.3.7 (Me4dt)Pt(d(G*G*T))
Three new pairs of G* H8 signals, downfield to the H8 signals of the free d(GGT) (8.15
(3′-G H8), 7.98 (5′-G H8) and 7.74 (5′-TH6) ppm), were observed within ~15 min of treating a
1.7 mM solution of d(GGT) in D2O (350 µL) with a 3.0 mM solution of (Me4dt)PtCl2 in DMSOd6 (200 µL). After ~2 days, no free d(GGT) signals were observed, indicating complete reaction.
For (Me4dt)Pt(d(G*G*T)), the relative intensities and shifts of the G* H8 signals were very
similar to the values observed for the (Me4dt)Pt(d(G*pG*)) adduct (Table 4.1 and Figure 4.9).
The H8 signals at 9.03 and 8.98 ppm and at 9.25 and 9.02 ppm were respectively connected with
NOE cross-peaks, indicating an HH conformation. The two G* residues of both the HH
conformers are anti, with an N-sugar for the 5′-G* and an S-sugar for the 3′-G*. The G* H8
signals mentioned above were assigned to the HH1 and HH2 conformers, respectively. The
signal assignment was based on the similarity in the H8 chemical shifts of (Me4dt)Pt(d(G*G*T))
with those of the (Me4dt)Pt(d(G*pG*)) adduct. The

31

P NMR signal shifts at -3.49 and -2.64

ppm for (Me4dt)Pt(d(G*G*T)) were similar to those of the HH1 and HH2 conformers of the
(Me4dt)Pt(d(G*pG*)) adduct, respectively. The T H6 signals at 7.83 and 7.90 ppm were
respectively assigned to the HH1 and HH2 conformers.
The absence of an NOE cross-peak between the H8 signals at 8.31 and 8.21 ppm
indicated an HT conformer for the (Me4dt)Pt(d(G*G*T)) adduct. The NMR data indicated an
anti,syn conformation, with an N- and S-sugar for the 5′- and 3′-G* bases, respectively. The
similarity of these H8 shifts to those of the ∆HT conformer of the (Me4dt)Pt(d(G*pG*)) adduct
allowed us to assign these signals to the ∆HT conformer of the (Me4dt)Pt(d(G*G*T)) adduct.
The T H6 signal at 7.93 ppm was assigned to the ∆HT conformer; the G*pG* 31P NMR signal in
the ∆HT conformer could not be identified because of the overlapping G*pT signals in the -4 to -
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4.6 ppm region of all the conformers. A very small fourth pair of G* H8 signals (at 8.59 and 8.86
ppm) was observed 4 days after initiation of the reaction but was not evaluated further because of
the low abundance (3%).The chemical shift pattern was similar to the ΛHT conformer (8.65 and
9.03 ppm) of the (Me4dt)Pt(d(G*pG*)) adduct. The final distribution of conformers for the
(Me4dt)Pt(d(G*G*T)) adduct was 48% HH2, 32% HH1, 17% ∆HT, and 3% ΛHT conformer
(Figure 4.9).
4.3.8 (Et4dt)Pt(d(G*G*T))
Three new pairs of G* H8 signals, downfield to the H8 signals of the free d(GGT), were
observed within ~20 min of mixing a 1.3 mM solution of d(GGT) in D2O (350 µL) with a 2.2
mM solution of (Et4dt)PtCl2 in DMSO-d6 (200 µL). After ~7 days, no free d(GGT) signals were
observed, indicating complete reaction. Assignments were based on the relative intensities and
the characteristic shifts of the G* H8 signals, as determined above for the (Et4dt)Pt(d(G*pG*))
and the (Me4dt)Pt(d(G*G*T)) adducts. The H8 signals of the (Et4dt)Pt(d(G*G*T)) adduct at
9.33 and 9.17 ppm and at 9.11 and 9.07 ppm were assigned to the HH1 and HH2 conformers,
respectively. The two most upfield G* H8 signals at 8.36 and 8.35 ppm were assigned to the
∆HT conformer of the (Et4dt)Pt(d(G*G*T)) adduct. The downfield

31

P NMR signals at -3.25

and -2.46 ppm are characteristic of the HH1 and HH2 conformers, respectively; these shifts are
consistent with the shifts of the respective HH conformers of the (Et4dt)Pt(d(G*pG*)) adduct.
However, the 31P NMR signal for the ∆HT conformer could not be identified because the G*pT
phosphate group signals overlapped in the -3.8 to -4.5 ppm region. The T H6 signals at 7.85,
7.91, and 7.78 ppm were assigned to the HH1, the HH2 and the ∆HT conformers, respectively.
Although observed for (Et4dt)Pt(d(G*pG*)), the signals for the ΛHT conformer of
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(Et4dt)Pt(d(G*G*T)) were not detected, even two weeks after initiation of the reaction (final
distribution of the conformers was 43% HH2, 35% HH1, and 22% ∆HT, Figure 4.10).
4.4 Discussion
To understand the effect of the carrier ligand, we compare the properties of the
(R4dt)Pt(d(G*pG*)) adducts with the results reported for other LPt(d(G*pG*)) (L = 5,5′′Me2bipy,23 Me2ppz,54 and Bip43,53) adducts. Both Me2ppz and Bip are sp3 N-donor ligands with
the bulk of the ligand lying out of the Pt coordination plane. However, R4dt and 5,5′′-Me2bipy
are planar, aromatic sp2 N-donor ligands with significant bulk located in the coordination plane.
For the (5,5′′-Me2bipy)Pt(d(G*pG*)) adduct, the H6/H6′ atoms of the carrier ligand point toward
the cis G* residues, restricting the rate of rotation about the Pt–N7 bond.23 In contrast, it was our
hypothesis that the sterically less demanding N lone pair on each triazine ring in the
(R4dt)Pt(d(G*pG*)) adducts is expected to provide space for the cis G* residue to seek a more
favorable position and to undergo rotation. We tested this hypothesis by assessing conformer
distribution for (R4dt)Pt(d(G*pG*)) and (R4dt)Pt(oligo) adducts. Fortunately, the observation of
the previously elusive ΛHT conformer provided both a novel observation as well as evidence
suggesting that the hypothesis was correct.
4.4.1 Distribution of (R4dt)Pt(d(G*pG*)) (R4dt = Me4dt, Et4dt) Conformers
In addition to the HH1, HH2, and ∆HT conformers commonly observed in
LPt(d(G*pG*)) adducts, for the first time, a fourth form of an LPt(d(G*pG*)) adduct was
observed at low pH. This unusually abundant and slowly forming species appears to be the
elusive ΛHT conformer.
By monitoring HPLC traces and NMR signals, the now well-established HH, HH2, and
∆HT conformers were identified and found to be present in the HPLC peak with the shortest
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retention time (contains ∆HT and HH2) and the peak with an intermediate retention time (HH1).
The fourth form, which became abundant only very slowly, was present in the peak with the
longest retention time (Figure 4.7). The isolation of the peaks, followed by re-injection after
various time periods, led to better separation (probably related to the residual HPLC buffer from
the initial separation). The HPLC analysis of the re-injected peaks gave evidence that the ∆HT,
HH2, and HH1 conformers interchanged relatively quickly. Considering the dilute conditions and
the fact that the adducts were formed prior to separation, the interconversion of these conformers,
which involves rotation of the G* bases and in some cases backbone rearrangement, is expected.
Of particular importance, the peaks with the common conformers on re-injection gave
evidence for formation of the peak with the long retention time. In turn, re-injection of this peak,
isolated by HPLC from the reaction solution in which the adduct was formed, led to the
formation of the well-known conformers. These findings are compelling evidence that this fourth
form is the elusive ΛHT conformer, the only conformer previously not present in an abundant
amount under conditions where the d(G*pG*) moiety is in the normal protonation state with N1
of both guanines protonated.
We can suggest with reasonable confidence that the ΛHT conformer, despite the normally
favorable HT base arrangement, which avoids base-base clashes and which benefits from
antiparallel base dipole - base dipole interactions, may be a sterically large conformer unable to
fit easily into the cavity provided by the typical L carrier ligand. Other results, in addition to the
previous failure to detect any such abundant species, support this viewpoint. In particular, the
amount of the ΛHT conformer was considerably less (17%) for R = Et than the 40% observed
for R = Me in (R4dt)Pt(d(G*pG*)) adducts. This increase means that low bulk favors the ΛHT
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conformer. In addition, whereas the 3′-T flanking a crosslink normally has no effect, the ΛHT
conformer becomes much less abundant in adducts with a 3′-residue.
Although our study was not designed to assess mechanism, the results provide a
particularly good indication of the likely processes involved in conformer interchange. As
mentioned, the interchange from one conformer to another involves at the very least rotation of a
G* base. Rotation of the 5′-G* base could in theory convert HH1 to ΛHT, and vice versa. We
cannot rule out this process completely, but we see no evidence for this isomerization. Because
the backbone propagation direction differs for these two conformers, (1) for HH1 and (2) for
ΛHT, both base rotation and backbone rearrangement are required. This combination of
processes may be extremely slow.

Figure 4.11. Scheme relating the conformers of an (R4dt)Pt(d(G*pG*)) adduct modified from
Figure 1 to show fast interconversion (depicted by long counter-parallel arrows) between the two
HH conformers and the ∆HT conformer and slow interconversion (depicted by short counterparallel arrows) between the HH2 conformer and the ΛHT conformer. The interconversion
between the HH1 and ΛHT conformer requires both backbone rearrangement and base rotation (a
process expected to be extremely slow) while the interconversion between the HH2 and ΛHT
conformer requires only a simple rotation of the 3′-G* base (a process expected to be relatively
fast)
On the other hand, HH2 could convert to ΛHT without backbone rearrangement by
simple rotation of the 3′-G* base. However, our data suggest that whatever process leads to
ΛHT, the interconversion between the now more commonly identified conformers is relatively
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much faster (although not fast in the normal sense of the word). Thus, it could be rather difficult
to decide which of the conformers produced ΛHT by using results obtained starting with these
conformers.
Fortunately, under the solution conditions dictated by the isolation of the HPLC peaks,
the data using the peak for the uncommon fourth conformer are rather informative. The rates of
interconversion are such that ΛHT preferentially forms the HH2 conformer. Thus we can modify
the general scheme relating the conformers as shown in figure 4.11.
For the (5,5-Me2bipy)Pt(d(G*pG*)) adduct, a fourth set of signals was detected but was
not evaluated further because of the low abundance (~4%).23 The first evidence for a ΛHT
conformer (called ΛHT2) was reported for the (R,S,S,R)-BipPt(G*pG*) adduct at pH ~10.53
However, this conformer was not detected for the (Me2ppz)Pt(d(G*pG*)) adduct. Apparently,
the ΛHT conformer forms more slowly than the other conformers in LPt(d(G*pG*)) adducts. At
equilibrium, the distribution of the HH1, HH2, ∆HT, and ΛHT conformers was 36%, 18%, 6%,
and 40%, respectively, for the (Me4dt)Pt(d(G*pG*)) adduct and 41%, 33%, 9%, and 17%,
respectively, for the (Et4dt)Pt(d(G*pG*)) adduct. Evidently at equilibrium, the HH2 conformer
is more favored and the ΛHT conformer is less favored for (Et4dt)Pt(d(G*pG*)) than for
(Me4dt)Pt(d(G*pG*)).
At equilibrium, a relatively large percentage of the HH2 conformer was obtained for the
(Et4dt)Pt(d(G*pG*)) adduct when compared to the (5,5′′-Me2bipy)Pt(d(G*pG*))23 and
(Me2ppz)Pt(d(G*pG*))54 adducts (Table 4.3). During the early stages of the formation reaction
for (Me4dt)Pt(d(G*pG*)), a large abundance (37%) of the HH2 conformer was observed, which
redistributed with other conformers to give a final distribution of 18%. The large abundance of
the HH conformers can be attributed to the overall low steric effects of the R4dt ligand, allowing
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ample space for the HH conformers to exist without significant clashes between the O6 groups of
the d(G*pG*) moiety. (A triazine ring N atom + N lone pair grouping is sterically less impeding
than the C6 atom + H atom grouping in the sp2 N-donor 5,5′′-Me2bipy ligand studied earlier.)
Table 4.3. Conformer Distribution (%) for LPt(d(G*pG*)) and LPt(oligo) Adducts at
equilibrium.
adduct

HH1 HH2 ∆HT ΛHT

(Me4dt)Pt(d(G*pG*))

36

18

6

40

(Me4dt)Pt(d(G*G*T))

48

32

17

3

(Me4dt)Pt(d(TG*G*))

99

(Me4dt)Pt(d(TG*G*T))

99

(Et4dt)Pt(d(G*pG*))

41

33

9

17

(Et4dt)Pt(d(G*G*T))

43

35

22

(Et4dt)Pt(d(TG*G*))

99

(5,5-Me4bipy)Pt(d(G*pG*))23 52

10

34

(Me2ppz)Pt(d(G*pG*))54

20

30

50

In Table 4.3, the conformer distributions of (R4dt)Pt(oligo) adducts are compared to
those for the respective (R4dt)Pt(d(G*pG*)) adducts. For the (R4dt)Pt(d(G*G*T)) adducts, the
three HH1, HH2 and ∆HT conformers were abundant, but the distribution of these conformers
was different from that for the (R4dt)Pt(d(G*pG*)) adducts (Table 4.3). A low abundance of the
ΛHT conformer (3%) was observed four days after initiation of the reaction for the
(Me4dt)Pt(d(G*G*T)) adduct. However, for (Et4dt)Pt(d(G*G*T)) the H8 signals of this
conformer were not detected even 4 weeks after initiation of the reaction. This finding is
consistent with the slow isomerization to the ΛHT conformer for the (Et4dt)Pt(d(G*pG*))
adducts. The ΛHT conformer is less favored for the (R4dt)Pt(d(G*G*T)) adducts when R = Et
than when R = Me. The number of conformers and the H8 signal shifts for the
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(R4dt)Pt(d(G*G*T)) and (R4dt)Pt(d(G*pG*)) adducts were very similar. Thus, it can be inferred
that the 3′-T residue does not influence the structure of the d(G*pG*) cross-link.
In

contrast,

for

the

(Me4dt)Pt(d(TG*G*)),

(Et4dt)Pt(d(TG*G*))

and

(Me4dt)Pt(d(TG*G*T)) adducts, the HH1 L conformer was ~100% favored at equilibrium
(Figures 4.8 and 4.9). The remaining three possible conformers were not detected for these
adducts. A preference for the HH1 conformer was also observed for (Me2ppz)Pt(d(TG*G*)) and
(Me2ppz)Pt(d(TG*G*T)).54 Thus, the presence of a 5′-flanking T residue highly favors the HH1
conformer, and this propensity is not affected by the addition of a 3′-T residue. The 5′-substituent
remains the key factor in influencing the distribution and H8 shifts of the cross-link moiety.
4.4.2 Sugar-phosphodiester
Conformers

Backbone

of

(R4dt)Pt(d(G*pG*))

and

(R4dt)Pt(oligo)

The observation of a 5′-G* H8-H3′ NOE cross-peak indicated that the 5′-G* residue of all
the conformers of (R4dt)Pt(d(G*pG*)) (R4 = Me4 and Et4) adopts the N-sugar pucker universally
found for the 5′-G* sugar in LPt(d(G*pG*)) cross-link adducts.27,50,51,54,76 Thus, the favored Npucker observed for the 5′-G* sugar appears to be independent of the carrier ligand. The absence
or weakness of the 3′-G* H8-H3′ cross-peak indicated that the 3′-G* sugar for all the four
conformers of the (R4dt)Pt(d(G*pG*)) adduct has the S-sugar pucker. The S-pucker is favored
by the 3′-G* in free d(GpG) and also for the conformers of (5,5′′-Me2bipy)Pt(d(G*pG*))23,
(Me2ppz)Pt(d(G*pG*))54 and BipPt(d(G*pG*)).43,50,53 Moreover, the shifts of the sugar proton
signals of the commonly observed HH1, HH2 and ∆HT conformers of the (R4dt)Pt(d(G*pG*))
adduct were very similar to those of the (5,5′′-Me2bipy)Pt(d(G*pG*))23 and the
(Me2ppz)Pt(d(G*pG*)) adducts.54 Such similarity in the chemical shifts indicates that the sugarphosphodiester backbone has a similar structure in all adducts.
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The similarity in

the structure-sensitive

31

P

NMR

chemical

shifts of the

(R4dt)Pt(d(G*pG*)) conformers and the respective conformers of the previously studied
LPt(d(G*pG*)) adducts (L = 5,5′′-Me2bipy,23 Me2ppz,54 (S,R,R,S)-Bip,43 and (R,S,S,R)-Bip50)
provides further evidence that the carrier ligand has little influence on the structure of the sugarphosphodiester backbone for all conformers of LPt(d(G*pG*)) adducts.
The
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P NMR shifts (for the HH conformers) and the H8 chemical shifts for the

d(G*pG*) moiety of the (R4dt)Pt(d(G*G*T)) adduct are very similar to those of the respective
(R4dt)Pt(d(G*pG*)) adduct (Figure 4.9 and 4.10) indicating that the 3′-T residue is positioned
far from the 3′-G* residue and has little effect on the structure of the G*pG* sugarphosphodiester backbone. The 3′-T flanking a crosslink normally has no effect, the ΛHT
conformer becomes much less abundant in adducts with a 3′-residue. These results are in
agreement with those for HH and ∆HT conformers of the (Me2ppz)Pt(d(G*G*T)) adduct68 as
well as for the HH conformers of the dynamic LPt(d(GGTT)) adducts (L = ethylenediamine and
(MeNH2)2).25
For LPt(oligo) adducts (L = sp3 N-donor ligands) having a 5′-T residue, a downfield 31P
NMR signal ~-2.5 to -3.2 ppm was observed, a characteristic shift of the HH1 conformation of
the G*pG* cross-link.25 The structure sensitive 31P NMR signal for the exclusively formed HH1
conformer of both the (R4dt)Pt(d(TG*G*)) and the (R4dt)Pt(d(TG*G*T) adducts is ~1 ppm
upfield from the
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P NMR shift of the HH1 conformer of the respective (R4dt)Pt(d(G*pG*))

adduct. The 31P NMR signal shifts for the HH1 conformer of these (R4dt)Pt(oligo) adducts were
very similar to the shifts for unstrained phosphodiester groups in oligos (~-4 ppm).25 This may be
attributed to the overall low steric effects of the R4dt ligand, with two N + N lone pair groupings
which allow more space for the HH conformer to exist65 resulting in a less distorted backbone
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structure. Thus, it can be said that a 5′-T residue in a (R4dt)Pt(oligo) may slightly affect the
conformation of the sugar-phosphodiester backbone.
4.4.3 Base Canting

Figure 4.12. HH1, HH2, ∆HT and ΛHT conformers, showing variants with left-handed and
right-handed canting.
Besides the HH or HT orientation and backbone propagation direction, the other
significant structural feature is base canting. The bases are not exactly perpendicular to the
coordination plane, and the degree and the direction (left- or right-handed, Figure 4.12) of
canting differ depending on a number of factors and particularly the carrier ligand, the presence
or absence of a link between the bases, the sugar (ribo or deoxyribo), and the single-stranded or
duplex character of the DNA. Fortunately, the G* H8 signals are a good probe for assessing the
degree of base canting.43 Typically, H8 signals of the HH conformers of LPt(d(G*pG*)) adducts
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have chemical shifts of ~7.8-8.1 ppm (canted base) and ~8.8-9.2 ppm (less canted base),
respectively.43 For the HH orientation, often only one base is significantly canted, such that the
H8 atom is positioned toward the other cis base, which is less canted.55,61,63 The H8 atom of the
canted base is within the shielding region of the less canted base and has a relatively upfield H8
signal. The H8 signal of the less canted base is relatively downfield because this H8 is far from
the cis base shielding region.61,62 The HH H8 signals can be dispersed by as much as ~1 ppm.43
4.4.3.1 (R4dt)Pt(d(G*pG*)). According to the H8 shift method43 for assessing base
canting in the HH conformers of d(G*pG*) adducts with sp3 N-donor ligands, an H8 signal shift
of ~9.0 (3′-G*) and ~8.7 (5′-G*) ppm is associated with less canted bases.43 The
(Me2ppz)Pt(d(G*pG*)) G* H8 shifts reported for the HH1 conformer at 8.93 (3′-G*) and 8.51
(5′-G*) ppm and for the HH2 conformer at 8.78 (3′-G*) and 8.71 (5′-G*) ppm indicate low base
canting.54 Also, the G* bases in the HH conformers of the (5,5′′-Me2bipy)Pt(d(G*pG*)) adduct
were relatively less canted, with H8 signals at 9.14 and 8.76 ppm for the HH1 L conformer and at
9.07 and 8.83 ppm for the HH2 R conformer.23 The relatively downfield H8 signals of the (5,5′′Me2bipy)Pt(d(G*pG*)) adduct were attributed to the greater inductive effect of Pt because of the
relatively poor electron-donating ability of the aromatic 5,5′′-Me2bipy ligand compared to that of
the Me2ppz ligand.23 The even more downfield H8 signals for the (R4dt)Pt(d(G*pG*)) adduct
can be attributed to the presence of six nitrogen atoms in the aromatic rings, making this ligand a
poorer electron donor than the 5,5′′-Me2bipy ligand. We have experimental evidence that the
presence of DMSO in the solvent mixture also causes the signals to have a more downfield shift
than in water. The H8 signals for the (R4dt)Pt(d(G*pG*)) solutions containing ~36% DMSO
were ~0.15 ppm more downfield than when the solution contained ~10% DMSO.
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For the HH1 and the HH2 conformers of the (R4dt)Pt(d(G*pG*)) adducts, only HH2
gives sufficient dispersion to assess the canting direction. The 5′-G* is slightly canted toward the
cis 3′-G*, hence a more upfield 5′-G* H8 signal compared to the 3′-G* H8 signal. The bases in
the HH2 conformer of (Me4dt)Pt(d(G*pG*)) and (Et4dt)Pt(d(G*pG*)) adducts are right-hand
canted (Figure 4.12). The H8 chemical shifts and the small dispersion between the H8 signals of
the HH conformers of the (Me4dt)Pt(d(G*pG*)) and (Et4dt)Pt(d(G*pG*)) adducts (Table 4.2)
suggest relatively less canted bases in all cases.
Shift relationships to canting are not so easily interpreted for the ∆HT conformer.23,54 For
the (R4dt)Pt(d(G*pG*)) adduct, both 3′- and 5′-G* H8 signals are upfield (Table 4.2) but are
comparatively more downfield than the H8 signals of 3′-G* (8.01 ppm) and the 5′-G* bases (8.18
ppm) of the ∆HT conformer of the 5,5′-Me2bipyPt(d(G*pG*)) adduct. However, allowing for
the poor electron-donating effect of the R4dt ligand and the solvent effect (discussed above), the
bases in the ∆HT conformer for (R4dt)Pt(d(G*pG*)) and (5,5′-Me2bipy)Pt(d(G*pG*)) will most
likely cant in almost identical manner.23
For the ΛHT conformer of the (R4dt)Pt(d(G*pG*)) adduct, the small separations of H8
shifts, 0.38 ppm for the (Me4dt)Pt(d(G*pG*)) adduct and 0.33 ppm for the (Et4dt)Pt(d(G*pG*))
adduct, suggest the conformer has relatively small base canting.
4.4.3.2 Influence of Flanking T Residues on Base Canting. In order to use chemical
shifts to assess the influence of the flanking residue (T) on the base canting, it is important to
allow for the possible through-space and inductive effects of the T residue on the chemical shifts.
These effects can alter the shifts of the G* H8 and sugar proton signals of the respective parent
(R4dt)Pt(d(G*pG*)) adduct. First, the anisotropic effect of the phosphate group can deshield the
nearest H8 atom. The presence of a 5′-p group was found to cause a downfield shift of the 5′-G
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H8 signal.25,46,78 When this group is on the 3′-carbon, it is too far from the G* H8 to have much
direct influence on the H8 shift. Second, the anisotropy of the T base might also influence the H8
signals.
•

Influence of the 3′′-T on G* Base Canting. The conformers of the

(R4dt)Pt(d(G*G*T)) adduct with a 3′-flanking T residue have 5′- and 3′-G* H8 signal shifts very
similar to the respective signals of the (R4dt)Pt(d(G*pG*)) adduct (Table 4.2). The 3′-residue
has no significant influence on the H8 chemical shifts or the degree of canting for the d(G*pG*)
moiety.68 These results are consistent with those reported for the (Me2ppz)Pt(d(G*G*T))
adduct.68 Because the 3′-T residue is far from the 3′-G* residue, it has little or no effect on the
direction or degree of canting.
•

Influence of the 5′′-T on G* Base Canting. For the (R4dt)Pt(d(TG*G*)) HH1

conformer, the 5′-G* H8 signals are slightly upfield from the 5′-G* H8 signals of the respective
(R4dt)Pt(d(G*pG*)) adduct; however, the 3′-G* H8 signals were considerably downfield [0.38
ppm for (Me4dt)Pt(d(TG*G*)) and 0.62 ppm for (Et4dt)Pt(d(TG*G*))] from the 3′-G* H8
signal of the respective (R4dt)Pt(d(G*pG*)) adduct (Table 4.2). A very downfield 3′-G* H8
signal compared to the 5′-G* H8 signal indicates L canting in the HH1 conformer.44,47,68 The
doublet of doublets coupling pattern of the 5′-T H1′ signal indicates an S-sugar for the HH L
conformer

of

(R4dt)Pt(d(TG*G*))

adducts.

From

X-ray

structural

data

of

cis-

Pt(NH3)2(d(pG*pG*) and cis-Pt(NH3)2(d(CG*G*), the ammine cis to the canted 5′-G* in Lcanted, single-stranded (ss) cross-links always has an H-bond to the oligo,24,49 and the 5′-flanking
residue has an S-sugar.24 Because R4dt ligands cannot form H-bonds, we conclude that the
degree of L canting is a consequence of the steric effects of the 5′ residue, and the H-bonding

115

interactions are inconsequential. Our results are in agreement with the findings for
(Me2ppz)Pt(d(TG*G*)) and (Me2ppz)Pt(d(TG*G*T)) showing that any 5′-substituent, including
the 5′-p group, favors the HH1 L conformer.68
4.5 Conclusions
We report here the first evidence of formation of a substantial amount of a fourth form of
an LPt(d(G*pG*)) adduct. HPLC data suggest that this is the elusive ΛHT conformer of the N7–
Pt–N7 d(G*pG*) cross-link adduct. The putative ΛHT conformer of (R4dt)Pt(d(G*pG*)) is
kinetically less favored when compared to the HH1, HH2 and ∆HT conformers and becomes
abundant slowly (~8 weeks) by conformer isomerization. It is possible that this ΛHT conformer
was not detected in the previously reported less dynamic adducts, even after long time periods,
because of its slow rate of formation. However, for the (R4dt)Pt(d(G*pG*)) adduct all four
expected conformers could be identified and characterized by 1H NMR spectroscopy. Our results
with (R4dt)Pt(5′-GMP)2 revealed that the R4dt carrier ligand is sterically less demanding and
allows a less restricted rotation of G about the Pt–N7 bond. The detection of all four conformers
and absence of any EXSY cross-peaks for the (R4dt)Pt(d(G*pG*)) adduct provides the first clear
evidence that the sugar-phosphodiester backbone between two adjacent G’s slows the exchange
between the conformers.
From

the

distribution

Me2bipy)Pt(d(G*pG*)),23

of

conformers

BipPt-(d(G*pG*))43,50

and

for

(R4dt)Pt(d(G*pG*)),

Me2ppzPt(d(G*pG*))54

(5,5′adducts,

regardless of the carrier ligand the HH1 conformer is most abundant. However, the
thermodynamically favored putative ΛHT conformer for (Me4dt)Pt(d(G*pG*)) was almost as
abundant as the HH1 conformer at equilibrium. NMR results in this study also show that the
structure of the sugar-phosphodiester backbone differ from conformer to conformer, but the 31P
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NMR data for the (R4dt)Pt(d(TG*G*)) adduct, for the first time indicated that for a given
conformer, the backbone structure may depend on the carrier ligand. The low steric effects of the
N lone pairs of the R4dt ligand allow more space for the HH conformer to exist resulting in a less
distorted backbone for the HH1 conformer.
For all the (Et4dt)Pt(d(G*pG*)) conformers (except for ∆HT conformer present in 9%
abundance only), weak NOE cross-peaks (comparable in size) between the 3′-G* H8 and the
methyl peaks of the carrier ligand indicated that the substituents at the 6/6′ position in a bis-3,3′(1,2,4-triaizine) are close to the cis G*. The (Et4dt)Pt(d(G*pG*)) conformers isolated by HPLC,
upon re-injection, redistributed slowly (~2 days) compared to the (Me4dt)Pt(d(G*pG*))
conformers, which interconverted significantly after ~1day.

Also, in contrast to the

(Me4dt)Pt(d(G*G*T)) adduct, the ΛHT conformer does not form for the (Et4dt)Pt(d(G*G*T))
adduct. These evidences in addition to the results from the (R4dt)Pt(5′-GMP)2 studies65 suggest
that placing greater bulk at the 6,6′ positions by changing R in R4dt from Me to Et has a clear
effect on the G* base rotation rate about Pt–N7 bond.
Because of the symmetrical nature of the carrier ligand in (R4dt)Pt(d(G*pG*)), the two
bases of the HH and HT conformers may ‘wag’ between R and L canting, causing the H8 signals
of the conformers to have relatively similar shifts. However, the H8 shifts also indicate that the
base canting in (R4dt)Pt(d(G*pG*)) conformers is small. These results agree with the low base
canting observed for the (5,5′-Me2bipy)Pt(d(G*pG*)) conformers. However, the presence of a
5′-flanking T residue on the d(GpG) sequence introduces L canting of the bases in the HH1
conformer. Unless a carrier ligand such as (R,S,S,R)-Bip (which favors right-handed canting) is
present,44,79 all single-stranded N7–Pt–N7 cross-links regardless of oligonucleotide length are
left-handed.20,54,68 The highly L nature of the ss adducts with a 5′-T residue is chiefly a
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consequence of the bulk of the 5′ substituents; factors such as H-bonding are inconsequential.
Also, the 5′-T residue maintains an S-sugar pucker in the ss adducts even in the absence of Hbonding, providing further support to the finding that the N-pucker of this residue in the Lippard
bp step of duplexes is related to stacking and Watson-Crick H-bonding and not to the
insignificance of ammine H-bonding.68
Several important points have emerged from a comparison of the (R4dt)Pt(oligo) adducts
with (R4dt)Pt(d(G*pG*)). For (R4dt)Pt adducts at equilibrium, d(G*pG*) and d(G*G*T)
uniquely have all the four conformers (except for the (Et4dt)Pt(d(G*G*T)) ΛHT conformer
which does not form), but, in contrast, d(TG*G*) has only the HH1 conformer. The ΛHT
conformer becomes much less abundant in adducts with a 3′-residue. The structure sensitive 31P
NMR

shifts

were

similar

for

the

HH

conformers

of

(R4dt)Pt(d(G*G*T))

and

(R4dt)Pt(d(G*pG*)), however, for the HH1 conformer of (R4dt)Pt(d(TG*G*)) the signals were
~1 ppm upfield to that for the respective (R4dt)Pt(d(G*pG*)). Evidently, the 3′-flanking T
residue has little or no effect, but the 5′-flanking T residue has a dramatic effect on the conformer
distribution and the d(G*pG*) cross-link structure.
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CHAPTER 5. LIGAND AND COORDINATION-PLANE DISTORTIONS IN Pt(II)
COMPLEXES OF ISOMERS OF DIMETHYL-2,2′′-BIPYRIDINE*
5.1 Introduction
Rosenberg’s serendipitous discovery of the anticancer activity of cisplatin, cisPt(NH3)2Cl2,1 has stimulated extensive interest in the interaction of Pt complexes with nucleic
acids. Pt compounds can bind to DNA by either covalent or non-covalent interactions. Cisplatin
and several other Pt anticancer drugs interact with nucleic acids by forming 1,2-intrastrand crosslinks having covalent Pt−N7 bonds with two adjacent guanines.2,3 Dichloro Pt(II) complexes of
aromatic sp2 N-donor ligands such as 5,5′-dimethyl-2,2′-bipyridine (5,5′′-Me2bipy),4 2,9dimethyl-1,10-phenanthroline (2,9-Me2phen)5 and 3-(4-methylpyridin-2′-yl)-5,6-dimethyl-1,2,4triazine (MepyMe2t)6 (Figure 5.1) also form adducts with Pt−N7 bonds to two guanine ligands.
From these adducts it is possible to gain insight into structure by using NMR methods, because
the dynamic motion around the Pt−N7 bonds is decreased compared to adducts of active drugs.
A Pt(II) complex having aromatic ligands can not only bind to nucleobases but can also
intercalate into DNA.7-14 Aromatic ring stacking between nucleobases and the intercalating
molecule is considered to be one of the driving forces leading to binding; the extent of binding is
expected to depend on the planarity of the complex.11,15
Because of the planar nature of bipyridine ligands, intercalation of Pt bipyridine
complexes has been the focus of considerable interest.9,11,16,17 The cation, [(bipy)2Pt]2+ (bipy =
2,2′-bipyridine), was reported to intercalate into DNA through only one of the bipy ligands.9
____________________________________________________________________________
* Reproduced with permission from International Union of Crystallography: Maheshwari, V.;
Carlone, M.; Fronczek, F. R.; Marzilli, L. G., "Ligand and Coordination-Plane Distortions in
Pt(II) Complexes of Isomers of Dimethyl-2,2′-bipyridine," Acta Crystallographica, Section B:
Structural Science, 2007, B63, 603-611. Copyright 2007 International Union of Crystallography.
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Figure 5.1 Stick representations and numbering schemes for coordinated (a) dimethyl-2,2′bipyridine (Me2bipy) and (b) 3-(4′-substituted pyridin-2′-yl)-5,6-disubstituted-1,2,4-triazine
(R1pyR2R3t) ligands.
For [(R2bipy)M(en)](ClO4)2 (M = Pt or Pd, R = H or CH3 and en = ethylenediamine)
complexes, the binding constant value was found to be higher for R = CH3 when M = Pd.11
Previously we speculated that the antiviral activity of the [(pyPh2t)2Pt](BF4)2 (pyPh2t = 3(pyridin-2-yl)-5,6-diphenyl-1,2,4-triazine) complex18 could arise from intercalation of the highly
planar [trans-(pyPh2t)2Pt](BF4)2 complex into nucleic acids.6
Because the uncoordinated 2,2′-bipyridine ligand is essentially planar with an anti
conformation,19,20 the H3 to H3′ repulsion is avoided. However, except in rare, unusual cases,
coordinated bipyridines have a syn conformation (Figure 5.1) leading to the possibility that the
H3 to H3′ repulsion will explain distortions from planarity found in the coordinated ligand.21 In
this study we have synthesized and crystallized such dimethyl-2,2′-bipyridine platinum
complexes as (Me2bipy)PtCl2 and [(Me2bipy)2Pt]X2. Structural analysis of these Me2bipy
complexes has allowed us to evaluate the effect of having methyl groups at the 4,4′, 5,5′, and 6,6′
positions on distortions from planarity of these complexes. The extent of distortion of
coordinated bipyridine ligands is characterized by parameters in Figure 5.2, defined by Hazell
(2004). We also discuss the extent of distortions by using the following dihedral angles: θdi,
between the best planes through the two pyridyl rings in a bipyridine ligand; and θS, between the
coordination plane (defined by the best plane through the four donor atoms surrounding the
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metal) and the plane of the aromatic portion of the bipyridine ligand (defined by NCC′N′ atoms)
(Figure 5.3).22 The structural features and coordination parameters of I-IV are compared with
those of published Pt/Pd complexes with bipyridine or 3-(pyridin-2′-yl)-5,6-disubstitued-1,2,4triazine (R1pyR2R3t) ligands (Figure 5.1). The latter have no H3 to H3′ repulsive interactions.6

Figure 5.2 Distortions in bipyridine ligands: (a) twist angle (θT), (b) bowing (θB), (c) S-shaped
distortion (ds), (d) in-plane bending (θP). θT, θB and θP are the angles between the best straight
lines (ax + c = z) through each pyridyl ring of the bipyridine ligand in the yz, xz and xy
projections, respectively. ds is the perpendicular distance between the best straight lines through
each pyridyl ring in the xz projection.21

Figure 5.3 The dihedral angles: θdi between the best planes through the two pyridyl rings in a
bipyridine ligand; and θS, between the metal coordination plane and the plane containing the
NCC′N′ atoms of the bipyridine ligand.
5.2 Experimental
5.2.1 Starting Materials
4,4′-Dimethyl-2,2′-bipyridine

(4,4′′-Me2bipy),

5,5′-dimethyl-2,2′-bipyridine

(5,5′′-

Me2bipy), and 6,6′-dimethyl-2,2′-bipyridine (6,6′′-Me2bipy) were used as received (Aldrich).
cis-Pt(Me2SO)2Cl2 was prepared as described in the literature.23
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5.2.2 NMR Measurements
1

H NMR spectra were recorded on a Bruker spectrometer operating at 400 MHz. TMS

was used to reference the signals.
5.2.3 General Synthesis of Dichloro Bipyridine Platinum Complexes
Two methods were employed to obtain (Me2bipy)PtCl2 complexes. Method A involved
heating a methanol solution (30 mL) of cis-Pt(Me2SO)2Cl2 (0.101 g, 0.24 mmol) and the desired
Me2bipy ligand (0.044 g, 0.24 mmol) at 60 °C for 12 h. The yellow solid that precipitated was
collected, washed with diethyl ether followed by chloroform, and dried in vacuo. This method
produced high yields of powdered (Me2bipy)PtCl2 complexes that required no further
purification. Method B, employed to obtain X-ray-quality crystals, involved mixing equal
volumes of 10 mM solutions of cis-Pt(Me2SO)2Cl2 and the ligand in acetonitrile (total volume ~2
mL) and allowing this mixture to stand at 25 °C. Yellow to orange colored crystals of the
(Me2bipy)PtCl2 complex were collected after 24 h.
5.2.3.1 Dichloro(4,4′′-dimethyl-2,2′′-bipyridyl)platinum(II) ((4,4′′-Me2bipy)PtCl2, I).
Method A gave a yellow precipitate: yield, 73.5 mg (68%). Method B afforded thin yellow
needles. C12H12Cl2N2Pt: yield, 1.7 mg (38%).1H NMR (ppm) in DMSO-d6: 9.27 (d, H6/6'), 8.44
(s, H3/3'), 7.66 (d, H5/5'), 2.48 (s, 4/4'-CH3).
5.2.3.2 Dichloro(5,5′′-dimethyl-2,2′′-bipyridyl)platinum(II) ((5,5′′-Me2bipy)PtCl2, II).
Method A resulted in a yellow powder: yield, 75.8 mg (70%). Yellow plates were obtained by
method B. C12H12Cl2N2Pt: yield, 1.9 mg (42%).1H NMR (ppm) in DMSO-d6: 9.28 (s, H6/6'),
8.42 (d, H3/3'), 8.23 (d, H4/4'), 2.49 (s, 5/5'-CH3).
5.2.3.3 Dichloro(6,6′′-dimethyl-2,2′′-bipyridyl)platinum(II) ((6,6′′-Me2bipy)PtCl2, III).
The complex was obtained as a yellow solid by method A: yield, 48.6 mg (45%). Slow
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evaporation of an acetonitrile solution of (6,6'-Me2bipy)PtCl2 (~10.0 mg in 1 mL) produced Xray quality orange needle-shaped crystals. The Pt(6,6′′-Me2bipy)Cl2 complex co-crystallized with
a molecule of acetonitrile. C12H12N2Cl2Pt•C2H3N: yield, 1.1 mg (25%).1H NMR (ppm) in
(CD3)2CO: 7.55 (d, H(5/5'), 8.15 (t, H4/4'), 8.22 (d, H3/3'), 2.99 (s, 6/6'-CH3).
5.2.3.4

Bis(4,4'-dimethyl-2,2'-bipyridyl)platinum(II)

Tetra-fluoroborate

([(4,4'-

Me2bipy)2Pt](BF4)2, IV). cis-Pt(Me2SO)2Cl2 (42.22 mg, 0.1 mmol) was added to a methanol
solution of 4,4'-Me2bipy (73.69 mg, 0.4 mmol, 10 mL), and the resulting suspension became a
solution when stirred at 60 °C for 24 h. The mixture was allowed to cool to room temperature.
Any precipitate that formed was removed by filtration. Crystals were obtained from the clear
filtrate by dropwise addition of a methanol solution of NaBF4 (10 mM, ~500 µL) to 10 mL of
filtrate. Thin, colorless, needle-shaped crystals of [(4,4'-Me2bipy)2Pt](BF4)2 co-crystallized with
uncomplexed ligand on allowing the solution to stand undisturbed for 24 h. A set of upfield
signals in the NMR spectrum of the crystals provided evidence of the free 4,4'-Me2bipy ligand.
C24H24N4B2F8Pt•C12H12N2: yield, 15 mg (21%). 1H NMR (ppm) in DMSO-d6: for [(4,4'Me2bipy)2Pt](BF4)2: 8.85 (d, H6/6'), 8.66 (s, H3/3'), 7.82 (d, H5/5'), 2.63 (s, 4/4'-CH3) and for
4,4'-Me2bipy: 8.49 (d, H6/6'), 8.19 (s, H3/3'), 7.24 (d, H5/5'), 2.38 (s, 4/4'-CH3).
5.2.4 X-ray Data Collection and Structure Determination
Single crystals were placed in a cooled nitrogen gas stream at 105 or 110 K on a Nonius
Kappa CCD diffractometer fitted with an Oxford Cryostream cooler with graphitemonochromated Mo Kα (0.71073 Å) radiation. Data reduction included absorption corrections
by the multi-scan method, using HKL Denzo and Scalepack.24 All X-ray structures were
determined by direct methods and difference Fourier techniques. SIR9725 and SHELXL9726
programs were used to solve and refine the crystal structures.
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All H atoms were visible in difference maps, but were placed in idealized positions, with
C−H = 0.95-1.00 Å, depending on atom type. A torsional parameter was refined for each methyl
group. Displacement parameters for H were assigned as Uiso = 1.2Ueq of the attached atom (1.5
for methyl groups). All non-hydrogen atoms were refined anisotropically. For all structures,
maximum residual densities were located near the Pt positions.
5.3 Results and Discussion
Structures of I-IV are reported here (Figure 5.4). Crystal data and structure refinement
parameters are listed in Table 5.1.

Figure 5.4 ORTEP plots of (4,4′′-Me2bipy)PtCl2 (I); (5,5′′-Me2bipy)PtCl2 (II); (6,6′′Me2bipy)PtCl2 (III); and [(4,4′′-Me2bipy)2Pt](BF4)2 (IV). The solvent molecule in III and the
uncomplexed 4,4′′-Me2bipy ligand and the counter ion (BF4) in IV are not shown for clarity.
Thermal ellipsoids are drawn with 50% probability.
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Table 5.1 Crystal Data and Experimental Details for (4,4′′-Me2bipy)PtCl2 (I), (5,5′′Me2bipy)PtCl2 (II), (6,6′′-Me2bipy)PtCl2 (III), and [(4,4′′-Me2bipy)2Pt](BF4)2 (IV).
I

II

III

IV

Chemical formula

C12H12Cl2N2Pt

C12H12Cl2N2Pt

C12H12Cl2N2Pt•
C2H3N

[Pt(C12H12N2)2](BF4)2•
C12H12N2

Mr

450.23

450.23

491.28

921.42

Cell setting, space
group

Monoclinic, P21/n

Monoclinic, C2/c

Triclinic, P 1

Triclinic, P 1

Temperature (K)

110

105

105

110

a, b, c (Å)

6.7739 (10), 10.755 13.162 (3), 9.088
(2), 17.312 (3)
(2), 12.125 (3)

8.1049 (10), 8.7028 7.3395 (10), 10.580 (2),
(10), 12.005 (2)
12.093 (2)

α, β, γ (°)

90, 93.80 (2), 90

90, 121.110 (11),
90

73.863 (5), 73.919
(5), 77.132 (6)

70.602 (9), 87.384 (12),
79.978 (12)

V (Å3)

1258.5 (4)

1241.8 (5)

771.78 (18)

872.1 (2)

4

4

2

1

Dx (Mg m )

2.376

2.408

2.114

1.754

Radiation type

Mo Kα

Mo Kα

Mo Kα

Mo Kα

µ (mm )

11.55

11.71

9.43

4.10

Crystal form,
colour

Needle, yellow

Plate, yellow

Needle, orange

Needle, colorless

Crystal size (mm)

0.22 × 0.10 × 0.10

0.11 × 0.10 × 0.04

0.15 × 0.05 × 0.05

0.15 × 0.05 × 0.03

Diffractometer

KappaCCD (with
Oxford
Cryostream)

KappaCCD (with
Oxford
Cryostream)

KappaCCD (with
Oxford
Cryostream)

KappaCCD (with
Oxford Cryostream)

Data collection
method

ω scans with κ
offsets

ω scans with κ
offsets

ω scans with κ
offsets

ω scans with κ offsets

Absorption
correction

Multi-scan (based
on symmetryrelated
measurements)

Multi-scan (based
on symmetryrelated
measurements)

Multi-scan (based
on symmetryrelated
measurements)

Multi-scan (based on
symmetry-related
measurements)

Tmin

0.150

0.341

0.380

0.578

Tmax

0.315

0.626

0.624

0.887

No. of measured,
independent and
observed
reflections

16686, 7208, 5830

15159, 2482, 2283

34009, 6114, 5654

19893, 6773, 6435

Criterion for
observed
reflections

I > 2σ(I)

I > 2σ(I)

I > 2σ(I)

I > 2σ(I)

Crystal data

Z
–3

–1

Data collection
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(table 5.1 continued)
Rint

0.039

0.025

0.022

0.045

θmax (°)

40.7

33.7

33.7

33.7

Refinement on

F2

F2

F2

F2

R[F2 > 2σ(F2)],
wR(F2), S

0.037, 0.085, 1.04

0.026, 0.056, 1.06

0.023, 0.045, 1.06

0.043, 0.082, 1.06

No. of relections

7208

2482

6114

6773

No. of parameters

157

80

193

245

H-atom treatment

Constrained to
parent site

Constrained to
parent site

Constrained to
parent site

Constrained to parent
site

Weighting scheme

w = 1/[σ2(Fo2) +
(0.0235P)2 +
6.6393P] where P
= (Fo2 + 2Fc2)/3

w = 1/[σ2(Fo2) +
(0.0176P)2 +
3.5799P] where P
= (Fo2 + 2Fc2)/3

w = 1/[σ2(Fo2) +
(0.0062P)2 +
1.4431P] where P
= (Fo2 + 2Fc2)/3

w = 1/[σ2(Fo2) +
(0.0253P)2 + 1.6231P]
where P = (Fo2 +
2Fc2)/3

(∆/σ)max

0.001

0.001

0.002

<0.0001

∆ρmax, ∆ρmin (e Å ) 2.84, –3.50

1.59, –2.48

1.23, –2.26

1.42, –1.87

Extinction method

SHELXL

SHELXL

SHELXL

SHELXL

Extinction
coefficient

0.00231 (17)

0.00066 (8)

0.0073 (2)

0.0013 (4)

Refinement

–3

Computer programs: COLLECT ;30 HKL Scalepack;24 HKL Denzo and Scalepack;24 SIR97;25 SIR97;25 SHELXL97;26 ORTEP-3 for Windows.31

The X-ray structures of (6,6′′-Me2bipy)PdCl2 and (6-Mebipy)PdCl2 complexes were
reported at room temperature by Newkome et al. (1982). The deformation calculations were
done using X-ray data at T = 100 K.27 The structure of II at room temperature was first reported
by Miskowski (1993) with Z′ = 1 in space group Cc. Marsh (1997), revisiting the perils of Cc,
pointed out that the structure can be better described with the molecule lying on a twofold axis in
C2/c.29 Our refinement using low-temperature data confirms Marsh’s assessment. In the structure
of IV, both the Pt complex and uncomplexed ligand lie on inversion centers. The acetonitrile
molecule in III is disordered into two orientations with populations 0.720(5):0.280(5), with a
common methyl site.
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5.3.1 Out-of-Plane Distortions
5.3.1.1 Dichloro Pt(II)/Pd(II) Complexes. Hazell noted that bipyridines are not planar
in metal complexes that have M−N distances within the typical range of ~2.0 to 2.2 Å.32 The outof-plane distortions that these complexes display can be described in terms of bowing, twisting,
and S-shaped deformation (Figure 5.2).21 Hazell examined distortions for 551 metal complexes
containing 2,2′-bipyridine (bipy) or substituted 2,2′-bipyridines from the Cambridge Structural
Database33 and calculated that the twist angle (θT) ranges from 0.0 to 26.1° and the bow angle
(θB) ranges from 0.0 to 19.8°.21
Table 5.2 Ligand deformation in platinum and palladium complexes.a
Compound

(4,4′′-Me2bipy)PtCl2 (I)b

Twist

Bow

S-shaped

In-plane

M−N

Dihedral

angle

angle

distortion

distortion

distance

angles

(θT)

(θB)

(ds)

(θP)

(Å)

(θdi)

2.4

0.1

0.002

5.9

2.023(3)

2.8(6)

89.49(4)

Cl−M−Cl

2.027(3)
(5,5′′-Me2bipy)PtCl2 (II)

b

(6,6′′-Me2bipy)PtCl2 (III)b

5.5

0.0

0.075

8.9

2.017(3)

5.56(6)

89.76(5)

6.1

19.2

0.000

10.9

2.028(2)

20.18(14)

86.25(2)

2.030(2)
(bipy)PtCl2

34

(bipy)PdCl235
c

(6,6′′-Me2bipy)PdCl2

0.0

0.0

0.000

8.8

2.009(6)

0.0

89.1(1)

2.3

1.9

0.009

8.9

2.03(1)

3.0

89.9(1)

1.2

15.7

0.039

10.0

2.059(1)

15.7(2)

86.42(2)

14.5(1)

88.74(1)

2.9

89.13(3)

9.4

90.12(13)

6.6

89.16(3)

2.043(1)
(6-Mebipy)PdCl2c

5.6

13.3

0.006

9.3

2.055(1)
2.021(1)

6

(pyMe2t)PtCl2

2.4

1.9

0.003

8.9

2.020(3)
2.001(3)

6

(pyPht)PtCl2

2.1

9.3

0.008

8.1

2.011(11)
1.996(11)

(pyPh2t)PtCl26

6.2

2.2

0.032

8.4

2.027(3)
1.996(3)

[(4,4′′-Me2bipy)2Pt](BF4)2

4.6

24.2

0.005

8.7

2.032(3)

24.8(2)

4.1

0.2

0.031

8.5

2.050(3)

4.1

(IV)b
[(pyPh2t)2Pt](BF4)26
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(table 5.2 continued)
2.019(3)
[(bipy)2Pt](NO3)2

32

39

[(bipy)2Pd](NO3)2

2.1

1.2

0.073

7.5

2.025(4)

2.3

10.4

0.4

0.006

7.4

2.028(5)

11.9

1.8

0.2

0.098

7.9

2.030(1)

1.8

2.030(1)
7.7

0.3

0.089

8.3

2.028(1)

7.7

2.050(1)
[(bipy)2Pd](BF4)2

40

8.8

0.2

0.089

8.9

2.031(4)

8.7

2.029(3)
7.9

2.1

0.104

8.5

2.031(4)

8.1

2.030(3)
[(bipy)2Pd](PF6)2

22

0.1

19.0

0.006

8.8

2.039(2)

19.1

2.032(2)
a

Angles are in degrees; ds and the M−N distances are in Å. θT, θB, θP, θdi and ds values were calculated by using a
program in FORTRAN provided by Dr. Alan Hazell. θdi for structures reported in this work were calculated using
SHELXL. b This work. c Newkome et al. (1982). Based on new refinements using 100 K data.27

No substantial twisting or bowing distortions were observed for the unsubstituted bipy
ligand in the (bipy)PtCl234 and (bipy)PdCl235 complexes (Table 5.2), although the small
distortions that do occur may be the result of packing forces.36-38 These complexes do show
typical θP (see below) values, but θdi values are small or zero (Table 5.2).

Figure 5.5 Side (left) and front (right) view of (6,6′′-Me2bipy)PtCl2 (III).
Among the dichloro Pt complexes in Table 5.2, (6,6′′-Me2bipy)PtCl2 (III) is the most
distorted, with an exceptionally large bowing angle (θB = 19.2°) and a comparatively large twist
angle (θT = 6.1°). These distortions can be attributed to steric repulsion resulting from the close
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proximity of the 6,6′ methyl groups and the cis chlorides. The θS value shows that the aromatic
portion of 6,6′′-Me2bipy in III is out of the Pt coordination plane by 36.73(11)° (Figure 5.5).
Similar out-of-plane distortions characterized by θS of 38.84(9)° for (6,6′′-Me2bipy)PdCl2 and
27.44(7)° for (6-Mebipy)PdCl2 (6-Mebipy = 6-methyl-2,2′-bipyridine) were observed. For all
the other dichloro complexes in Table 5.2, the θS values are small, ranging from 0 to 8°. No Sshaped distortion (Figure 5.2) is observed for III (Table 5.2). The S-shaped distortions
characterized by the ds values and calculated for all the dichloro metal complexes listed in Table
5.2, are within the 0-0.127 Å range reported by Hazell (2004).
In contrast to the Pt/Pd dichloro complexes of 6,6′′-Me2bipy and 6-Mebipy, for all the
other Pt/Pd dichloro bipyridine complexes studied here and for those in Table 5.2, the distortion
is characterized more by twisting than bowing (Table 5.2). The two pyridyl rings of the ligand in
(4,4′′-Me2bipy)PtCl2 (I) and (5,5′′-Me2bipy)PtCl2 (II) were only slightly twisted with respect to
each other. The θS values for I (3.9(5)°) and II (0.6(2)°) suggest that the aromatic portion of the
ligands is only slightly out of the Pt coordination plane. The weakness of the interactions
between the H6,6′ hydrogens and the cis chlorides may explain the relatively undistorted
structures of I, II, (bipy)PtCl2 and (bipy)PdCl2. A comparison of these dichloro bipyridine
complexes with (R1pyR2R3t)PtCl2 complexes is revealing. The twisting and bowing are smaller
in (pyMe2t)PtCl2 (pyMe2t = 3-(pyridin-2′-yl)-5,6-dimethyl-1,2,4-triazine) and generally similar
for those in the dichloro bipyridine Pt/Pd complexes. In (pyPh2t)PtCl2 (pyPh2t = 3-(pyridin-2′yl)-5,6-diphenyl-1,2,4-triazine), the pyridyl and the triazine rings are more twisted (θT = 6.2°),
whereas in (pyPht)PtCl2 (pyPht = 3-(pyridin-2′-yl)-5-phenyl-1,2,4-triazine), the pyridyl and the
triazine rings are more bowed (θB = 9.3°). However, the interactions which can occur in the
(R1pyR2R3t)PtCl2 complexes should be similar. Thus, the larger distortions in the complexes
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with phenyl substituents are undoubtedly due to solid state effects. These effects are apparently
less important for ligands with the smaller methyl substituents.

Figure 5.6 (a) Canting, and (b) bow-incline deformations in [(bipy)2Pt]X2 complexes.
5.3.1.2 Bis Chelate Pt/Pd Complexes. For bis bipyridine metal complexes, the hydrogen
atoms on the 6,6′ carbons of opposite ligands are expected to have a non-bonded internuclear
separation less than the sum of the van der Waals radii (2.4 Å).41 Consequently, to relieve this
steric strain, the molecule undergoes either a tetrahedral deformation at the metal, resulting in
canting of the ligands relative to each other, or bowing of the two pyridyl rings of the bipyridine
ligand (Figure 5.6).6,42 The bis bipyridine Pt/Pd complexes are more distorted than the dichloro
bipyridine complexes (Table 5.2). However, the ds values for the S-shaped distortion (Figure 5.2)
calculated for all the bis chelate metal complexes in Table 5.2 were comparable to those for the
dichloro metal complexes. The θT and θB values calculated for all the metal complexes in Table
5.2, except θB in [(4,4′′-Me2bipy)2Pt](BF4)2 (IV), lie within the range calculated by Hazell
(2004). The strain induced by the close approach of the H6 hydrogens on the opposing ligands in
IV is relieved partly by adopting an incline conformation and partly by bowing of the two
pyridyl rings of the 4,4′′-Me2bipy ligand. The incline conformation in bis chelate complexes is
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characterized by the dihedral angle (θS), between the metal coordination plane and the NCC′N′
ligand plane (18.80(13)°). Figure 5.7 shows that the two pyridyl rings of 4,4′′-Me2bipy ligands in
IV are bowed (θB = 24.2°) away from each other. This type of bow-incline distortion has been
described previously as a bow-step distortion.22 A slight twisting (θT = 4.6°) of the two pyridyl
rings in 4,4′′-Me2bipy in IV is also seen.

Figure 5.7 Side (left) and front (right) view of [(4,4′′-Me2bipy)2Pt](BF4)2 (IV).
An alternative distortion to relieve steric stress is canting (Figure 5.6). The canting angle
(θC) is defined by the dihedral angle between the best planes through the two bipyridine ligands.
In contrast to the bow-incline distortion in IV, Pt and Pd complexes of the unsubstituted
bipyridine distort more frequently by canting. In [(bipy)2Pt](NO3)2,32 the two bipy ligands are
canted relative to one another (θC = 34.47°). In order to further relieve the repulsion due to the
interligand 6,6′-hydrogens, each bipy ligand is also twisted, with one bipy twisted (θT = 10.4°)
more than the other (θT = 2.1°). A very similar structure was reported for [(bipy)2Pd](NO3)239
(Table 5.2). In [(bipy)2Pd](BF4)240 the two bipy ligands are canted (θC = 36.45°) and also twisted
(θT = 8.8° and 7.9°). In contrast, a bow-incline distortion (θB = 19.0°, θS = 21.6°) similar to that
in IV was found for the PF6 salt, [(bipy)2Pd](PF6)2.40 However, unlike IV, the bipy ligands in
[(bipy)2Pd](PF6)2 are not twisted.
In contrast to [(4,4′′-Me2bipy)2Pt](BF4)2, the geometry of [trans-(pyPh2t)2Pt](BF4)2 is
planar and symmetrical because of the trans relationship of the coordinated pyPh2t ligands.6 The
complex, [trans-(pyPh2t)2Pt](BF4)2, has no apparent bowing or canting. The attractive
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interaction between the lone pairs on the non-bonded triazine N of one ligand and the pyridyl
H6′ of the opposing ligand is probably responsible for the planarity of [trans-(pyPh2t)2Pt](BF4)2.
The interactions between the juxtaposed groups on the two rings ortho to the bridging carbons
and on the periphery of the bidentate ligand are favorable for R1pyR2R3t ligands but unfavorable
for 2,2′-bipyridine-type ligands. For all the bis bipyridine metal complexes discussed above, the
interligand hydrogen-hydrogen separations are less than the sum of the van der Waals radii,
indicating that unfavorable repulsions lead to the canting and bow-incline distortions. These
distortions must be similar in energy with solid-state effects determining which distortion occurs
for a particular cation/anion combination.
5.3.2 In-Plane Bending and Coordination-Plane Distortion of Dichloro Pt(II)/Pd(II)
Complexes
5.3.2.1 In-Plane Bending. The in-plane bending for all the metal complexes studied here
is well within the range (θP = 2.9-12.5°) reported by Hazell (2004). As mentioned, the repulsive
interaction of the H3 to H3′ in the metal complexes bearing bipyridine ligands was postulated to
cause an in-plane bending.32 However, for all the dichloro bipyridine Pt/Pd complexes and
(R1pyR2R3t)PtCl2 complexes in Table 5.2, the M−N distances are comparable. It is noteworthy
that in-plane bending in Pt complexes of R1pyR2R3t ligands, unlike bipyridines, cannot be
increased by H3-H3′ repulsions because the pyridyl H3 is near the lone-pair-bearing triazine N;
this juxtaposition should create a slight favorable attractive interaction. Therefore, any stress
resulting from H3 to H3′ repulsion in bipyridine metal complexes does not produce any
substantial effect on the in-plane bending. Rather, coordination of these bidentate ligands to the
metal may require in-plane bending of the ligands in order to allow optimal overlap of the N and
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metal orbitals. This interpretation is consistent with the report that the θP values decrease with
increasing M−N distances.21
The Cl–Pt–Cl bond angle is significantly smaller in III and (6,6′′-Me2bipy)PdCl2 than in
all other dichloro bipyridine metal complexes in Table 5.2. The Cl–M–Cl bond angle increases in
the order: III ≈ (6,6′′-Me2bipy)PdCl2 < (6-Mebipy)PdCl2 < (pyMe2t)PtCl2 ≈ (pyPh2t)PtCl2 < I ≈
II ≈ (bipy)PtCl2 ≈ (bipy)PdCl2 (Table 5.2). Complexes with larger θP values are observed to
have generally smaller Cl−Pt−Cl bond angles (Table 5.2).
For III and (6,6′′-Me2bipy)PdCl2, the θP values are comparatively larger and the Cl–M–
Cl bond angles are smaller than those for all other dichloro metal complexes in Table 5.2. A
large in-plane bending will cause the 6,6′ methyl groups to be closer to the Cl’s. The internuclear
distances between the C’s of the methyl groups and the cis chlorides (CMe⋅⋅⋅Cl) are 3.138 and
3.186 Å for III and 3.151 and 3.178 Å for (6,6′′-Me2bipy)PdCl2. These values are even smaller
than the sum of the minimum value calculated for the van der Waals radii of the methyl group43
and the Cl atom (3.461 Å), as well as for the C and the Cl atoms (3.45 Å).41 Thus, the repulsions
between the 6,6′ methyl groups and the cis chlorides push the Cl atoms toward one another,
causing the Cl–Pt–Cl bond angle to be smaller than that for the other dichloro metal complexes
in Table 5.2. The Cl to Cl internuclear distance (3.148 Å) in III and (6,6′′-Me2bipy)PdCl2 is
smaller than the sum of the van der Waals radii (3.5 Å), resulting in repulsive interactions.
5.3.2.2 Coordination-Plane Distortion. Cl-to-Cl and Cl-to-methyl group repulsions can
distort the coordination plane (Figure 5.8). This distortion is best analyzed using the dihedral
angle (α) between the N,M,N′ plane and Cl,M,Cl plane. The α values for III and (6,6′′Me2bipy)PdCl2 are 11.5(3)° and 14.3(1)°, whereas for the less distorted dichloro metal
complexes listed in Table 5.1, the α values range from 0° to 4.3°.
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Figure 5.8 Stick representation of (a) (6,6′′-Me2bipy)PtCl2, (b) (6,6′′-Me2bipy)PdCl2, (c) (6Mebipy)PdCl2, (d) ((−
−)-sparteine)PdCl2 and (e) ((−
−)-α
α-isosparteine)PdCl2.
In order to understand better the steric effect of the group on the carbon adjacent to the
coordinated N on the Cl−M−Cl grouping, we compared the complexes studied here with ((−
−)-α
αisosparteine)PdCl2 and ((−
−)-sparteine)PdCl2.44 For the symmetrical ((−
−)-α
α-isosparteine)PdCl2,
the Cl–M–Cl angle (86.205(15)°) and the internuclear separations found between the C’s
adjacent to the coordinated N’s and the cis Cl’s (3.130 and 3.168 Å) are comparable to those in
III and in (6,6′′-Me2bipy)PdCl2. Because of the bulk near the coordinated N’s of ((−
−)-α
αisosparteine)PdCl2, the Cl atoms are largely pushed out of the N,Pd,N′ plane (α = 22.1°) and are
3.172 Å apart. Because of the less accommodating geometry of the (−
−)-sparteine than the (−
−)-α
αisosparteine or bipyridine-type ligands, ((−
−)-sparteine)PdCl2 has an even smaller Cl−Pd−Cl
angle (83.09(3)°) and shorter C⋅⋅⋅Cl (3.034 and 3.072 Å) and Cl⋅⋅⋅Cl (3.071 Å) distances. One of
the Cl atoms in the unsymmetrical ((−
−)-sparteine)PdCl2 complex is displaced from the N,Pd,N′
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plane, while the other Cl is located close to this plane (α = 9.9°) (Figure 5.8). For the
unsymmetrical (6-Mebipy)PdCl2 complex, the Cl cis to the 6-methyl group is displaced from the
N,Pd,N′ plane, but the Cl cis to the H6' is closer to the plane (Figure 5.8). Both the Cl–Pd–Cl
angle and α (14.30(7)°) are larger than those for ((−
−)-sparteine)PdCl2. Thus, dichloro complexes
with ligands accommodating distortions characterized by larger values of α tend to have a less
distorted Cl−M−Cl grouping.
5.4 Conclusions
The platinum complexes characterized here have typical M−N distances of ~2.0 Å, and
thus can be viewed as being representative of pseudo square-planar complexes of bipyridine-type
ligands. When combined with literature data, the new results allow conclusions to be reached
about the relative influence on structural distortions of intramolecular interactions vs. solid-state
effects.
The distortions in (6,6'-Me2bipy)PtCl2 (III) are best appreciated by comparison to its
relatively undistorted isomers, I and II, which have 6,6′ hydrogens. The Cl−M−Cl grouping in
the latter is normal, indicating good overlap of the metal and chloride bonding orbitals, a
situation allowed by the weakness of the repulsive 6,6′-C to Cl interactions for the distances of
~3.1 Å. Also, attractive interactions between the 6,6′ hydrogens and the cis chlorides may exist.
However, the presence of 6,6′ methyl groups in the 6,6'-Me2bipy ligand of III and its Pd
analogue gives rise to a highly distorted structure, characterized by large bowing and an incline
of the aromatic ring relative to the coordination plane. This bow-incline distortion creates ~3.1 Å
C to Cl distances and allows the chlorides to remain close to the coordination plane in these Pt
and Pd complexes. When the bulky ligand is not aromatic, the complex must either distort the
coordination plane (e.g. ((−
−)-α
α-isosparteine)PdCl2) or adopt an acute Cl-Pd-Cl angle (e.g. ((−
−)-
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sparteine)PdCl2) to maintain the ~3.1 Å C to Cl distances. The coordination plane of ((−
−)sparteine)PdCl2 is less distorted and has an α value similar to those in III and also in the
structurally similar 2,9-Me2phen45 and Pd analogues of III. Thus, distortions found in dichloro
complexes are quite diverse but are not dependent on whether the metal is Pt or Pd. In contrast,
as discussed next, we can conclude that the highly distorted dichloro compounds have some
features that can be related to those found for bis bipyridine-type complexes.
In bis bipyridine complexes, the strain induced by the close proximity of the H’s on the
C6 carbons of the opposing ligands is relieved either by a bow-incline distortion or by canting of
the two bipyridine ligands. Of the five relevant structures in Table 5.2, three have canting and
two have bow-incline distortion. The structure of IV adds a new bipyridine ligand to the existing
bis bipyridine structures and also demonstrates that the bow-incline distortion can occur in a Pt
complex. Consequently, there are now examples of both types of distortions for both Pt and Pd.
It is reasonable to conclude that these two types of distortions are similar in energy and that
minor solid-state effects determine which distortion type is observed. In contrast to IV, [trans(pyPh2t)2Pt](BF4)2 has a relatively planar structure, which can be attributed to the favorable
juxtaposition of the pyridyl H6′ proton and the triazine lone pair of electrons, adding support to
the conclusion that the distortions in bis bipyridine complexes arise from interligand repulsions
involving 6,6' hydrogens.
Average values of θP for bipyridine complexes I to IV and for the four pyridyl triazine
complexes in Table 5.2 are very similar. Thus, while the present study indicates that interligand
repulsions involving H6 and H6' influence structure, sometimes dramatically, H3 to H3'
intraligand repulsions have no evident effect on structure.
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CHAPTER 6. SUMMARY AND CONCLUSIONS
The platinum complexes of the type LPtCl2 and [L2Pt]2+ (L = bidentate sp2 Ndonor ligands) were successfully synthesized and crystallized. The platinum complexes
characterized here have typical M−N distances of ~2.0 Å, and thus can be viewed as
being representative of pseudo square-planar complexes of bipyridine-type ligands. The
X-ray crystallographic data allowed conclusions to be reached about the relative
influence of intramolecular interactions on the structural distortions.
The LPtCl2 complexes with L = dimethyl-2,2′-bipyridine (Me2bipy) have a more
planar structure when compared to complexes having 3-(2′-pyridyl)-1,2,4-triazine (pyt)
ligands. For the 4,4′′- and the 5,5′′- Me2bipy, the attractive interactions between the H6
protons and the cis Cl results in a highly planar structure. However, presence of 6,6′
methyl groups in the 6,6'-Me2bipy ligand gives rise to a highly distorted structure,
characterized by large bowing and an incline of the aromatic ring relative to the
coordination plane. On the contrary the L2Pt2+ complexes with L = Me2bipy are more
distorted than when L = pyt. The juxtaposition of the pyridyl H6 proton and the triazine
lone pair of electrons in [L2Pt]X2 allows formation of a planar structure. Also, this
juxtaposition favors the trans arrangement of the bidentate ligands in [(pyt)2Pt]X2. For a
given bidentate ligand, the interactions between the juxtaposed groups on the two rings
ortho to the bridging carbons and on the periphery of the bidentate ligand are favorable
for pyt ligands but unfavorable for Me2bipy.
The reaction of LPtCl2 complexes (L = 5,5′′-Me2bipy, MepyMe2t and bis-3,3′(5,6-disubstituted-1,2,4-triazine) (R4dt)) with guanine derivatives (G) were informative.
The bulk of the bidentate sp2 N-donor ligands is sufficient to impede the rotation of the G
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bases about the Pt–N7 bonds of the LPtG2 adducts; thus, H8 signals for conformers could
be resolved and assigned. From NMR data (including EXSY results), for LPt(GMP)2, the
qualitative rates of conformer interconversion follow the order, Me4dt > Et4dt >
MepyMe2t > 5,5′′-Me2bipy. Thus, we conclude that the pyridyl H6′ atom strongly
impedes the rotation of the cis G base about the Pt–N7 bond by clashing with G O6,
whereas the equivalently placed lone pair of the relevant non-bonded N of the triazine
does not so strongly impede G rotation. Thus, the triazine ring has a lower overall steric
effect than the pyridyl ring. Our conclusion that the lone pair on the non-bonded nitrogen,
N1, of the triazine ring is not sterically demanding is also supported by results from the
reaction of (MepyMe2t)PtCl2 with Guo to form a [(MepyMe2t)Pt(Guo)2]2+ adduct. The
intermediate properties of MepyMe2t, with one triazine and one pyridyl ring led to
EXSY data for the (MepyMe2t)Pt(5′-GMP)2 adduct that allowed us to unambiguously
determine and assign the conformation of the two HH conformers, HHa and HHb.
The nature of the carrier ligand in LPtG2 adducts influences the distribution of
conformers and their characteristics. Typically, one HT conformer dominates over the
other HT and the HH conformer at low pH (~4), especially at neutral pH. We have
discovered that carrier ligands of the type, R4dt, lead to the HH having almost
comparable abundance to the total of the two HT conformers for the (R4dt)Pt(5′-GMP)2
adduct at equilibrium at pH 4. We conclude that the sterically less demanding nature of
the R4dt ligand allows ample space for the HH conformer to exist with less significant
clashes between the O6 atoms of the 5′-GMP’s. Normally, second-sphere communication
raises the abundance of one HT conformer as the pH is raised to near neutrality. This
trend was found for the (R4dt)Pt(5′-GMP)2 adducts. However, the abundance of the HH
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isomer remains high. Given the finding that carrier ligands favoring the HH conformer in
the cross-link are associated with anticancer activity,1 Pt complexes of R4dt ligand
should be tested for activity.
The interesting results with (R4dt)Pt(GMP)2 adducts led us to expand our study to
single-stranded (ss) DNA adducts. Studies with the (R4dt)Pt(d(G*pG*)) adduct provided
the first evidence of formation of a substantial amount of a fourth form of an
LPt(d(G*pG*)) adduct. HPLC data suggest that this is the elusive ΛHT conformer of the
N7–Pt–N7

d(G*pG*)

cross-link

adduct.

The

putative

ΛHT

conformer

of

(R4dt)Pt(d(G*pG*)) is kinetically less favored when compared to the HH1, HH2 and
∆HT conformers and becomes abundant slowly (~8 weeks) by conformer isomerization.
It is possible that this ΛHT conformer was not detected in the previously reported less
dynamic adducts, even after long time periods, because of its slow rate of formation.
However, for the (R4dt)Pt(d(G*pG*)) adduct all four expected conformers could be
identified and characterized by 1H NMR spectroscopy. Our results with (R4dt)Pt(5′GMP)2 revealed that the R4dt carrier ligand is sterically less demanding and allows a less
restricted rotation of G about the Pt–N7 bond. The detection of all four conformers and
absence of any EXSY cross-peaks for the (R4dt)Pt(d(G*pG*)) adduct provides the first
clear evidence that the sugar-phosphodiester backbone between two adjacent G’s slows
the exchange between the conformers.
From

the

distribution

of

conformers

for

(R4dt)Pt(d(G*pG*)),

(5,5′-

Me2bipy)Pt(d(G*pG*)),2 BipPt-(d(G*pG*))3,4 and Me2ppzPt(d(G*pG*))5 adducts,
regardless of the carrier ligand the HH1 conformer is most abundant. However, the
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thermodynamically favored putative ΛHT conformer for (Me4dt)Pt(d(G*pG*)) was
almost as abundant as the HH1 conformer at equilibrium.
NMR results in this study also show that the structure of the sugar-phosphodiester
backbone differ from conformer to conformer, but the

31

P NMR data for the

(R4dt)Pt(d(TG*G*)) adduct, for the first time indicated that for a given conformer, the
backbone structure may depend on the carrier ligand. The low steric effects of the N lone
pairs of the R4dt ligand allow more space for the HH conformer to exist resulting in a
less distorted backbone for the HH1 conformer.
The effect of flanking residues in LPt(d(oligo)) adducts is presented here for the
first time for L = planar sp2 N-donor ligand. Several important points have emerged from
a comparison of the (R4dt)Pt(oligo) adducts with (R4dt)Pt(d(G*pG*)). For (R4dt)Pt
adducts at equilibrium, d(G*pG*) and d(G*G*T) uniquely have all the four conformers
(except for the (Et4dt)Pt(d(G*G*T)) ΛHT conformer which does not form). The ΛHT
conformer becomes much less abundant in adducts with a 3′-residue. However, the 5′flanking T residue exclusively favors the HH1 L conformer. The highly L nature of the
single-strand DNA adducts with a 5′-T residue is chiefly a consequence of the bulk of the
5′ substituents; factors like H-bonding are inconsequential. Evidently, the 3′-flanking T
residue has little or no effect, but the 5′-flanking T residue has a dramatic effect on the
the d(G*pG*) cross-link structure, conformer distribution and canting.
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APPENDIX A. SUPPLEMENTARY MATERIAL FOR CHAPTER 2
A.1 1H NMR Spectra of [L2Pt]2+ Complexes.

Figure A.1 1H NMR spectra of [(pyPht)2Pt]2+, [(pyPh2t)2Pt]2+, [(MepyMe2t)2Pt]2+, and
[(MepyPh2t)2Pt]2+ in DMSO-d6 solution at 25 °C. The signals for the substituents on C5 and C6
are assigned by type only, except for [(pyPht)2Pt]2+, which is completely assigned.
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A.2 1H NMR Chemical Shifts for [L2Pt]2+ Complexes
Table A.1 1H NMR Chemical Shifts (ppm) in DMSO-d6 for [L2Pt]X2 Complexes

a

[L2Pt]2+

H6′

H5′

C4′
substituent

H3′

C5, C6 substituentsa

[(MepyMe2t)2Pt]2+

9.99(d)

8.23(d)

2.74(s, CH3)

8.60(s)

2.91(s, CH3), 3.01(s, CH3)

[(pyPht)2Pt]2+

10.23(d)

8.80(t)

8.42(t, H)

9.15(d)

10.51(s, H), 8.78(d, o-PhH),
7.96(t, p-PhH), 7.83(t, m-PhH)

[(pyPh2t)2Pt]2+

10.18(d)

8.81(t)

8.50(t, H)

9.06(d)

7.86(d, o-PhH), 7.95(d, o-PhH),
7.71(t, m-PhH), 7.59(t, p-PhH)

[(MepyPh2t)2Pt]2+

9.99(d)

8.34(d)

2.58(s, CH3)

8.92(s)

7.83(d, o-PhH), 7.96(d, o-PhH),
7.70(m-PhH), 7.58(t, p-PhH)

The C5 and C6 substituents were not specifically assigned, except for [(pyPht)2Pt]2+.

A.3 Reactions of pyMe2t and cis-Pt(Me2SO)2Cl2 Studied by 1H NMR Spectroscopy.
A.3.1 Formation and Properties of (pyMe2t)PtCl2.
Cis-Pt(Me2SO)2Cl2 (1.16 mg, 5 mM) was added to a DMSO-d6 solution (550 µL) of
pyMe2t (0.51 mg, 5 mM) to obtain a 1:1 molar ratio of Pt:pyMe2t. Within 1 h of mixing, two
new sets of bound pyMe2t signals in a ratio of ∼4:1 were observed (Figure A.2). The intensity of
the new sets of signals increased with time. Two experiments were performed to assign the
products and to determine if either product had the triazine ring bound to the Pt through N4
instead of N2.
Two separate solutions of (pyMe2t)PtCl2 (1.25 mg, 5 mM) in DMSO-d6 (550 µL) were
prepared. Within 5 min of dissolving (pyMe2t)PtCl2 in DMSO-d6, two sets of signals were
observed in a ratio of ∼4:1, which remained constant, even after three days. These were the same
signals observed in the 1:1 reaction. To the first solution [NEt4]Cl (2 mM) was added; the H6′
signal corresponding to the minor complex (at 9.44 ppm) disappeared, while the intensity of the
H6′ signal (at 9.61 ppm) of the major complex increased. We attribute this result to conversion
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of a minor solvolysis product to the dichloro complex by the high concentration of chloride.
Thus, the H6′ doublet at 9.61 ppm was assigned to (pyMe2t)PtCl2, and the doublet at ~9.44 ppm
was assigned to [(pyMe2t)Pt(Me2SO-d6)Cl]+. To the second solution, 10% D2O was added, and
within 30 min the intensity of the H6 signal at 9.44 ppm increased, while that of the signal at
9.61 ppm decreased, confirming that the 9.44 and 9.61 signals are due to a solvolysis product and
to the dichloro complex, respectively. No isomer of the pyridyl triazine with L bound via N4 was
detected.
A.3.2 Formation of [(pyMe2t)2Pt]2+.
Cis-Pt(Me2SO)2Cl2 (1.16 mg, 5 mM) was added to a DMSO-d6 solution (550 µL) of
pyMe2t (2.05 mg, 20 mM) to obtain a 1:4 molar ratio of Pt:pyMe2t. After 1 h of mixin, one set
of new signals appeared in addition to the signals of the uncomplexed pyMe2t ligand (Figure
A.2). In this 4:1 experiment, the same doublet found in the 1:1 experiment at 9.61 ppm was
present as the most downfield of the four new signals and was assigned to (pyMe2t)PtCl2. Within
~2 h, the neutral (pyMe2t)PtCl2 complex started precipitating. After ~1 day, four additional, but
very weak signals for bound L were observed, the most downfield signal appearing at 10.2 ppm.
This second reaction did not go to completion even in the presence of a threefold excess of
pyMe2t ligand. However, on addition of 10% D2O to the sample, the signal at 10.2 ppm grew
almost immediately. After ~1 h, signals assigned to (pyMe2t)PtCl2 disappeared, while the more
downfield set of signals for bound L remained (Figure A.2). Again, no evidence for platinum
binding at N4 of the triazine ring was observed in any spectra. The doublet at 10.2 ppm was thus
assigned to the pyridyl H6′ of the [(pyMe2t)2Pt]2+ cation having a trans relationship of the bound
pyMe2t ligands as found crystallographically for 8. These findings indicate that the bound
dichloro complex is favored thermodynamically in DMSO-d6 and does not lose the chloro ligand
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unless enough water is present to solvate the released chloride. Therefore, in studying the
reaction of (pyMe2t)PtCl2 with Guo we used a D2O/DMSO-d6 solution as the solvent.

Figure A.2 1H NMR spectra, using numbering system in Scheme 2.1, of DMSO-d6 solutions at
25 °C: pyMe2t (bottom); 1:1 reaction mixture of pyMe2t and cis-Pt(Me2SO)2Cl2, 1 h after
mixing (middle); and 4:1 reaction mixture of pyMe2t and cis-Pt(Me2SO)2Cl2, 1 h after addition
of 10% D2O (top).
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APPENDIX B. SUPPLEMENTARY MATERIAL FOR CHAPTER 3
B.1 Conformer Assignment And Their Characteristics
B.1.1 (Me4dt)Pt(5′′-GMP)2.
Within 24 h of mixing 1 equiv of (Me4dt)PtCl2 with 2 equiv of 5′-GMP at pH 4.0, six
new broad and poorly resolved downfield H8 NMR signals (at ~25 °C) were observed,
suggesting relatively fast 5′-GMP rotation. Most spectra were collected at 5 °C, where the
reduced rate of G base rotation led to resolved sharp signals. Of the six new 5′-GMP H8 signals
of (Me4dt)Pt(5′-GMP)2, the two comparably intense H8 signals at 8.87 and 8.82 ppm diminished
with time, and after 4 days these were very small compared to the other four H8 signals (Figure
B.1). These two H8 signals were the major signals when (Me4dt)PtCl2 and 5′-GMP were mixed
in a 1:1 ratio and were absent when the two were mixed in a 1:3 ratio; thus, the two signals were
assigned to the two rotamers of the mono 5′-GMP Pt adduct. The 5′-GMP in the mono 5′-GMP
Pt adduct can have the H8 atom pointing either upward or downward out of the Pt coordination
plane.

Figure B.1 H8 region of 1H NMR spectra of (Me4dt)Pt(5′-GMP)2 at 5 °C. The H8 signals of the
1:1 adduct are labeled with asterisks.
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Figure B.2 ROESY spectrum of the (Me4dt)Pt(5′-GMP)2 adduct in the H8 region at pH 4.0 and
5 °C. The cross-peak labeled as HH is an NOE between the H8 signals of the HH conformer. The
other labeled cross-peaks are EXSY cross-peaks between the H8 signals of two different
conformers.
Solution studies of the (Me4dt)Pt(GMP)2 adducts were conducted in the pH range of ~4
to ~7 because decomposition produced free GMP at high pH. For the (Me4dt)Pt(5′-GMP)2
adduct, from pH 4.0-7.0 the two H8 signals at 9.10 and 8.66 ppm shifted downfield to 9.27 and
8.74 ppm, respectively. These signals were assigned to the HH conformer because they remained
nearly equal throughout the pH titration, and they were connected by an NOE cross-peak in a
ROESY spectrum (Figure B.2). Upon aising the pH from 4.0 to 7.0, the H8 signals at 9.08 and
8.96 ppm belonging to the HT rotamers shifted slightly upfield to 9.06 and 8.95 ppm,
respectively (Table 3.1 and Figure B.1). At pH ~4, the HT H8 signals are nearly equal in
intensity, the weak CD signal is consistent with nearly equal abundance of the ∆HT and ΛHT
conformers. At pH 7.0 the H8 signal at 8.95 ppm became the dominant H8 signal. The CD signal
shape at pH ~7 (Figure B.3) is characteristic of the ΛHT conformer1-5 favored by SSC on
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phosphate deprotonation.5-8 Thus, the H8 signal at 8.95 ppm was assigned to the ΛHT
conformer. The remaining H8 signal at 9.06 ppm (pH 7.0) was assigned to the ∆HT conformer.

Figure B.3 CD spectra of (Me4dt)Pt(5′-GMP)2 and (Me4dt)Pt(3′-GMP)2 at 25 °C.
For the (Me4dt)Pt(5′-GMP)2 adduct at pH 7.0, the H8 signal of the major ΛHT conformer
is upfield to that of the minor ∆HT conformer, as also observed for the (Et4dt)Pt(5′-GMP)2
adduct. In both cases, if the major ΛHT conformer is the ‘6-out’ form and the minor ∆HT
conformer is the ‘6-in’ form, the canting is R-handed.
A ROESY spectrum of (Me4dt)Pt(5′-GMP)2 at pH 4.0 shows four EXSY cross-peaks
even at 5 °C (Figure B.2). Both the HHd signal (9.10 ppm) and the HHu signal (8.66 ppm) have
an EXSY cross-peak with the H8 signal (8.96 ppm) of the ΛHT rotamer. A ∆HT H8 - HHu H8
EXSY cross-peak is seen, but no ∆HT H8 - HHd H8 cross-peak could be detected because the
two H8 signals have very similar shifts. Also, the presence of a weak EXSY cross-peak between
the H8 signals of the ∆HT and the ΛHT rotamers indicates that this interconversion is rapid, even
though it proceeds via the intermediacy of the HH rotamer. Thus, relatively faster interchange
occurs between the rotamers for the (Me4dt)Pt(5′-GMP)2 adduct than for adducts with ligands
containing a pyridyl moiety.
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Increasing the pH from 4.0 to 7.0 changed the abundance of the HH, ΛHT, and ∆HT
atropisomers of (Me4dt)Pt(5′-GMP)2 adduct from 40%, 30%, and 30% to 35%, 46%, and 19%,
respectively (Figure B.1). At pH 4.0, the two HT conformers are equally abundant, and the HH
conformer has a relatively high abundance. With increasing pH, SSC effects favor the ΛHT
conformer; however, the abundance of the HH conformer is still relatively high, as compared to
previously studied LPt(5′-GMP)2 adducts.
B.1.2 (Me4dt)Pt(3′′-GMP)2.

Figure B.4. H8 region of the 1H NMR spectrum of (Me4dt)Pt(3′-GMP)2 at pH 4.0 and 5 °C. The
H8 signal of the 1:1 adduct is indicated by an asterisk.
Three new H8 signals were observed downfield to the free 3′-GMP H8 signal at 5 °C and
pH 4.0 (Figure B.4). The most upfield H8 signal (at 8.78 ppm, Figure B.4), which disappeared
with time, was assigned to the two rapidly interconverting rotamers of the 1:1 3′-GMP adduct.
After 2 days, only the two downfield H8 signals at 8.85 and 8.83 ppm were present in a 3:1 ratio.
The CD signal shape observed at pH ~4 (Figure B.3) is characteristic of the ∆HT
conformation,1,3,4,8 which is the usually favored conformer by SSC at pH ~7 and below.5-8
Therefore, at pH 4.0, the dominant H8 signal at 8.85 ppm was assigned to the ∆HT conformer
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(major) and that at 8.83 ppm was assigned to the ΛHT conformer (minor). The ‘6-in’ major form
is the ∆HT R conformer and the ‘6-out’ minor form is the ΛHT R. No evidence for the HH
rotamer of the (Me4dt)Pt(3′-GMP)2 adduct was detected, even at 5 °C. At pH 7.0 the H8 signals
are highly overlapped, but we estimate that the percent abundance of the ∆HT H8 signal
increases from 75% to over 80%.

B.2 Chemical Shifts of the H1′′ and H6/H6′′ Signals of LPt(GMP)2 Adducts
Table B.1 Chemical Shifts of the H1′ Signals of LPt(GMP)2 Adducts (L = 5,5′-Me2bipy, Et4dt,
Me4dt) and the H6/H6′ Signals of (5,5′-Me2bipy)Pt(GMP)2 Adducts at 5 °C a
complex

pH

(5,5′-Me2bipy)Pt(5′-GMP)2b

4.0

∆HT

ΛHT

HHd

HHu

H1′

6.03

6.00

6.10

6.08

4.0

H6/H6′

7.78

7.90

7.72

7.82

7.5

H1′

6.00

5.97

6.09

6.04

7.5

H6/H6′

7.84

8.03

7.70

7.84

4.0

H1′

6.12

6.03

c

c

4.0

H6/H6′

8.06

7.79

c

c

7.5

H1′

6.12

6.01

c

c

7.5

H6/H6′

8.24

7.82

c

c

(Et4dt)Pt(5′-GMP)2

4.0

H1′

6.07

6.03

6.08

6.03

(Et4dt)Pt(3′-GMP)2

4.0

H1′

6.10

6.07

c

c

7.5

H1′

6.07

6.07

c

c

4.0

H1′

6.11

6.06

6.11

6.02

7.0

H1′

6.10

6.03

6.09

6.03

4.0

H1′

6.11

6.09

c

c

7.0

H1′

6.10

6.10

c

c

(5,5′-Me2bipy)Pt(3′-GMP)2b

(Me4dt)Pt(5′-GMP)2

(Me4dt)Pt(3′-GMP)2

a

Signal assignments are based on the 2D NMR studies.
Signal not detected.
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b

NMR spectrum recorded at 25 °C.

c

Table B.2 Chemical Shifts of the H1′and the H6′ Signals of (MepyMe2t)Pt(GMP)2 Adducts at
25 °C a
complex

pH

∆HT

HHa

ΛHT

HHb

∆HTd ∆HTu ΛHTd ΛHTu HHad HHau HHbd HHbu
(py)
(MepyMe2t)Pt(5′- 2.5 H1′ 6.05
GMP)2

(t)

(py)

(t)

(t)

(py)

(t)

(py)

6.09

6.05

6.05

6.05

6.05

6.07

6.07

2.5 H6′ 8.09

8.09

8.09

8.02

7.5 H6′ 8.10

8.25

8.10

7.99

(MepyMe2t)Pt(3′- 4.5 H1′ 6.12
GMP)2

6.09

4.5 H6′ 8.25
7.5 H1′ 6.29
7.5 H6′ 8.44

6.07

6.06

b

b

6.25

b

b

8.02
6.29

6.25
8.02

a

The py and t notations designate G's cis to the pyridyl and triazine rings, respectively. Signal
assignments are based on the 2D NMR and pH titration studies. b Signal not detected.
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APPENDIX C. SUPPLEMENTARY MATERIAL FOR CHAPTER 4
C.1 Conformational Features of (Et4dt)Pt(d(G*pG*)) Conformers.
The H8 peaks of (Et4dt)Pt(d(G*pG*)) at 8.97 and 9.04 ppm are connected by H8-H8
NOE cross-peaks. The H8-H2′ cross-peaks are stronger than the H8-H1′ cross-peaks (Figure
C1), indicating a predominantly anti conformation for both 3′-G* and 5′-G* nucleotides. A 5′-G*
H8-H3′ NOE cross-peak and a doublet for the H1′ signal (6.39 ppm) is characteristic of an Nsugar of a 5′-G (Figure C1).1-6 The H8 signal at 8.97 ppm, which must be the 3′-G* H8 signal,
has no H8-H3′ cross-peak, the H1′ signal at 6.43 ppm is doublet of a doublet, thus indicating an
S-sugar pucker. Therefore, the dominant (Et4dt)Pt(d(G*pG*)) conformer is an anti,anti-HH1
conformer, as observed for the (Me4dt)Pt(d(G*pG*)).

Figure C1. 1H-1H ROESY spectrum (700 MHz, 600 ms mixing time) of a 1-week-old
(Et4dt)Pt(d(G*pG*)) sample at pH 4.0 and 25 °C, showing G* H8 to sugar NOE cross-peaks for
the HH1, HH2, and ∆HT and ΛHT conformers.
The two most downfield H8 signals at 9.23 and 9.10 ppm connected by an H8-H8 NOE
cross-peak belong to the HH2 conformer (minor). The G* H8 signal at 9.10 ppm has a strong
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H8-H3′ cross-peak, indicating an N-sugar pucker for the 5′-G* nucleotide (Figure C1). For the
5′-G* residue, a strong H8-H2′ cross-peak and the absence of an H8-H1′ NOE cross-peak
indicate an anti G* conformation (Figure C1). The 9.23 ppm H8 signal belongs to the 3′-G*
because of the S-sugar pucker indicated by the absence of an H8-H3′ NOE cross-peak. This H8
signal has a weak NOE cross-peak to the H1′ signal and a strong NOE to the H2′ signal.
Therefore, this HH2 conformer has an anti,anti conformation.
The upfield pair of H8 signals at 8.29 and 8.32 ppm for the (Et4dt)Pt(d(G*pG*)) adduct
has no H8-H8 NOE cross-peak, indicating that the bases of this form adopt the HT
arrangement.2,3,7 These upfield H8 signal positions are characteristic of the ∆HT conformer. The
chemical shifts of these HT H8 signals were similar to those of the (Me4dt)Pt(d(G*pG*)) ∆HT
conformer. The H8 peak at 8.32 ppm exhibits an intraresidue H8-H3′ NOE cross-peak (Figure
C1) consistent with an N-sugar pucker. Because the H1′ signal of this conformer at 6.35 ppm
overlaps with H1′ signals of the other (Et4dt)Pt(d(G*pG*)) conformers, the coupling pattern
could not be determined. However, because all the d(G*pG*) adducts typically adopt a 5′-G* Nsugar pucker, we can assign the downfield signal of this conformer to the 5′-G* sugar residue.
The presence of a strong H8-H2′ cross-peak (Figure C2) and a weak H8-H1′ cross-peak indicates
an anti 5′-G* conformation. The presence of an intraresidue H8-H1′ NOE cross-peak for the
upfield ∆HT H8 signal at 8.29 ppm (which must be the 3′-G* H8) suggests that the conformation
of 3′-G* is syn. Both the H8-H2′/H2′′ and the H8-H3′ cross-peaks were absent. The doublet of
doublets coupling of the 3′-G* H1′ signal (6.19 ppm) is typical of an S-sugar. Thus, this
(Et4dt)Pt(d(G*pG*)) conformer has an anti,syn-∆HT conformation. In contrast to the H8 shifts
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of the (Me4dt)Pt(d(G*pG*)) ∆HT conformer, the 5′-G* H8 signal for the (Et4dt)Pt(d(G*pG*))
∆HT conformer is downfield to the 3′-G* H8 signal.
For the (Et4dt)Pt(d(G*pG*)) adduct, no H8-H8 NOE cross-peak was observed for the
fourth pair of G* H8 signals at 8.66 and 8.99 ppm, indicating that the bases adopt an HT
arrangement that could possibly be the elusive ΛHT conformer. The G* H8 signals have strong
H8-H2′ cross-peaks and weak H8-H1′ cross-peaks (Figure C1), indicating an anti conformation
for both G* nucleotides. A strong H8-H3′ NOE cross-peak for the H8 signal at 8.99 ppm and a
doublet for the H1′ signal indicate an N-sugar pucker. Thus, the 8.99 ppm H8 signal was
assigned to the 5′-G* residue. For the H8 signal at 8.68 ppm, an H8-H3′ cross-peak was absent
and the doublet of doublets coupling pattern indicated an S-sugar pucker. Thus, this upfield
signal was assigned to the 3′-G*. This HT conformer has an anti,anti conformation. For the
putative ΛHT conformer of the (Et4dt)Pt(d(G*pG*)) adduct, the 5-G* H8 signal is downfield of
the 3-G* H8 signal, as observed for the putative ΛHT conformer of the (Me4dt)Pt(d(G*pG*))
adduct.
C.2 (Me4dt)Pt(d(G*pG*)).
Within ~30 min of mixing (Me4dt)PtCl2 and d(GpG) in a 1:1 molar ratio in 64:36
D2O:DMSO-d6 solution at pH ∼4.0 at 5 °C, the (Me4dt)Pt(d(G*pG*)) adduct was fully formed.
The eight H8 signals of the four conformers of the (Me4dt)Pt(d(G*pG*)) adduct are fully
resolved (Figure C2). The intensity of the H8 signals for the putative ΛHT conformer at 9.04 and
8.65 ppm slowly increased during a period ~3 months (Figure C2). A ROESY spectrum of this
3-months-old sample (Figure C3) helped us to confirm the sugar signal assignment for the
(Me4dt)Pt(d(G*pG*)) conformers.
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Figure C2. 1H NMR spectra (400 MHz) in the H8 region for (Me4dt)Pt(d(G*pG*)) collected at
25 °C after 1 week (bottom) and after 3 months (top) (pH 4.0, in D2O/DMSO-d6).

Figure C3. 1H-1H ROESY spectrum (400 MHz, 500 ms mixing time) of a 3-months-old
(Me4dt)Pt(d(G*pG*)) sample at pH 4.0 and 25 °C, showing G* H8 to sugar NOE cross-peaks.
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